{"59bae06e4e467d5127f1175e8334cd8a1378da38": [["L ong before microbes were discovered, a sudden occurrence of disease in a society would trigger fear, accompanied by rational and irrational responses.", [["disease", "PROBLEM", 62, 69], ["disease", "OBSERVATION", 62, 69]]], ["A mysterious, highly contagious disease that spread across the Mediterranean and killed a quarter of the population of Athens is the first recorded pandemic (1).", [["A mysterious, highly contagious disease", "PROBLEM", 0, 39], ["highly", "OBSERVATION_MODIFIER", 14, 20], ["contagious", "OBSERVATION_MODIFIER", 21, 31], ["disease", "OBSERVATION", 32, 39]]]], "PMC7089069": [["IntroductionViral infections are the leading causes of upper and lower airway acute illnesses in all age groups of otherwise healthy individuals and have also been implicated in acute exacerbations of chronic respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD).", [["airway", "ANATOMY", 71, 77], ["respiratory", "ANATOMY", 209, 220], ["pulmonary", "ANATOMY", 270, 279], ["IntroductionViral infections", "DISEASE", 0, 28], ["respiratory disorders", "DISEASE", 209, 230], ["asthma", "DISEASE", 239, 245], ["chronic obstructive pulmonary disease", "DISEASE", 250, 287], ["COPD", "DISEASE", 289, 293], ["upper", "ORGANISM_SUBDIVISION", 55, 60], ["pulmonary", "ORGAN", 270, 279], ["IntroductionViral infections", "PROBLEM", 0, 28], ["upper and lower airway acute illnesses", "PROBLEM", 55, 93], ["chronic respiratory disorders", "PROBLEM", 201, 230], ["asthma", "PROBLEM", 239, 245], ["chronic obstructive pulmonary disease", "PROBLEM", 250, 287], ["COPD)", "PROBLEM", 289, 294], ["infections", "OBSERVATION", 18, 28], ["upper", "ANATOMY_MODIFIER", 55, 60], ["lower", "ANATOMY_MODIFIER", 65, 70], ["airway", "ANATOMY", 71, 77], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["illnesses", "OBSERVATION", 84, 93], ["acute", "OBSERVATION_MODIFIER", 178, 183], ["exacerbations", "OBSERVATION", 184, 197], ["chronic", "OBSERVATION_MODIFIER", 201, 208], ["respiratory disorders", "OBSERVATION", 209, 230], ["asthma", "OBSERVATION", 239, 245], ["chronic", "OBSERVATION_MODIFIER", 250, 257], ["obstructive", "OBSERVATION_MODIFIER", 258, 269], ["pulmonary", "ANATOMY", 270, 279], ["disease", "OBSERVATION", 280, 287], ["COPD", "OBSERVATION", 289, 293]]], ["Human rhinovirus (HRV), respiratory syncytial virus (RSV), influenza virus and coronaviruses are considered the most important viral respiratory pathogens.", [["Human rhinovirus (HRV)", "DISEASE", 0, 22], ["respiratory syncytial virus (RSV)", "DISEASE", 24, 57], ["influenza virus and coronaviruses", "DISEASE", 59, 92], ["Human rhinovirus", "ORGANISM", 0, 16], ["HRV", "ORGANISM", 18, 21], ["respiratory syncytial virus", "ORGANISM", 24, 51], ["RSV", "ORGANISM", 53, 56], ["influenza virus", "ORGANISM", 59, 74], ["coronaviruses", "ORGANISM", 79, 92], ["Human", "SPECIES", 0, 5], ["rhinovirus", "SPECIES", 6, 16], ["respiratory syncytial virus", "SPECIES", 24, 51], ["influenza virus", "SPECIES", 59, 74], ["Human rhinovirus", "SPECIES", 0, 16], ["HRV", "SPECIES", 18, 21], ["respiratory syncytial virus", "SPECIES", 24, 51], ["RSV", "SPECIES", 53, 56], ["influenza virus", "SPECIES", 59, 74], ["Human rhinovirus (HRV)", "PROBLEM", 0, 22], ["respiratory syncytial virus (RSV)", "PROBLEM", 24, 57], ["influenza virus", "PROBLEM", 59, 74], ["coronaviruses", "PROBLEM", 79, 92], ["viral respiratory pathogens", "PROBLEM", 127, 154], ["respiratory", "ANATOMY", 24, 35], ["syncytial virus", "OBSERVATION", 36, 51], ["influenza virus", "OBSERVATION", 59, 74], ["respiratory pathogens", "OBSERVATION", 133, 154]]], ["Although parainfluenza viruses (hPIVs) are common respiratory pathogens that cause infections without ethnic, socioeconomic, gender, age, or geographic boundaries [1] and most frequently induce acute respiratory tract diseases in infants and immunocompromised adults [2, 3], their role in exacerbation of chronic respiratory disorders has received relatively little attention.", [["respiratory tract", "ANATOMY", 200, 217], ["respiratory", "ANATOMY", 313, 324], ["parainfluenza viruses", "DISEASE", 9, 30], ["hPIVs", "DISEASE", 32, 37], ["respiratory pathogens", "DISEASE", 50, 71], ["infections", "DISEASE", 83, 93], ["respiratory tract diseases", "DISEASE", 200, 226], ["respiratory disorders", "DISEASE", 313, 334], ["parainfluenza viruses", "ORGANISM", 9, 30], ["hPIVs", "CANCER", 32, 37], ["tract", "ORGANISM_SUBDIVISION", 212, 217], ["parainfluenza", "SPECIES", 9, 22], ["infants", "SPECIES", 230, 237], ["parainfluenza viruses", "SPECIES", 9, 30], ["parainfluenza viruses (hPIVs)", "PROBLEM", 9, 38], ["common respiratory pathogens", "PROBLEM", 43, 71], ["infections", "PROBLEM", 83, 93], ["acute respiratory tract diseases", "PROBLEM", 194, 226], ["immunocompromised adults", "PROBLEM", 242, 266], ["chronic respiratory disorders", "PROBLEM", 305, 334], ["parainfluenza viruses", "OBSERVATION", 9, 30], ["acute", "OBSERVATION_MODIFIER", 194, 199], ["respiratory tract", "ANATOMY", 200, 217], ["chronic", "OBSERVATION_MODIFIER", 305, 312], ["respiratory disorders", "OBSERVATION", 313, 334]]], ["In non-immune compromised individuals, hPIV infections are typically transient and mild; however, in patients with asthma or COPD, these infections may be associated with severe respiratory symptom exacerbations [4].", [["respiratory", "ANATOMY", 178, 189], ["infections", "DISEASE", 44, 54], ["asthma", "DISEASE", 115, 121], ["COPD", "DISEASE", 125, 129], ["infections", "DISEASE", 137, 147], ["hPIV", "ORGANISM", 39, 43], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["hPIV", "SPECIES", 39, 43], ["non-immune compromised individuals", "PROBLEM", 3, 37], ["hPIV infections", "PROBLEM", 39, 54], ["asthma", "PROBLEM", 115, 121], ["COPD", "PROBLEM", 125, 129], ["these infections", "PROBLEM", 131, 147], ["severe respiratory symptom exacerbations", "PROBLEM", 171, 211], ["non-immune compromised", "OBSERVATION_MODIFIER", 3, 25], ["infections", "OBSERVATION", 44, 54], ["mild", "OBSERVATION_MODIFIER", 83, 87], ["asthma", "OBSERVATION", 115, 121], ["COPD", "OBSERVATION", 125, 129], ["may be associated with", "UNCERTAINTY", 148, 170], ["severe", "OBSERVATION_MODIFIER", 171, 177]]], ["Having in mind increasing number of reports on the potential role of parainfluenza viruses in the exacerbation of chronic airway disorders, we aimed to update the potential readers on the epidemiology, immunology and novel clinical aspects of hPIV infections in asthma and COPD.EpidemiologyAfter respiratory syncytial virus, hPIVs are the second most common causes of acute respiratory tract infections among children aged <5 years, possibly accounting for up to 17% of hospitalizations [5].", [["airway", "ANATOMY", 122, 128], ["respiratory tract", "ANATOMY", 374, 391], ["parainfluenza viruses", "DISEASE", 69, 90], ["airway disorders", "DISEASE", 122, 138], ["infections", "DISEASE", 248, 258], ["asthma", "DISEASE", 262, 268], ["COPD", "DISEASE", 273, 277], ["respiratory syncytial virus", "DISEASE", 296, 323], ["hPIVs", "DISEASE", 325, 330], ["respiratory tract infections", "DISEASE", 374, 402], ["parainfluenza viruses", "ORGANISM", 69, 90], ["airway", "MULTI-TISSUE_STRUCTURE", 122, 128], ["hPIV", "ORGANISM", 243, 247], ["EpidemiologyAfter respiratory syncytial virus", "ORGANISM", 278, 323], ["tract", "ORGANISM_SUBDIVISION", 386, 391], ["children", "ORGANISM", 409, 417], ["parainfluenza", "SPECIES", 69, 82], ["respiratory syncytial virus", "SPECIES", 296, 323], ["children", "SPECIES", 409, 417], ["hPIV", "SPECIES", 243, 247], ["EpidemiologyAfter respiratory syncytial virus", "SPECIES", 278, 323], ["parainfluenza viruses", "PROBLEM", 69, 90], ["chronic airway disorders", "PROBLEM", 114, 138], ["hPIV infections", "PROBLEM", 243, 258], ["asthma", "PROBLEM", 262, 268], ["COPD", "PROBLEM", 273, 277], ["EpidemiologyAfter respiratory syncytial virus", "PROBLEM", 278, 323], ["acute respiratory tract infections", "PROBLEM", 368, 402], ["increasing", "OBSERVATION_MODIFIER", 15, 25], ["number", "OBSERVATION_MODIFIER", 26, 32], ["parainfluenza viruses", "OBSERVATION", 69, 90], ["chronic", "OBSERVATION_MODIFIER", 114, 121], ["airway disorders", "OBSERVATION", 122, 138], ["infections", "OBSERVATION", 248, 258], ["asthma", "OBSERVATION", 262, 268], ["COPD", "OBSERVATION", 273, 277], ["syncytial virus", "OBSERVATION", 308, 323], ["acute", "OBSERVATION_MODIFIER", 368, 373], ["respiratory tract", "ANATOMY", 374, 391]]], ["Although age-specific rates of lower respiratory tract infections vary significantly in different populations, the medical burden of hPIVs is similar to that of RSV infection in children [6].", [["lower respiratory tract", "ANATOMY", 31, 54], ["respiratory tract infections", "DISEASE", 37, 65], ["hPIVs", "DISEASE", 133, 138], ["RSV infection", "DISEASE", 161, 174], ["lower", "ORGANISM", 31, 36], ["respiratory tract", "ORGANISM_SUBDIVISION", 37, 54], ["RSV", "ORGANISM", 161, 164], ["children", "ORGANISM", 178, 186], ["children", "SPECIES", 178, 186], ["RSV", "SPECIES", 161, 164], ["lower respiratory tract infections", "PROBLEM", 31, 65], ["the medical burden of hPIVs", "PROBLEM", 111, 138], ["RSV infection", "PROBLEM", 161, 174], ["lower", "ANATOMY_MODIFIER", 31, 36], ["respiratory tract", "ANATOMY", 37, 54], ["RSV", "OBSERVATION_MODIFIER", 161, 164], ["infection", "OBSERVATION", 165, 174]]], ["Serological surveys have indicated that 60% of the children are infected with hPIV-3 by 2 years of age, and this number increases to up to 80% by 4 years of age [7].", [["children", "ORGANISM", 51, 59], ["hPIV-3", "ORGANISM", 78, 84], ["children", "SPECIES", 51, 59], ["Serological surveys", "TEST", 0, 19], ["infected", "OBSERVATION", 64, 72], ["increases", "OBSERVATION_MODIFIER", 120, 129]]], ["Among adults, most infections manifest as mild upper respiratory tract symptoms; however, more severe diseases may also occur, particularly in older adults and the immunocompromised [1].EpidemiologyAlthough hPIV infections occur throughout the year, several studies have documented distinct temporal trends for hPIV serotypes.", [["upper respiratory tract", "ANATOMY", 47, 70], ["infections", "DISEASE", 19, 29], ["upper respiratory tract symptoms", "DISEASE", 47, 79], ["hPIV infections", "DISEASE", 207, 222], ["upper", "ORGANISM_SUBDIVISION", 47, 52], ["respiratory tract", "ORGANISM_SUBDIVISION", 53, 70], ["hPIV", "SPECIES", 207, 211], ["hPIV", "SPECIES", 311, 315], ["most infections", "PROBLEM", 14, 29], ["mild upper respiratory tract symptoms", "PROBLEM", 42, 79], ["more severe diseases", "PROBLEM", 90, 110], ["hPIV infections", "PROBLEM", 207, 222], ["several studies", "TEST", 250, 265], ["hPIV serotypes", "PROBLEM", 311, 325], ["mild", "OBSERVATION_MODIFIER", 42, 46], ["upper", "ANATOMY_MODIFIER", 47, 52], ["respiratory tract", "ANATOMY", 53, 70], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["diseases", "OBSERVATION", 102, 110], ["infections", "OBSERVATION", 212, 222]]], ["A strong relationship has been observed between hPIV serotypes and specific clinical syndromes, the age of the child and the time of year when the infection occurred [1].", [["infection", "DISEASE", 147, 156], ["hPIV serotypes", "PROBLEM", 48, 62], ["specific clinical syndromes", "PROBLEM", 67, 94], ["the infection", "PROBLEM", 143, 156], ["infection", "OBSERVATION", 147, 156]]], ["The peak seasonal activity for hPIV-1 occurs biennially from late September to December during odd-numbered years.", [["hPIV-1", "GENE_OR_GENE_PRODUCT", 31, 37], ["hPIV", "PROTEIN", 31, 35], ["hPIV-1", "SPECIES", 31, 37]]], ["The hPIV-2 season occurs from October through December, and the peak season for hPIV-3 occurs annually each spring from April to June [8] or May to September in England [9].", [["hPIV", "TEST", 80, 84]]], ["Frost et al. [10] recently described the year-round prevalence of hPIV-4 infections, with peaks in the autumn of odd-numbered years.", [["infections", "DISEASE", 73, 83], ["hPIV-4", "ORGANISM", 66, 72], ["hPIV", "PROBLEM", 66, 70], ["4 infections", "PROBLEM", 71, 83]]], ["Seasonal activity also varied between different years, with higher hPIV-3 activity in years when hPIV-1 was not circulating and conversely, with significantly lower hPIV-3 activity during the years of peak hPIV-1 activity [10].", [["hPIV-3", "GENE_OR_GENE_PRODUCT", 67, 73], ["hPIV-1", "GENE_OR_GENE_PRODUCT", 97, 103], ["hPIV-3", "GENE_OR_GENE_PRODUCT", 165, 171], ["hPIV-1", "GENE_OR_GENE_PRODUCT", 206, 212], ["hPIV", "PROTEIN", 67, 71], ["hPIV", "PROTEIN", 97, 101], ["hPIV", "PROTEIN", 165, 169], ["hPIV-1", "SPECIES", 97, 103], ["Seasonal activity", "PROBLEM", 0, 17], ["higher hPIV", "PROBLEM", 60, 71], ["significantly lower hPIV", "PROBLEM", 145, 169]]], ["These phenomena potentially reflect the heterotypic cross protection of antibodies.Structural organization and viral replicationThe human parainfluenza viruses belong to a diverse group of enveloped single-stranded RNA viruses within the Paramyxoviridae family, a large and expanding group of viruses that includes metapneumovirus and the mumps, measles and respiratory syncytial viruses.", [["parainfluenza viruses", "DISEASE", 138, 159], ["metapneumovirus and the mumps", "DISEASE", 315, 344], ["measles", "DISEASE", 346, 353], ["respiratory syncytial viruses", "DISEASE", 358, 387], ["human", "ORGANISM", 132, 137], ["parainfluenza viruses", "ORGANISM", 138, 159], ["metapneumovirus", "ORGANISM", 315, 330], ["measles", "ORGANISM", 346, 353], ["respiratory syncytial viruses", "ORGANISM", 358, 387], ["antibodies", "PROTEIN", 72, 82], ["human", "SPECIES", 132, 137], ["parainfluenza", "SPECIES", 138, 151], ["human parainfluenza viruses", "SPECIES", 132, 159], ["respiratory syncytial viruses", "SPECIES", 358, 387], ["These phenomena", "PROBLEM", 0, 15], ["the heterotypic cross protection of antibodies", "PROBLEM", 36, 82], ["viral replication", "TREATMENT", 111, 128], ["The human parainfluenza viruses", "PROBLEM", 128, 159], ["stranded RNA viruses", "PROBLEM", 206, 226], ["a large and expanding group of viruses", "PROBLEM", 262, 300], ["metapneumovirus", "PROBLEM", 315, 330], ["the mumps", "PROBLEM", 335, 344], ["measles", "PROBLEM", 346, 353], ["respiratory syncytial viruses", "PROBLEM", 358, 387], ["viral replication", "OBSERVATION", 111, 128], ["parainfluenza viruses", "OBSERVATION", 138, 159], ["large", "OBSERVATION_MODIFIER", 264, 269], ["metapneumovirus", "OBSERVATION", 315, 330], ["syncytial viruses", "OBSERVATION", 370, 387]]], ["Based on genetic and antigenic analyses, hPIVs have been divided into four major subtypes (hPIV-1 to hPIV-4), classified into Respirovirus (hPIV-1 and hPIV-3) and Rubulavirus (hPIV-2 and hPIV-4) genera within the Paramyxovirinae subfamily (Table 1). hPIVs may be phenotypically distinguished from other members of Paramyxoviridae based on neuraminidase expression or the presence of thicker nucleocapsids [1, 11].", [["hPIVs", "GENE_OR_GENE_PRODUCT", 41, 46], ["hPIV-1", "ORGANISM", 91, 97], ["hPIV-4", "ORGANISM", 101, 107], ["Respirovirus", "GENE_OR_GENE_PRODUCT", 126, 138], ["hPIV-1", "ORGANISM", 140, 146], ["hPIV-3", "ORGANISM", 151, 157], ["Rubulavirus", "GENE_OR_GENE_PRODUCT", 163, 174], ["hPIV-2", "ORGANISM", 176, 182], ["hPIV-4", "ORGANISM", 187, 193], ["hPIVs", "GENE_OR_GENE_PRODUCT", 250, 255], ["Paramyxoviridae", "GENE_OR_GENE_PRODUCT", 314, 329], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 339, 352], ["hPIVs", "PROTEIN", 41, 46], ["hPIV", "DNA", 101, 105], ["Paramyxovirinae subfamily", "DNA", 213, 238], ["neuraminidase", "PROTEIN", 339, 352], ["genetic and antigenic analyses", "TEST", 9, 39], ["hPIV", "TEST", 91, 95], ["hPIV", "TEST", 101, 105], ["Respirovirus", "TEST", 126, 138], ["hPIV", "TEST", 140, 144], ["hPIV", "TEST", 151, 155], ["Rubulavirus", "TEST", 163, 174], ["hPIV", "TEST", 176, 180], ["hPIVs", "TREATMENT", 250, 255], ["Paramyxoviridae", "TREATMENT", 314, 329], ["neuraminidase expression", "TREATMENT", 339, 363], ["thicker nucleocapsids", "PROBLEM", 383, 404]]]], "a3c157930997428c8654eb8356bee274984e3ee0": [["The infection caused by the human corona virus COVID-19 (SARS-CoV2) resulted in a worldwide pandemic affecting several million people and causing severe disease and fatality mostly based on virus mediated lung failure [1, 2] .", [["lung", "ANATOMY", 205, 209], ["infection", "DISEASE", 4, 13], ["SARS-CoV2", "DISEASE", 57, 66], ["lung failure", "DISEASE", 205, 217], ["human", "ORGANISM", 28, 33], ["corona virus COVID-19", "ORGANISM", 34, 55], ["SARS-CoV2", "ORGANISM", 57, 66], ["people", "ORGANISM", 127, 133], ["lung", "ORGAN", 205, 209], ["human", "SPECIES", 28, 33], ["corona virus", "SPECIES", 34, 46], ["people", "SPECIES", 127, 133], ["human corona virus COVID-19", "SPECIES", 28, 55], ["The infection", "PROBLEM", 0, 13], ["the human corona virus COVID", "TEST", 24, 52], ["severe disease", "PROBLEM", 146, 160], ["fatality", "PROBLEM", 165, 173], ["virus mediated lung failure", "PROBLEM", 190, 217], ["infection", "OBSERVATION", 4, 13], ["severe", "OBSERVATION_MODIFIER", 146, 152], ["disease", "OBSERVATION", 153, 160], ["lung", "ANATOMY", 205, 209], ["failure", "OBSERVATION", 210, 217]]], ["Thus far, no effective therapy is available and, therefore, contact precautions, hygiene measures, contact tracing, social distancing and quarantine are the methods of choice to control the spread of this infection [3, 4] .", [["infection", "DISEASE", 205, 214], ["effective therapy", "TREATMENT", 13, 30], ["hygiene measures", "TREATMENT", 81, 97], ["contact tracing", "TEST", 99, 114], ["this infection", "PROBLEM", 200, 214]]], ["However, epidemics with respiratory virus such as not only influenza but also human corona viruses are prevalent in the Northern hemisphere over several months during the cold season and then disappear whereas influenza remains prevalent in tropical regions throughout the whole year [5] [6] [7] .", [["respiratory virus", "DISEASE", 24, 41], ["influenza", "DISEASE", 59, 68], ["influenza", "DISEASE", 210, 219], ["human corona viruses", "ORGANISM", 78, 98], ["human", "SPECIES", 78, 83], ["human corona viruses", "SPECIES", 78, 98], ["epidemics", "PROBLEM", 9, 18], ["respiratory virus", "PROBLEM", 24, 41], ["influenza", "PROBLEM", 59, 68], ["human corona viruses", "PROBLEM", 78, 98], ["influenza", "PROBLEM", 210, 219], ["respiratory virus", "OBSERVATION", 24, 41], ["corona", "OBSERVATION_MODIFIER", 84, 90], ["viruses", "OBSERVATION", 91, 98]]], ["The reasons for this decline are still incompletely understood.", [["this decline", "PROBLEM", 16, 28]]], ["We thus questioned whether or not the COVID-19 pandemic will be in part slowed down by the change from the cold to the warm seasons in the Northern hemisphere.", [["the COVID", "TEST", 34, 43], ["warm", "OBSERVATION", 119, 123], ["Northern hemisphere", "ANATOMY", 139, 158]]]], "PMC6880008": [["IntroductionThe West African outbreak of Ebola Virus Disease (EVD) of 2014-16 was the most devastating outbreak of the virus on record with more than 28,000 cases and 11,000 deaths (World Health Organization, 2016).", [["Ebola Virus Disease", "DISEASE", 41, 60], ["EVD", "DISEASE", 62, 65], ["deaths", "DISEASE", 174, 180], ["Ebola Virus", "ORGANISM", 41, 52], ["Ebola Virus", "SPECIES", 41, 52], ["Ebola Virus", "SPECIES", 41, 52], ["Ebola Virus Disease", "PROBLEM", 41, 60], ["EVD", "TEST", 62, 65], ["the virus", "PROBLEM", 115, 124], ["Ebola Virus Disease", "OBSERVATION", 41, 60], ["devastating", "OBSERVATION_MODIFIER", 91, 102]]], ["It is believed that the outbreak began with a single case in a boy in rural Guinea in late 2013, but due to a slow initial response (Gr\u00e9pin, 2015; International Ebola Response Team et al., 2016), the virus spread quickly to both rural and urban communities throughout Guinea, Liberia, and Sierra Leone.", [["Ebola", "DISEASE", 161, 166], ["a slow initial response", "PROBLEM", 108, 131], ["the virus spread", "PROBLEM", 196, 212], ["Sierra Leone", "OBSERVATION", 289, 301]]], ["While the outbreak was largely contained by early 2015, it was not before it had significant economic and social effects in the heavily affected countries (Bowles, Hjort, Melvin, & Werker, 2015; World Health Organization, 2016).IntroductionMany lessons have been learned about EVD as a result of the West African outbreak, including a much better understanding of the zoonotic origins of the disease and the development of vaccines against the virus.", [["EVD", "TREATMENT", 277, 280], ["the disease", "PROBLEM", 388, 399], ["vaccines", "TREATMENT", 423, 431], ["the virus", "PROBLEM", 440, 449], ["significant", "OBSERVATION_MODIFIER", 81, 92], ["economic", "OBSERVATION_MODIFIER", 93, 101], ["social effects", "OBSERVATION", 106, 120], ["disease", "OBSERVATION", 392, 399]]], ["But while biology may help to explain why EVD emerged in Guinea, it is ultimately the social, behavioral, and environmental factors that explain why outbreaks spread and become epidemics (Heymann, 2005).", [["EVD", "DISEASE", 42, 45], ["EVD", "PROBLEM", 42, 45]]], ["Ebola has been described as a \u201cdisease of social intimacy\u201d, in that it is mainly transmitted from infected patients to others through intimate social interactions (Richards et al., 2015): to loved ones who are tasked for caring for the sick, to front line health workers that have been tasked with saving those fighting for their lives, and to community members when tasked with burying the remains of those that they have lost.", [["Ebola", "DISEASE", 0, 5], ["Ebola", "ORGANISM", 0, 5], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115]]], ["Poverty has also been implicated as an important determinant of EVD (Fallah, Skrip, Gertler, Yamin, & Galvani, 2015).", [["Poverty", "DISEASE", 0, 7]]], ["However, many factors likely contributed to the transmission of the virus in West Africa and to date there has been little formal evaluation of these relationships.", [["the virus", "PROBLEM", 64, 73]]], ["Since the West African outbreak, three Ebola outbreaks have already been reported in the Democratic Republic of the Congo (DRC), including one outbreak that at the time of the writing of this article had already become the second largest outbreak of the disease in history.", [["Ebola", "DISEASE", 39, 44], ["Ebola", "ORGANISM", 39, 44], ["largest", "OBSERVATION_MODIFIER", 230, 237], ["disease", "OBSERVATION", 254, 261]]], ["A better understanding of the determinants of EVD exposure is therefore important not just to understand why the outbreak spread so widely and so quickly throughout West Africa but also from the perspective of preparing for future epidemics (Phua & Lee, 2005).IntroductionA sizeable literature has established that SES, whether it is measured as wealth, income, or related indicators, is an important determinant of health (Feinstein, 1993; Marmot, 2007a).", [["EVD exposure", "TREATMENT", 46, 58]]], ["In almost all cases, people or populations of higher SES enjoy longer and healthier lives, both through lower levels of exposure to risk factors and better ability to recover when ill.", [["people", "ORGANISM", 21, 27], ["people", "SPECIES", 21, 27], ["risk factors", "PROBLEM", 132, 144]]], ["Although the bulk of the literature has focused on high-income countries, similar associations have also been documented in low and middle-income countries (LMICs), including countries in Africa (Amouzou & Hill, 2004; Marmot, 2007b).", [["bulk", "OBSERVATION_MODIFIER", 13, 17]]], ["Social epidemiologists usually distinguish between diseases associated with relative poverty, which has to do with a person's comparative economic position in society, and absolute poverty, which has to do with a person being deprived of basic needs such as running water, sanitation systems, and adequate nutrition (Marmot, 2005).", [["person", "SPECIES", 117, 123], ["person", "SPECIES", 213, 219], ["sanitation systems", "TREATMENT", 273, 291]]], ["Infectious diseases, especially those that contribute to higher rates of child mortality in LMICs, and which help to explain much of the gap in life expectancy observed between high-income and LMICs, are largely believed to be associated with conditions of absolute poverty (Marmot, 2005).", [["Infectious diseases", "DISEASE", 0, 19]]], ["Non-communicable diseases (NCDs), which are believed to be largely caused by behavioral factors, also form along SES gradients such that lower SES groups also develop a higher burden of disease relative to higher SES groups.", [["Non-communicable diseases", "DISEASE", 0, 25], ["NCDs", "DISEASE", 27, 31], ["Non-communicable diseases", "PROBLEM", 0, 25], ["behavioral factors", "PROBLEM", 77, 95], ["lower SES groups", "PROBLEM", 137, 153], ["a higher burden of disease", "PROBLEM", 167, 193], ["believed to be", "UNCERTAINTY", 44, 58], ["higher", "OBSERVATION_MODIFIER", 169, 175], ["burden", "OBSERVATION_MODIFIER", 176, 182], ["disease", "OBSERVATION", 186, 193]]], ["By contrast, these health gradients are theorized to form as a consequence of greater knowledge, prestige and power being concentrated among higher SES groups allowing them to reduce their exposure to risk factors and to gain access to more effective health services when ill (Link & Phelan, 1995).IntroductionHowever, less is known about the association between SES and the so called emerging infectious diseases (EIDs) with epidemic potential, including EVD but also Zika, SARS, and MERS.", [["infectious diseases", "DISEASE", 394, 413], ["EIDs", "DISEASE", 415, 419], ["SARS", "DISEASE", 475, 479], ["EVD", "PROBLEM", 456, 459], ["Zika", "PROBLEM", 469, 473], ["SARS", "PROBLEM", 475, 479], ["infectious", "OBSERVATION", 394, 404]]], ["At the country level, poorer countries are generally thought to have higher rates of these diseases.", [["these diseases", "PROBLEM", 85, 99], ["diseases", "OBSERVATION", 91, 99]]], ["EVD and Zika seem to follow this pattern as they first emerged in low-income countries (DRC and Uganda respectively) thus supporting the view that absolute poverty may be an important determinant of exposure to these viruses.", [["EVD", "TREATMENT", 0, 3], ["these viruses", "PROBLEM", 211, 224], ["viruses", "OBSERVATION", 217, 224]]], ["However, SARS and MERS were both first detected in relatively well-off countries, Hong Kong and Saudi Arabia respectively, suggesting a more complex relationship may exist between SES and infectious disease exposure the population level.IntroductionOne pathway that may lead to increased exposure to these diseases is proximity to the sources of the viruses.", [["SARS", "DISEASE", 9, 13], ["SARS", "PROBLEM", 9, 13], ["MERS", "PROBLEM", 18, 22], ["infectious disease exposure", "PROBLEM", 188, 215], ["increased exposure", "PROBLEM", 278, 296], ["these diseases", "PROBLEM", 300, 314], ["the viruses", "PROBLEM", 346, 357], ["infectious", "OBSERVATION", 188, 198], ["diseases", "OBSERVATION", 306, 314], ["viruses", "OBSERVATION", 350, 357]]], ["In the case of EVD, bats are the likely zoonotic reservoirs, which are common in sparsely populated, forested areas of Africa (Pigott et al., 2014).", [["EVD", "TREATMENT", 15, 18], ["EVD", "OBSERVATION", 15, 18], ["likely", "UNCERTAINTY", 33, 39], ["zoonotic", "OBSERVATION_MODIFIER", 40, 48], ["reservoirs", "OBSERVATION", 49, 59], ["common", "OBSERVATION_MODIFIER", 71, 77], ["forested", "OBSERVATION_MODIFIER", 101, 109], ["areas", "OBSERVATION_MODIFIER", 110, 115]]], ["For SARS, civets and bats have been identified as likely reservoirs of the virus (Shi & Hu, 2008).", [["SARS", "DISEASE", 4, 8], ["SARS", "PROBLEM", 4, 8], ["civets", "TREATMENT", 10, 16], ["the virus", "PROBLEM", 71, 80]]], ["For MERS, bats and camels have been identified as zoonotic reservoirs (Mohd, Al-Tawfiq, & Memish, 2016).", [["bats", "ORGANISM", 10, 14], ["camels", "ORGANISM", 19, 25], ["MERS", "PROBLEM", 4, 8]]], ["Therefore, for EVD and other EIDs, exposure is likely related to ecological factors, such as vegetation, elevation, temperature that bring communities into contact with the zoonotic reservoirs and vectors of the viruses.", [["EVD", "TREATMENT", 15, 18], ["ecological factors", "PROBLEM", 65, 83], ["vegetation", "PROBLEM", 93, 103], ["elevation", "PROBLEM", 105, 114], ["likely related to", "UNCERTAINTY", 47, 64], ["vegetation", "OBSERVATION", 93, 103], ["elevation", "OBSERVATION_MODIFIER", 105, 114], ["viruses", "OBSERVATION", 212, 219]]], ["For EVD, exposure would likely be higher in populations and communities located poorer parts of Africa.", [["EVD", "PROBLEM", 4, 7], ["would likely be", "UNCERTAINTY", 18, 33], ["higher", "OBSERVATION_MODIFIER", 34, 40]]], ["We illustrate this pathway, as well as additional pathways we discuss below in a conceptual model to help conceptualize how various SES determinants may lead to EVD exposure in Fig. 1.", [["EVD", "DISEASE", 161, 164], ["EVD exposure in Fig", "PROBLEM", 161, 180]]], ["Increased exposure may also be due to higher rates of international travel among some relatively higher income countries, or some communities (Bogoch et al., 2014).", [["Increased exposure", "PROBLEM", 0, 18], ["may also be due to", "UNCERTAINTY", 19, 37]]], ["This explanation may help to explain why EVD eventually spread to countries in Europe and the United States and may have played some role in the spread of the outbreak within West Africa, including the spread to Nigeria.IntroductionA number of studies have also explored determinants of EIDs at the sub-national level.", [["EIDs", "DISEASE", 287, 291], ["EVD", "PROBLEM", 41, 44], ["studies", "TEST", 244, 251]]], ["For example, a study from Brazil found that cases of Zika were more common in neighborhoods in Rio that were less likely to be connected to the municipal water source (Fuller et al., 2017).", [["Zika", "DISEASE", 53, 57], ["a study", "TEST", 13, 20], ["Zika", "PROBLEM", 53, 57]]], ["A study of the spread of SARS in Hong Kong found a negative relationship between income and incidence rates across estates in the special administrative region (Bucchianeri, 2010).", [["SARS", "DISEASE", 25, 29], ["A study", "TEST", 0, 7]]], ["We posit that these associations may be due to access to infrastructure or compositional effects, in which lower wealth communities due to poorer infrastructure and overcrowding within urban centers may be at higher risk of being exposed to disease.", [["poorer infrastructure", "PROBLEM", 139, 160], ["disease", "PROBLEM", 241, 248], ["poorer", "OBSERVATION_MODIFIER", 139, 145], ["infrastructure", "OBSERVATION", 146, 160]]], ["In the case of EVD in West Africa, a number of studies have found evidence to support these associations.", [["EVD", "DISEASE", 15, 18], ["EVD", "TREATMENT", 15, 18], ["EVD", "OBSERVATION", 15, 18]]], ["For example, one study in Montserrado County, a largely urban county where the Liberian capital of Monrovia is located, found that infected individuals from low SES areas were more likely to have more contacts and were more likely to have been linked to secondary cases of EVD (Fallah et al., 2015).", [["EVD", "DISEASE", 273, 276], ["one study", "TEST", 13, 22], ["infected individuals from low SES areas", "PROBLEM", 131, 170], ["EVD", "PROBLEM", 273, 276], ["infected", "OBSERVATION", 131, 139], ["more likely", "UNCERTAINTY", 176, 187], ["EVD", "OBSERVATION", 273, 276]]], ["Another study that classified sub-districts in Liberia in terms of their social vulnerability found the sub-districts with the highest measures of social vulnerability also had the highest number of reported cases of EVD (Stanturf, Goodrick, Warren, Charnley, & Stegall, 2015).", [["EVD", "DISEASE", 217, 220], ["Another study", "TEST", 0, 13], ["sub", "OBSERVATION_MODIFIER", 30, 33]]], ["However, the capital Montserrado county, which also scored low in terms of social vulnerability, was an exception as it also had a large number of cases, perhaps due to its larger urban population.", [["capital", "OBSERVATION_MODIFIER", 13, 20], ["low", "OBSERVATION_MODIFIER", 59, 62], ["large", "OBSERVATION_MODIFIER", 131, 136], ["larger", "OBSERVATION_MODIFIER", 173, 179]]], ["In addition, another study that compared measures of population density and wealth index found that both were positively associated with the transmission rate of the virus at the district-level across West Africa (Krauer, Gsteiger, Low, Hansen, & Althaus, 2016).", [["another study", "TEST", 13, 26], ["population density", "PROBLEM", 53, 71], ["wealth index", "TEST", 76, 88], ["the virus", "PROBLEM", 162, 171], ["population", "OBSERVATION_MODIFIER", 53, 63], ["density", "OBSERVATION", 64, 71]]], ["Similarly, another study found that population density and education, both measured at the regional-level, were also both positively associated with epidemic size and spread across West Africa (Valeri et al., 2016).IntroductionOn the other hand, studies have also shown that communities played an important role in the prevention, transmission and response to the outbreak effectively containing EVD in spite of resource constraints (Abramowitz et al., 2015).", [["another study", "TEST", 11, 24], ["epidemic size", "PROBLEM", 149, 162], ["EVD", "TREATMENT", 396, 399], ["population", "OBSERVATION_MODIFIER", 36, 46], ["density", "OBSERVATION", 47, 54], ["epidemic", "OBSERVATION_MODIFIER", 149, 157], ["size", "OBSERVATION_MODIFIER", 158, 162], ["spread", "OBSERVATION_MODIFIER", 167, 173]]], ["The availability of health infrastructure at the community-level was associated with the amplification of EVD but also played an essential role in containing the outbreak (Chowell & Nishiura, 2014; International Ebola Response Team et al., 2016).", [["Ebola", "DISEASE", 212, 217], ["EVD", "TREATMENT", 106, 109]]], ["Many communities adopted innovative coping strategies to help contain the outbreak in Liberia (Abramowitz et al., 2015).", [["innovative coping strategies", "TREATMENT", 25, 53]]], ["Therefore, community-level factors also likely influenced why some people living in certain areas may have had more or less exposure to the virus, however, it is less clear how these factors would vary along SES lines.IntroductionAnother strand of the literature has investigated how individual or household-level risk factors were associated with exposure to EVD during the West African outbreak.", [["EVD", "DISEASE", 360, 363], ["people", "ORGANISM", 67, 73], ["SES lines", "CELL", 208, 217], ["SES lines", "CELL_LINE", 208, 217], ["people", "SPECIES", 67, 73], ["the virus", "PROBLEM", 136, 145], ["EVD", "TREATMENT", 360, 363]]], ["Early in the outbreak, funerals and transmission to health workers were important sources of exposure to EVD, but their importance declined markedly over time, likely due to public health efforts to improve safe burial practices and provide access to personal protective equipment (International Ebola Response Team et al., 2016).", [["EVD", "TREATMENT", 105, 108], ["safe burial practices", "TREATMENT", 207, 228]]], ["Studies have also shown that the bulk of reported exposures occurred from one family member to another, or from a close friend or neighbor (International Ebola Response Team et al., 2016).", [["Ebola", "DISEASE", 154, 159]]], ["Therefore, people living in larger households might be expected to be more likely to be exposed to the virus, which is also likely associated with lower SES.", [["people", "ORGANISM", 11, 17], ["people", "SPECIES", 11, 17], ["the virus", "PROBLEM", 99, 108], ["virus", "OBSERVATION", 103, 108]]], ["Other individual behaviors may have also influenced exposure to the illness.", [["illness", "DISEASE", 68, 75], ["the illness", "PROBLEM", 64, 75]]], ["For example, people in Monrovia with higher trust in government were more likely use public health services during and immediately after the peak of the outbreak and were more likely to comply with public health directives (Blair, Morse, & Tsai, 2017; Morse, Gr\u00e9pin, Blair, & Tsai, 2016).", [["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19]]], ["However, it is unclear how these determinants are likely to be associated with SES.IntroductionThere is evidence that occupation may have also led some people to be more or less exposed the virus.", [["people", "ORGANISM", 152, 158], ["people", "SPECIES", 152, 158], ["the virus", "PROBLEM", 186, 195], ["virus", "OBSERVATION", 190, 195]]], ["For example, health workers represented a disproportionately large share of total cases in the West African outbreak, likely due to increased contact with EVD patients (Evans, Goldstein, & Popova, 2015).", [["EVD", "DISEASE", 155, 158], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["likely due to", "UNCERTAINTY", 118, 131]]], ["Migration, especially migration from rural to urban areas, has also been implicated in the transmission of the virus and was also likely linked to occupation (Alexander et al., 2015).", [["Migration", "PROBLEM", 0, 9], ["migration", "OBSERVATION_MODIFIER", 22, 31], ["virus", "OBSERVATION", 111, 116]]], ["Some of these occupations might be associated with higher SES groups while others may be associated with lower SES, but occupation is an important variable that should be explored as a determinant of exposure to the virus.IntroductionGender, which is also likely confounded by SES, also likely played an important role in the transmission of the outbreak since gendered roles, for example the fact that women were more likely to provide care to sick household members than men, likely shaped exposure and care seeking patterns (Harman, 2016).", [["women", "ORGANISM", 403, 408], ["men", "ORGANISM", 473, 476], ["women", "SPECIES", 403, 408], ["men", "SPECIES", 473, 476], ["the virus", "PROBLEM", 212, 221]]], ["However, there is less evidence available to substantiate gendered differences in either exposure or transmission according to gender, during previous outbreaks of EVD, mostly due to limited ability of gender disaggregated data on EVD cases (Nkangu, Olatunde, & Yaya, 2017).", [["EVD", "DISEASE", 164, 167], ["EVD", "TREATMENT", 164, 167], ["EVD cases", "TEST", 231, 240]]], ["However, it may be an important variable to investigate in the context of EVD exposure.IntroductionThere is also evidence that we might expect the relationship between SES and disease transmission to change as epidemics spread or mature.", [["EVD exposure", "TREATMENT", 74, 86], ["EVD", "OBSERVATION", 74, 77]]], ["Similar changes have been observed, for example, in the SES determinants of HIV since it first recognized approximately 40 years ago.", [["HIV", "ORGANISM", 76, 79], ["HIV", "SPECIES", 76, 79], ["HIV", "SPECIES", 76, 79], ["HIV", "PROBLEM", 76, 79]]], ["While early studies of risk factors of HIV in sub-Saharan Africa initially found a positive relationship between wealth and education and HIV (Fox, 2012; Hargreaves et al., 2002), over time, the relationship appears to have changed as the epidemic matured (Gr\u00e9pin & Bharadwaj, 2015; Hargreaves et al., 2008; Parkhurst, 2010).", [["HIV", "DISEASE", 39, 42], ["HIV", "SPECIES", 39, 42], ["HIV", "SPECIES", 39, 42], ["HIV", "SPECIES", 138, 141], ["HIV", "PROBLEM", 39, 42]]], ["There is also evidence of a \u201ccrossover\u201d in the relationship between SES and mortality outcomes during the Spanish Flu outbreak in Norway during the early 20th century (Mamelund, 2018).", [["Flu", "CHEMICAL", 114, 117]]], ["Taken together, these studies suggest that the inverse relationship between SES and infectious disease outcomes in outbreaks should not always be taken as a given and that the relationship may actually be a dynamic one.", [["these studies", "TEST", 16, 29], ["the inverse relationship between SES and infectious disease outcomes", "PROBLEM", 43, 111], ["infectious", "OBSERVATION_MODIFIER", 84, 94]]], ["As our data were collected towards the end of the outbreak, these dynamic relationships may shape the patterns we observe in our data.IntroductionA common challenge plaguing all studies to date of EVD in West Africa is the lack of population-based data on either individuals exposed to EVD or with the virus as well as the risk factors likely associated with EVD.", [["EVD", "DISEASE", 197, 200], ["EVD", "DISEASE", 286, 289], ["EVD", "DISEASE", 359, 362], ["our data", "TEST", 3, 11], ["all studies", "TEST", 174, 185], ["EVD", "TREATMENT", 197, 200], ["EVD", "TREATMENT", 286, 289], ["the virus", "PROBLEM", 298, 307], ["EVD", "PROBLEM", 359, 362]]], ["Previous studies were limited to patient-level data that was collected on cases during the outbreak, but which were only collected from people with the diseases and only collected very limited individual-level data on SES.", [["patient", "ORGANISM", 33, 40], ["people", "ORGANISM", 136, 142], ["patient", "SPECIES", 33, 40], ["people", "SPECIES", 136, 142], ["Previous studies", "TEST", 0, 16], ["patient-level data", "TEST", 33, 51], ["the diseases", "PROBLEM", 148, 160], ["diseases", "OBSERVATION", 152, 160]]], ["In addition, data from patient-level databases have not been made widely available to the research community, making it challenging to even use those data to study the socio-economic determinants of EVD (Helleringer, Gr\u00e9pin, & Noymer, 2015).", [["EVD", "DISEASE", 199, 202], ["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30], ["data from patient-level databases", "TEST", 13, 46], ["EVD", "PROBLEM", 199, 202]]], ["Another common challenge that faced previous studies was the lack of data on either income or wealth of individuals exposed to EVD, and therefore either had to rely upon geographic level estimates of wealth, which could mask important differences in relative wealth of individuals even within absolutely poor areas (de Alencar Ximenes et al., 2009).", [["previous studies", "TEST", 36, 52], ["EVD", "TREATMENT", 127, 130]]], ["Even if commonly used measures of household SES, such as the wealth index, were available on patients, such measures are themselves only relative measures based on distributions in a given country, which could mask important differences in absolute wealth that may exists across countries (Poirier, Grignon, Gr\u00e9pin, & Dion, 2018).IntroductionIn an attempt to address the gap in the literature, this paper explores the distribution of exposure to EVD during the outbreak in West Africa relative to individual, household, and community measures of SES.", [["EVD", "DISEASE", 446, 449], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["IntroductionIn", "TREATMENT", 330, 344], ["EVD", "TREATMENT", 446, 449]]], ["We use a measure of EVD exposure that is different than those explored in previous studies, namely whether or not an individual knew a close friend or family member who were infected by Ebola, which was collected in nationally representative public opinion polls conducted in Liberia and Sierra Leone in early 2015.", [["Ebola", "DISEASE", 186, 191], ["Ebola", "ORGANISM", 186, 191], ["EVD exposure", "TREATMENT", 20, 32], ["previous studies", "TEST", 74, 90]]], ["The findings of this study will hopefully be able to contribute to planning against future outbreaks of EVD and potentially inform ongoing outbreaks as well.Data ::: Material and methodsData on exposure to EVD, individual, household, and community characteristics were all drawn from the 6th wave of the Afrobarometer survey, a nationally representative household survey of public attitudes towards governance, economic and other issues that has been conducted in more than 30 African countries since 1999 (\u201cAfrobarometer,\u201d 2016).", [["EVD", "DISEASE", 104, 107], ["this study", "TEST", 16, 26], ["EVD", "TREATMENT", 104, 107], ["EVD", "TREATMENT", 206, 209]]], ["Afrobarometer uses a clustered, stratified, multi-stage proportion probability sampling procedure that is designed to generate samples that are nationally representative of voting age citizens.", [["multi-stage proportion probability sampling procedure", "TREATMENT", 44, 97]]], ["Sampling units are first randomly selected from national surveys, usually censuses, and then within sampling units, households are randomly selected for participation into the survey.", [["Sampling units", "TREATMENT", 0, 14]]], ["In the 6th round, Afrobarometer interviewed 1199 respondents in Liberia and 1191 respondents in Sierra Leone, for a total of 2390 respondents.Data ::: Material and methodsSurveys had been planned for all three of the heavily affected countries prior to the Ebola outbreak, but were not fielded until the outbreaks had largely been controlled in 2015.", [["Ebola", "DISEASE", 257, 262], ["methodsSurveys", "TEST", 164, 178], ["the Ebola outbreak", "PROBLEM", 253, 271]]], ["In Sierra Leone and Liberia, additional questions were added to the survey to ask respondents about their experiences during the Ebola outbreak.", [["Ebola", "DISEASE", 129, 134], ["Ebola", "ORGANISM", 129, 134]]], ["Specifically, in both countries the survey asked respondents \u201cDo you know a close friend or relative who was infected with Ebola?\u201d with yes, no, refused, and don't know as potential answers.", [["Ebola", "DISEASE", 123, 128], ["Ebola", "ORGANISM", 123, 128]]], ["Regardless of their answer the first question, the survey then also asked \u201cDo you know a close friend who died of Ebola?\u201d with the same set of potential answers.", [["Ebola", "DISEASE", 114, 119], ["Ebola", "ORGANISM", 114, 119]]], ["Similar questions were not included in Guinea and thus data from that country were not included in this study.", [["this study", "TEST", 99, 109]]], ["Field dates for the survey were May 6-22, 2015 in Liberia and May 22- June 10, 2015 in Sierra Leone.", [["the survey", "TEST", 16, 26]]], ["By May 6, 2015 in Liberia almost 98% of eventual cases were already reported (10,564 of 10,675) while by May 27, 2015 in Sierra Leone almost 90% of eventual cases had already been reported (12,706 of 14,124) therefore these represent time periods towards the tail end of the outbreaks in both countries.", [["Sierra Leone", "TEST", 121, 133]]], ["We acknowledge that this measure of exposure to the virus is less than ideal for the broad measurement of EVD exposure.", [["the virus", "PROBLEM", 48, 57], ["EVD exposure", "TREATMENT", 106, 118], ["virus", "OBSERVATION", 52, 57], ["EVD", "OBSERVATION", 106, 109]]], ["For example, the survey does not ask how many people the respondent knew with the virus, or of cases of people who are not considered close friends or family members, or ask questions on network size, all which could allow for network-based modeling or the calculation of exposure in additional groups of the population.", [["people", "ORGANISM", 46, 52], ["people", "ORGANISM", 104, 110], ["network", "MULTI-TISSUE_STRUCTURE", 187, 194], ["people", "SPECIES", 46, 52], ["people", "SPECIES", 104, 110]]], ["We believe, however, that nonetheless the measure is useful for an exploration of the determinants of EVD the population level given that the question was asked in the same way across areas.Data ::: Material and methodsIndividual-level characteristics drawn from the survey included the age of the respondent, whether the respondent was male or female, and the level of education completed (no formal education, some primary education, some secondary education, and some post-secondary education).", [["an exploration", "TEST", 64, 78], ["EVD the population level", "TEST", 102, 126]]], ["There were 15 second-level administrative units in Liberia and 5 second-level administrative units in Sierra Leone.", [["Liberia", "TREATMENT", 51, 58]]], ["We refer to these as regions in the rest of the paper.MethodsDependent variable.", [["variable", "OBSERVATION_MODIFIER", 71, 79]]], ["We defined two EVD exposure variables, both binary variables, which were defined as 1 if the survey respondent reported knowing one or more close friends or family members who had Ebola or 0 otherwise, and the second which was coded as 1 if the respondent knew a friend who died of Ebola or 0 otherwise.MethodsIndependent variables.", [["Ebola", "DISEASE", 180, 185], ["Ebola", "DISEASE", 282, 287], ["Ebola", "ORGANISM", 282, 287], ["two EVD exposure variables", "PROBLEM", 11, 37], ["Ebola", "PROBLEM", 282, 287], ["two", "OBSERVATION_MODIFIER", 11, 14], ["EVD", "OBSERVATION", 15, 18]]], ["We constructed two measures of wealth-related SES, one at the household-level, and the other at the community-level, using principal component analysis (PCA) of available assets or resources.", [["principal component analysis", "TEST", 123, 151]]], ["At the household-level, the wealth index was built based on ownership of the following assets or goods: shelter type, roofing material, water source, toilet location, radio, television, vehicle, mobile phone, receive remittance, always have food, always have water, always have medications, always have fuel, and always have cash.", [["the wealth index", "TEST", 24, 40], ["medications", "TREATMENT", 278, 289]]], ["We first calculated the wealth index using pooled data from all households in both Sierra Leone and Liberia after ensuring all data were coded uniformly and then calculated the wealth index quintiles for the full sample as well as for country-specific samples.", [["samples", "ANATOMY", 252, 259], ["pooled data", "TEST", 43, 54]]], ["As a robustness check, a household index was also created using a weighted average approach after selecting variables using Cronbach's alpha and item-response correlation (Anderson, 2012) but since the estimates were similar we use the measures of SES constructed PCA methodology.", [["a robustness check", "TEST", 3, 21], ["a household index", "TEST", 23, 40], ["a weighted average approach", "TREATMENT", 64, 91], ["Cronbach's alpha", "TEST", 124, 140]]], ["In addition, to wealth, we also examined the relationship between educational attainment and Ebola exposure at an individual and community level.", [["Ebola", "DISEASE", 93, 98], ["Ebola", "ORGANISM", 93, 98], ["Ebola exposure", "PROBLEM", 93, 107]]], ["Community-level education is measured by taking the average education level in the province or county and dividing into three groups of equivalent size.MethodsWe also adjusted models for demographics (urban residence, age of the respondent, the number of adults in the respondent's household, and gender of the respondent) as well as the region of the household.", [["equivalent", "OBSERVATION_MODIFIER", 136, 146], ["size", "OBSERVATION_MODIFIER", 147, 151]]], ["Given that the size of the units may vary across countries, we include one specification that includes dummy variables to control for these regions, and one that does not.", [["size", "OBSERVATION_MODIFIER", 15, 19]]], ["The main results are based on logistic regression using STATA 14 (College Station, TX, USA), using survey weights, population-weighted post-stratification across countries, and jackknife variance estimation.", [["survey weights", "TEST", 99, 113], ["jackknife variance estimation", "TEST", 177, 206], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["The logistic regressions were run on both the full-sample with data pooled across both countries and then separately for each country individually.ResultsThe summary statistics for our sample are presented in Table 1, both for the full sample as well as for Liberia and Sierra Leone separately.", [["The logistic regressions", "PROBLEM", 0, 24]]], ["Overall, approximately 41% of the respondents in the pooled sample knew a close friend or family member who had been infected with Ebola and only slightly lower percentage reported knowing a close friend who had died of Ebola (38%).", [["Ebola", "DISEASE", 131, 136], ["Ebola", "DISEASE", 220, 225], ["Ebola", "ORGANISM", 131, 136], ["Ebola", "ORGANISM", 220, 225], ["Ebola", "PROBLEM", 220, 225]]], ["A slightly higher percentage of people had been exposed to cases of Ebola in Liberia than in Sierra Leone.", [["Ebola", "DISEASE", 68, 73], ["people", "ORGANISM", 32, 38], ["Ebola", "ORGANISM", 68, 73], ["people", "SPECIES", 32, 38], ["Ebola", "PROBLEM", 68, 73], ["slightly", "OBSERVATION_MODIFIER", 2, 10], ["higher", "OBSERVATION_MODIFIER", 11, 17], ["percentage", "OBSERVATION_MODIFIER", 18, 28], ["Ebola", "OBSERVATION", 68, 73]]], ["The sample was well distributed in terms of ages, but was slightly older in Sierra Leone.", [["The sample", "TEST", 0, 10], ["slightly", "OBSERVATION_MODIFIER", 58, 66], ["Sierra Leone", "OBSERVATION", 76, 88]]], ["About half of the sample had more than a primary education, but the Liberian sample was slightly more educated than in Sierra Leone.", [["the Liberian sample", "TEST", 64, 83]]], ["Households in both countries were large (mean 6.5\u20136.7 adults per household).", [["large", "OBSERVATION_MODIFIER", 34, 39]]], ["Based on the full-sample pooled common asset score, we find that households in both countries were similar in terms of overall wealth, but that communities in Liberia fared better in terms of access to community-level resources than in Sierra Leone.ResultsIn Table 2, we present our regression results which explore the determinants of Ebola exposure along individual, household, and community lines.", [["Ebola", "DISEASE", 336, 341], ["Ebola", "ORGANISM", 336, 341], ["Ebola exposure", "PROBLEM", 336, 350], ["community lines", "OBSERVATION", 384, 399]]], ["The dependent variable in all of the specifications is a binary variable reporting knowing at least one close friend or family member with Ebola and the models are all estimated using logistic regression.", [["Ebola", "DISEASE", 139, 144], ["Ebola", "ORGANISM", 139, 144], ["dependent", "OBSERVATION_MODIFIER", 4, 13], ["variable", "OBSERVATION_MODIFIER", 14, 22]]], ["The first set of columns correspond to the results for the pooled sample, while the second and third sets of columns present the same analysis for Sierra Leone and Liberia separately.", [["the pooled sample", "TEST", 55, 72]]], ["In columns 1,4, and 7, we regress knowing a close friend or family member with Ebola with individual and household-level factors alone.", [["Ebola", "DISEASE", 79, 84], ["Ebola", "ORGANISM", 79, 84]]], ["In columns 2, 5, and 8 we add community-level factors while in the last set columns in each set we also control for region-level fixed effects.ResultsIn the full sample, we find that after controlling for all other variables, individual-level education as well as an indicator that the household lives in an urban area are both positively and significantly associated with knowing a close friend or family member with Ebola.", [["Ebola", "DISEASE", 418, 423], ["Ebola", "ORGANISM", 418, 423], ["community-level factors", "TREATMENT", 30, 53], ["the last set columns", "TREATMENT", 63, 83], ["region-level fixed effects", "PROBLEM", 116, 142]]], ["When we use the same specification in the country-specific models, controlling for all other variables, we find that the individual-level educational effect is only significant in Sierra Leone and the urban effect is only significant in Liberia, although the patterns observed were consistent across countries, but were just not significant.", [["significant", "OBSERVATION_MODIFIER", 222, 233]]], ["We also find that the pooled sample masks important differences in the association between household wealth and exposure at the country-level.", [["the pooled sample masks", "TREATMENT", 18, 41]]], ["While there is no measurable effect in the pooled sample, after controlling for other variables, in Sierra Leone, higher wealth index quintile households were more likely to report knowing a close friend or family member with Ebola, while in Liberia we get the opposite finding with higher SES households less likely to report knowing someone with Ebola.", [["Ebola", "DISEASE", 226, 231], ["Ebola", "DISEASE", 348, 353], ["Ebola", "ORGANISM", 226, 231], ["Ebola", "ORGANISM", 348, 353], ["measurable effect", "PROBLEM", 18, 35], ["the pooled sample", "TEST", 39, 56], ["no", "UNCERTAINTY", 15, 17], ["measurable", "OBSERVATION_MODIFIER", 18, 28], ["effect", "OBSERVATION_MODIFIER", 29, 35]]], ["Whether or not the respondent was male or the number of adults in the household had little impact on exposure in any sample.", [["adults", "ORGANISM", 56, 62]]], ["Overall age had little impact, with the exception of older respondents in Liberia being more likely to report knowing someone with Ebola.ResultsWe then explore whether controlling for community and region-level factors influence these relationships by adding the average educational levels and socio-economic status measured at the community-levels.", [["Ebola", "DISEASE", 131, 136], ["Ebola", "ORGANISM", 131, 136], ["community and region-level factors", "PROBLEM", 184, 218], ["socio-economic status", "TEST", 294, 315], ["little impact", "OBSERVATION_MODIFIER", 16, 29]]], ["We find that community-level education is positively associated with Ebola exposure but that this effect appears to be mainly concentrated in Sierra Leone.", [["Ebola", "DISEASE", 69, 74], ["Ebola", "ORGANISM", 69, 74], ["Ebola exposure", "PROBLEM", 69, 83], ["Sierra Leone", "OBSERVATION", 142, 154]]], ["When we control for community-level education we also reduce the associations with individual-level measures of education, but only slightly and it remains significant in Sierra Leone.", [["community-level education", "TREATMENT", 20, 45]]], ["Adding sub-national regional fixed-effects also does not affect our observed effects, although we do observe some regions have higher or lower propensity to reporting knowing someone with Ebola (not shown, but available upon request).", [["Ebola", "DISEASE", 188, 193], ["Ebola", "ORGANISM", 188, 193], ["Ebola", "PROBLEM", 188, 193]]], ["We also replicate all of the same regression results using knowing someone who died of Ebola, and the results are presented in Appendix Table 2.", [["Ebola", "DISEASE", 87, 92], ["Ebola", "ORGANISM", 87, 92], ["Ebola", "PROBLEM", 87, 92], ["Ebola", "OBSERVATION", 87, 92], ["Appendix", "ANATOMY", 127, 135]]], ["Given the similarity in this measure with our other dependent variable, unsurprisingly, we find nearly the exact same pattern of associations as with knowing someone with Ebola.ResultsWe also explore the determinants of Ebola exposure in a model that has been stratified by rural and urban populations in Appendix Table 4.", [["Ebola", "DISEASE", 171, 176], ["Ebola", "DISEASE", 220, 225], ["Ebola", "ORGANISM", 171, 176], ["Ebola", "ORGANISM", 220, 225], ["Ebola exposure", "PROBLEM", 220, 234], ["Ebola", "OBSERVATION", 220, 225], ["Appendix", "ANATOMY", 305, 313]]], ["Despite the much smaller sample sizes, which makes it more difficult to find strong associations, we also see some differences in the sub-samples.", [["the much smaller sample sizes", "PROBLEM", 8, 37], ["smaller", "OBSERVATION_MODIFIER", 17, 24], ["sample", "OBSERVATION_MODIFIER", 25, 31], ["sizes", "OBSERVATION_MODIFIER", 32, 37]]], ["For example, while there is no association between gender and exposure in the full sample, we see that males were more likely to be exposed in the rural sample but not in the urban sample.DiscussionSocio-economic status, in particular poverty, has been implicated as an important driver of the transmission of EVD during the West African outbreak, however, previous studies have not always found consistent results and also were not based on nationally representative data of EVD exposure nor were they able to adequately control for individual, household, and community-level factors, all of which might independently help to explain exposure patterns to EVD.", [["EVD", "DISEASE", 310, 313], ["EVD", "DISEASE", 656, 659], ["EVD", "TREATMENT", 310, 313], ["previous studies", "TEST", 357, 373], ["EVD exposure", "PROBLEM", 476, 488], ["EVD", "TREATMENT", 656, 659], ["no association", "UNCERTAINTY", 28, 42]]], ["In this paper, we developed a conceptual model which provided pathways through which both high and low levels of SES might be associated with increased EVD exposure at the population and community-levels as well as the individual and household-levels.", [["increased EVD exposure", "PROBLEM", 142, 164], ["high", "OBSERVATION_MODIFIER", 90, 94], ["increased", "OBSERVATION_MODIFIER", 142, 151], ["EVD", "OBSERVATION", 152, 155]]], ["Data from a nationally representative household-level survey data from Sierra Leone and Liberia, the two most heavily affected countries during the West African outbreak, we explored how various measures of exposure to EVD were associated with measures of SES at different levels.", [["EVD", "DISEASE", 219, 222], ["EVD", "TREATMENT", 219, 222]]], ["We make a number of important contributions to the literature.DiscussionFirst, while we find no overall association between household-level wealth and EVD exposure, we find that within countries there are very different patterns of exposures, with higher SES households reporting more exposure to the virus in Sierra Leone and the opposite effect in Liberia.", [["EVD exposure", "TREATMENT", 151, 163], ["the virus", "PROBLEM", 297, 306]]], ["This finding suggests that there appears to have been different factors driving exposure patterns in these neighboring countries during the outbreak.", [["different", "OBSERVATION_MODIFIER", 54, 63], ["factors", "OBSERVATION", 64, 71]]], ["It also suggests that it is too simplistic to simply assume that poverty was an important driver of the outbreak, as it may have been in some areas, but not others.", [["poverty", "DISEASE", 65, 72]]], ["It may also be that absolute poverty might help explain why West Africa was particular hard hit by the outbreak, perhaps due to its proximity to the zoonotic reservoirs of EVD, but that relative wealth appears to be more important within countries in explaining patterns of exposure.", [["EVD", "DISEASE", 172, 175], ["EVD", "TREATMENT", 172, 175], ["may also be", "UNCERTAINTY", 3, 14], ["zoonotic", "OBSERVATION_MODIFIER", 149, 157]]], ["Given this finding, we believe there is an urgent need to better explore these patterns, perhaps spatially or using qualitative approaches to better understand why wealth might have had such a differential effect in these two different countries.DiscussionSecond, across our various specifications, we also find that education of the survey respondent was consistently positively associated with Ebola exposure overall, although the estimates were not always significant.", [["Ebola", "DISEASE", 396, 401], ["Ebola", "ORGANISM", 396, 401], ["Ebola exposure", "PROBLEM", 396, 410]]], ["More educated people were more likely to report knowing someone with Ebola, even after controlling for household, community, and regional-level factors although our associations are reduced.", [["Ebola", "DISEASE", 69, 74], ["people", "ORGANISM", 14, 20], ["Ebola", "ORGANISM", 69, 74], ["people", "SPECIES", 14, 20]]], ["While our data do not allow us to pinpoint the reasons for this association, we speculate that it could be that more educated people in general know more people in their communities or may have more knowledge of the people in their networks.", [["people", "ORGANISM", 126, 132], ["people", "ORGANISM", 154, 160], ["people", "ORGANISM", 216, 222], ["people", "SPECIES", 126, 132], ["people", "SPECIES", 154, 160], ["people", "SPECIES", 216, 222]]], ["Also, given that some professions, for example health workers, were identified in other studies as having had higher levels of exposure to EVD than the general population, it may also be that specific jobs or occupations, which would be associated with education levels, may have made these people more likely to come into contact with more cases of EVD (Evans et al., 2015).", [["EVD", "DISEASE", 139, 142], ["EVD", "DISEASE", 350, 353], ["people", "ORGANISM", 291, 297], ["people", "SPECIES", 291, 297], ["other studies", "TEST", 82, 95], ["EVD", "TREATMENT", 139, 142]]], ["Unfortunately, we were unable to control for occupation in our analysis to further explore this potential channel.DiscussionThird, urban households were more likely than rural households to report higher levels of exposure of the outbreak, however, the reasons for this association are not clear but it does not seem to be explained simply by higher incomes in urban areas and important associations between other SES variables persist even within the urban sample.", [["our analysis", "TEST", 59, 71]]], ["People in urban areas may also know more people or again know more about the people in their network.", [["People", "ORGANISM", 0, 6], ["people", "ORGANISM", 41, 47], ["people", "ORGANISM", 77, 83], ["People", "SPECIES", 0, 6], ["people", "SPECIES", 41, 47], ["people", "SPECIES", 77, 83]]], ["Unfortunately, we were unable to control for network size in our analysis but it points to the need to control for such factors in future analyses and to collect such data in future surveys.DiscussionWhile our study has helped to shed some light on the exposure patterns of EVD along SES lines, it has many important limitations that must be taken into consideration when interpreting out results.", [["our analysis", "TEST", 61, 73], ["such factors", "PROBLEM", 115, 127], ["our study", "TEST", 206, 215], ["EVD along SES lines", "TREATMENT", 274, 293], ["size", "OBSERVATION_MODIFIER", 53, 57]]], ["First, our measure of EVD exposure, namely whether or not people reported knowing a close friend or family member with Ebola or knowing someone who died of Ebola is different from actual cases of EVD or other ways to define exposure.", [["Ebola", "DISEASE", 119, 124], ["Ebola", "DISEASE", 156, 161], ["EVD", "DISEASE", 196, 199], ["people", "ORGANISM", 58, 64], ["Ebola", "ORGANISM", 119, 124], ["Ebola", "ORGANISM", 156, 161], ["people", "SPECIES", 58, 64], ["Ebola", "PROBLEM", 156, 161], ["EVD", "TREATMENT", 196, 199]]], ["Plus, this simple measure of exposure lacks information on how many cases a person knew, or of cases that they would not define as close friends or family members.", [["person", "SPECIES", 76, 82]]], ["However, if we assume that there were approximately 25,000 cases of Ebola in the 2 countries with a combined population of approximately 13,000,000 people, then it would mean that 1 in 520 people in those countries were actually infected with EVD.", [["Ebola", "DISEASE", 68, 73], ["EVD", "DISEASE", 243, 246], ["Ebola", "ORGANISM", 68, 73], ["people", "ORGANISM", 148, 154], ["people", "ORGANISM", 189, 195], ["people", "SPECIES", 148, 154], ["people", "SPECIES", 189, 195], ["Ebola", "PROBLEM", 68, 73], ["EVD", "TREATMENT", 243, 246], ["Ebola", "OBSERVATION", 68, 73], ["infected", "OBSERVATION", 229, 237]]], ["Given that in our sample, roughly 40% of people knew a close friend or family member with Ebola, assuming random mixing, it means that on average people must have at least 200 people in their close circle of friends or family members, which is a plausible figure given estimates of network sizes that have been observed in different human populations (Dunbar, 1993).", [["Ebola", "DISEASE", 90, 95], ["people", "ORGANISM", 41, 47], ["Ebola", "ORGANISM", 90, 95], ["people", "ORGANISM", 146, 152], ["network", "MULTI-TISSUE_STRUCTURE", 282, 289], ["human", "ORGANISM", 333, 338], ["people", "SPECIES", 41, 47], ["people", "SPECIES", 146, 152], ["people", "SPECIES", 176, 182], ["human", "SPECIES", 333, 338], ["human", "SPECIES", 333, 338]]], ["Given that cases of EVD likely clustered, we might be worried that this estimate would underestimate the number of close friends and colleagues each individual would have to have, since people who knew one case likely knew more than one, however, on the other hand given that many of the people who actually knew cases also died, this might bias the estimates in the other direction since people who died did not answer the survey.", [["EVD", "DISEASE", 20, 23], ["people", "ORGANISM", 186, 192], ["people", "ORGANISM", 288, 294], ["people", "ORGANISM", 389, 395], ["people", "SPECIES", 186, 192], ["people", "SPECIES", 288, 294], ["people", "SPECIES", 389, 395], ["EVD", "TREATMENT", 20, 23]]], ["Third, we are comparing data from two countries with sub-national units of different sizes (counties vs. provinces and potentially also at the sampling unit).", [["sizes", "OBSERVATION_MODIFIER", 85, 90]]], ["These differences could also potentially affect our estimates, especially with regards to the calculation of the community-level variables which have been aggregated at the sampling unit-level.ConclusionsThe recent West African outbreak of EVD was a wake-up call to the global health community that we need to do a better job at preventing and mitigating the spread of infectious diseases with epidemic potential.", [["EVD", "DISEASE", 240, 243], ["infectious diseases", "DISEASE", 369, 388], ["EVD", "TREATMENT", 240, 243], ["infectious diseases", "PROBLEM", 369, 388], ["infectious", "OBSERVATION", 369, 379]]], ["Knowing how the virus may spread along SES lines is one way to help prepare for future outbreaks.", [["SES lines", "CELL_LINE", 39, 48], ["the virus", "PROBLEM", 12, 21]]], ["Our study suggests that there is a lot that we still do not fully understand about the way in which EVD spread along individual, household, and community-levels but it is too simplistic to simply assume that poorer people living in poorer communities were more exposed.", [["people", "ORGANISM", 215, 221], ["people", "SPECIES", 215, 221], ["Our study", "TEST", 0, 9]]], ["There is an urgent need to better understand these patterns to help prepare for future infectious disease outbreaks.Research ethics statementThis paper relies entirely on secondary data, therefore, research ethics approval was not required.", [["infectious disease outbreaks", "DISEASE", 87, 115], ["future infectious disease outbreaks", "PROBLEM", 80, 115]]]], "PMC3688998": [["IntroductionJapanese encephalitis (JE) is caused by the Japanese encephalitis virus (JEV), and is one of the most important mosquito-borne diseases with a mortality rate as high as 20% to 50%, and is widely distributed in most of East and South-east Asia and parts of Oceania.", [["IntroductionJapanese encephalitis", "DISEASE", 0, 33], ["JE", "DISEASE", 35, 37], ["Japanese encephalitis", "DISEASE", 56, 77], ["JEV", "DISEASE", 85, 88], ["mosquito-borne diseases", "DISEASE", 124, 147], ["Japanese encephalitis virus", "ORGANISM", 56, 83], ["JEV", "ORGANISM", 85, 88], ["Japanese encephalitis virus", "SPECIES", 56, 83], ["Japanese encephalitis virus", "SPECIES", 56, 83], ["JEV", "SPECIES", 85, 88], ["IntroductionJapanese encephalitis", "PROBLEM", 0, 33], ["the Japanese encephalitis virus (JEV)", "PROBLEM", 52, 89], ["a mortality rate", "TEST", 153, 169], ["encephalitis", "OBSERVATION", 21, 33], ["encephalitis", "OBSERVATION", 65, 77], ["widely", "OBSERVATION_MODIFIER", 200, 206], ["distributed", "OBSERVATION_MODIFIER", 207, 218]]], ["Up to 50,000 human cases of JE are reported annually in Asian countries, of which 10,000\u201315,000 result in fatality [1].", [["JE", "DISEASE", 28, 30], ["human", "ORGANISM", 13, 18], ["JE", "ORGANISM", 28, 30], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18]]], ["A high proportion (nearly 50%) of survivors, especially young children and those greater than 65 years of age, exhibit permanent neurologic and psychiatric sequelae.", [["neurologic", "ANATOMY", 129, 139], ["neurologic and psychiatric sequelae", "DISEASE", 129, 164], ["children", "ORGANISM", 62, 70], ["children", "SPECIES", 62, 70], ["permanent neurologic and psychiatric sequelae", "PROBLEM", 119, 164], ["high", "OBSERVATION_MODIFIER", 2, 6]]], ["A wide range of animals including swine, equines and birds can also be infected.", [["animals", "ORGANISM", 16, 23], ["swine", "ORGANISM", 34, 39], ["birds", "ORGANISM", 53, 58], ["swine", "SPECIES", 34, 39], ["swine", "SPECIES", 34, 39], ["wide", "OBSERVATION_MODIFIER", 2, 6], ["infected", "OBSERVATION", 71, 79]]], ["Pigs, as well as birds, serve as amplifying and reservoir hosts [2], [3].", [["Pigs", "ORGANISM", 0, 4], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4]]], ["Further, JEV infection has accounted for significant economic losses in the pig industry due to fetal encephalitis and reproductive failure in pregnant sows and hypospermia in boars [4].", [["fetal", "ANATOMY", 96, 101], ["JEV infection", "DISEASE", 9, 22], ["fetal encephalitis", "DISEASE", 96, 114], ["reproductive failure", "DISEASE", 119, 139], ["hypospermia", "DISEASE", 161, 172], ["JEV", "ORGANISM", 9, 12], ["pig", "ORGANISM", 76, 79], ["fetal", "ANATOMICAL_SYSTEM", 96, 101], ["sows", "ORGANISM_SUBDIVISION", 152, 156], ["pig", "SPECIES", 76, 79], ["JEV", "SPECIES", 9, 12], ["pig", "SPECIES", 76, 79], ["JEV infection", "PROBLEM", 9, 22], ["significant economic losses", "PROBLEM", 41, 68], ["the pig industry", "TREATMENT", 72, 88], ["fetal encephalitis", "PROBLEM", 96, 114], ["reproductive failure", "PROBLEM", 119, 139], ["hypospermia", "PROBLEM", 161, 172], ["JEV infection", "OBSERVATION", 9, 22], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["economic", "OBSERVATION_MODIFIER", 53, 61], ["losses", "OBSERVATION", 62, 68], ["fetal", "ANATOMY", 96, 101], ["encephalitis", "OBSERVATION", 102, 114], ["reproductive", "OBSERVATION_MODIFIER", 119, 131], ["failure", "OBSERVATION", 132, 139]]], ["There is no specific treatment available for JE, and vaccination is the only effective way to prevent JEV infection in humans and domestic animals.", [["JE", "DISEASE", 45, 47], ["JEV infection", "DISEASE", 102, 115], ["JE", "ORGANISM", 45, 47], ["JEV", "ORGANISM", 102, 105], ["humans", "ORGANISM", 119, 125], ["humans", "SPECIES", 119, 125], ["JEV", "SPECIES", 102, 105], ["humans", "SPECIES", 119, 125], ["JE", "PROBLEM", 45, 47], ["vaccination", "TREATMENT", 53, 64], ["JEV infection in humans", "PROBLEM", 102, 125], ["no", "UNCERTAINTY", 9, 11], ["JEV", "OBSERVATION_MODIFIER", 102, 105], ["infection", "OBSERVATION", 106, 115]]], ["JEV non-structural protein 1 (NS1) has been shown to induce both humoral and cell-mediated immunity against JE [5], [6].", [["cell", "ANATOMY", 77, 81], ["JE", "DISEASE", 108, 110], ["JEV non-structural protein 1", "GENE_OR_GENE_PRODUCT", 0, 28], ["NS1", "GENE_OR_GENE_PRODUCT", 30, 33], ["cell", "CELL", 77, 81], ["JEV non-structural protein 1", "PROTEIN", 0, 28], ["NS1", "PROTEIN", 30, 33], ["JEV", "SPECIES", 0, 3], ["JEV non-structural protein", "TEST", 0, 26]]], ["Further, like other flaviviruses, NS1 is able to elicit protective immunity without the risk of antibody-dependent enhancement.", [["NS1", "GENE_OR_GENE_PRODUCT", 34, 37], ["NS1", "PROTEIN", 34, 37], ["other flaviviruses", "PROBLEM", 14, 32], ["NS1", "PROBLEM", 34, 37], ["antibody-dependent enhancement", "PROBLEM", 96, 126], ["flaviviruses", "OBSERVATION", 20, 32], ["antibody", "OBSERVATION", 96, 104], ["dependent", "OBSERVATION_MODIFIER", 105, 114], ["enhancement", "OBSERVATION", 115, 126]]], ["These characteristics make NS1 an attractive alternative immunogen.", [["NS1", "GENE_OR_GENE_PRODUCT", 27, 30], ["NS1", "PROTEIN", 27, 30], ["NS1 an attractive alternative immunogen", "TREATMENT", 27, 66]]], ["As such, much research is currently being devoted to NS1-based vaccine development [7], [8], [9].", [["NS1", "GENE_OR_GENE_PRODUCT", 53, 56], ["[8]", "SIMPLE_CHEMICAL", 88, 91], ["NS1", "PROTEIN", 53, 56], ["NS1-based vaccine development", "TREATMENT", 53, 82]]], ["Although NS1 is not present in the virion, NS1-induced antibodies can protect against infection in vivo by an undetermined mechanism, which presumably depends on the Fc portion of the antibody since they kill their target cells through a complement-dependent pathway [10], [11].IntroductionJEV is a member of the family Flaviviridae, and the genus Flavivirus, and is primarily transmitted by Culex mosquitoes.", [["virion", "ANATOMY", 35, 41], ["cells", "ANATOMY", 222, 227], ["infection", "DISEASE", 86, 95], ["NS1", "GENE_OR_GENE_PRODUCT", 9, 12], ["virion", "CELLULAR_COMPONENT", 35, 41], ["NS1", "GENE_OR_GENE_PRODUCT", 43, 46], ["cells", "CELL", 222, 227], ["Culex mosquitoes", "ORGANISM", 392, 408], ["NS1", "PROTEIN", 9, 12], ["NS1", "PROTEIN", 43, 46], ["antibodies", "PROTEIN", 55, 65], ["Fc portion", "PROTEIN", 166, 176], ["target cells", "CELL_TYPE", 215, 227], ["Culex mosquitoes", "SPECIES", 392, 408], ["NS1", "PROBLEM", 9, 12], ["the virion", "TREATMENT", 31, 41], ["NS1-induced antibodies", "TREATMENT", 43, 65], ["infection", "PROBLEM", 86, 95], ["a complement-dependent pathway", "TREATMENT", 236, 266], ["Flaviviridae", "TREATMENT", 320, 332], ["the genus Flavivirus", "PROBLEM", 338, 358], ["NS1", "OBSERVATION", 9, 12], ["virion", "ANATOMY", 35, 41], ["genus Flavivirus", "ANATOMY", 342, 358]]], ["Besides JEV, the Japanese encephalitis virus serocomplex of Flaviviridae includes the West Nile virus (WNV), Saint Louis encephalitis virus (SLEV) and Murray Valley encephalitis virus (MVEM).", [["JEV", "DISEASE", 8, 11], ["Japanese encephalitis", "DISEASE", 17, 38], ["Saint Louis encephalitis", "DISEASE", 109, 133], ["Murray Valley encephalitis", "DISEASE", 151, 177], ["JEV", "ORGANISM", 8, 11], ["Japanese encephalitis virus", "ORGANISM", 17, 44], ["Flaviviridae", "ORGANISM", 60, 72], ["West Nile virus", "ORGANISM", 86, 101], ["WNV", "ORGANISM", 103, 106], ["Saint Louis encephalitis virus", "ORGANISM", 109, 139], ["SLEV", "ORGANISM", 141, 145], ["Murray Valley encephalitis virus", "ORGANISM", 151, 183], ["MVEM", "CANCER", 185, 189], ["Japanese encephalitis virus", "SPECIES", 17, 44], ["West Nile virus", "SPECIES", 86, 101], ["Saint Louis encephalitis virus", "SPECIES", 109, 139], ["Murray Valley encephalitis virus", "SPECIES", 151, 183], ["JEV", "SPECIES", 8, 11], ["Japanese encephalitis virus", "SPECIES", 17, 44], ["West Nile virus", "SPECIES", 86, 101], ["WNV", "SPECIES", 103, 106], ["Saint Louis encephalitis virus", "SPECIES", 109, 139], ["SLEV", "SPECIES", 141, 145], ["Murray Valley encephalitis virus", "SPECIES", 151, 183], ["JEV", "PROBLEM", 8, 11], ["the Japanese encephalitis virus", "PROBLEM", 13, 44], ["Flaviviridae", "TREATMENT", 60, 72], ["the West Nile virus", "PROBLEM", 82, 101], ["Saint Louis encephalitis virus", "PROBLEM", 109, 139], ["Murray Valley encephalitis virus", "PROBLEM", 151, 183], ["JEV", "OBSERVATION", 8, 11]]], ["JEV serogroup viruses and Dengue virus (DENV) have a similar ecology; it is very common that two or more of these flaviviruses co-circulate in some regions of the world [12]\u2013[15], and cross-reactivity can be demonstrated among these flaviviruses in serological tests.", [["JEV serogroup viruses", "DISEASE", 0, 21], ["Dengue virus", "DISEASE", 26, 38], ["flaviviruses", "DISEASE", 114, 126], ["JEV serogroup viruses", "ORGANISM", 0, 21], ["Dengue virus", "ORGANISM", 26, 38], ["DENV", "ORGANISM", 40, 44], ["JEV serogroup viruses", "SPECIES", 0, 21], ["Dengue virus", "SPECIES", 26, 38], ["JEV serogroup viruses", "SPECIES", 0, 21], ["Dengue virus", "SPECIES", 26, 38], ["DENV", "SPECIES", 40, 44], ["JEV serogroup viruses", "PROBLEM", 0, 21], ["Dengue virus (DENV", "PROBLEM", 26, 44], ["these flaviviruses", "PROBLEM", 108, 126], ["serological tests", "TEST", 249, 266], ["flaviviruses", "OBSERVATION", 114, 126]]], ["These cross-reactive responses could confound the interpretation of results during serological testing, including neutralization tests and enzyme-linked immunosorbent assays (ELISA) [16].", [["serological testing", "TEST", 83, 102], ["neutralization tests", "TEST", 114, 134], ["enzyme", "TEST", 139, 145], ["immunosorbent assays", "TEST", 153, 173]]], ["This serves to emphasize the utility of virus-specific epitopes for the differential diagnosis of disease and epidemiological surveys.", [["virus", "PROBLEM", 40, 45], ["disease", "PROBLEM", 98, 105], ["epidemiological surveys", "TEST", 110, 133]]], ["The serological cross-reactivity is primarily caused by cross-reactive epitopes on the structural protein E [17], [18].", [["cross-reactive epitopes", "PROTEIN", 56, 79], ["The serological cross-reactivity", "TEST", 0, 32], ["cross-reactive epitopes", "PROBLEM", 56, 79], ["the structural protein E", "TEST", 83, 107]]], ["In contrast, NS1 is more specific in serological testing of flavivirus infections, and it has been reported that NS1 can induce antibodies without cross-reactivity among flaviviruses [14], and even among different serotypes of DENV [19], [20], therefore the development of an NS1-based specific serological diagnosis is of great interest [14], [21], [22].", [["flavivirus infections", "DISEASE", 60, 81], ["NS1", "GENE_OR_GENE_PRODUCT", 13, 16], ["flavivirus", "ORGANISM", 60, 70], ["NS1", "GENE_OR_GENE_PRODUCT", 113, 116], ["DENV", "ORGANISM", 227, 231], ["NS1", "GENE_OR_GENE_PRODUCT", 276, 279], ["NS1", "PROTEIN", 13, 16], ["NS1", "PROTEIN", 113, 116], ["antibodies", "PROTEIN", 128, 138], ["NS1", "PROTEIN", 276, 279], ["flavivirus", "SPECIES", 60, 70], ["DENV", "SPECIES", 227, 231], ["NS1", "PROBLEM", 13, 16], ["serological testing", "TEST", 37, 56], ["flavivirus infections", "PROBLEM", 60, 81], ["NS1", "PROBLEM", 113, 116], ["cross-reactivity among flaviviruses", "PROBLEM", 147, 182], ["DENV", "PROBLEM", 227, 231], ["an NS1", "TEST", 273, 279], ["flavivirus infections", "OBSERVATION", 60, 81], ["NS1", "OBSERVATION", 276, 279]]], ["First, it is necessary to precisely identify the B-cell epitopes on NS1.", [["B-cell", "ANATOMY", 49, 55], ["B-cell", "CELL", 49, 55], ["NS1", "GENE_OR_GENE_PRODUCT", 68, 71], ["B-cell epitopes", "PROTEIN", 49, 64], ["NS1", "PROTEIN", 68, 71], ["NS1", "TREATMENT", 68, 71]]], ["In this study we have identified and characterized five JEV NS1-specific epitopes with monoclonal antibodies.", [["JEV", "ORGANISM", 56, 59], ["NS1", "GENE_OR_GENE_PRODUCT", 60, 63], ["JEV NS1-specific epitopes", "PROTEIN", 56, 81], ["monoclonal antibodies", "PROTEIN", 87, 108], ["JEV", "SPECIES", 56, 59], ["this study", "TEST", 3, 13], ["JEV NS1", "TEST", 56, 63], ["monoclonal antibodies", "PROBLEM", 87, 108], ["JEV NS1", "OBSERVATION", 56, 63], ["monoclonal antibodies", "OBSERVATION", 87, 108]]], ["This work demonstrates progress toward the development of a specific serological diagnostic test for JEV infection, extends our understanding of the antigenic structure of JEV NS1, and could help inform vaccine design.Ethics statement ::: Materials and MethodsCare of laboratory animals and animal experimentation was performed in accordance with animal ethics guidelines and approved protocols.", [["JEV infection", "DISEASE", 101, 114], ["JEV", "ORGANISM", 101, 104], ["JEV", "ORGANISM", 172, 175], ["NS1", "ORGANISM", 176, 179], ["JEV NS1", "PROTEIN", 172, 179], ["JEV", "SPECIES", 101, 104], ["JEV", "SPECIES", 172, 175], ["a specific serological diagnostic test", "TEST", 58, 96], ["JEV infection", "PROBLEM", 101, 114], ["laboratory animals", "TEST", 268, 286], ["animal experimentation", "TEST", 291, 313], ["infection", "OBSERVATION", 105, 114]]], ["The Animal Ethics Committee approval number was SYXK (Hei) 2011\u2013022.Cell lines, virus and serum ::: Materials and MethodsMyeloma cell line SP2/0 and baby hamster kidney BHK-21 cells (CCL-10, American Type Culture Collection) were cultured in RPMI-1640 (Gibco, Grand Island, NY, USA) and Dulbecco's modified Eagle's medium (DMEM; Gibco, Invitrogen, Carlsbad, CA, USA), respectively, in a humidified 5% CO2 atmosphere at 37\u00b0C. All culture media were supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco), 100 U/ml penicillin and 100 \u00b5g/ml streptomycin (Gibco).", [["Cell lines", "ANATOMY", 68, 78], ["serum", "ANATOMY", 90, 95], ["Myeloma cell line SP2/0", "ANATOMY", 121, 144], ["kidney BHK-21 cells", "ANATOMY", 162, 181], ["CCL-10", "ANATOMY", 183, 189], ["fetal bovine serum", "ANATOMY", 487, 505], ["FBS", "ANATOMY", 507, 510], ["Myeloma", "DISEASE", 121, 128], ["CO2", "CHEMICAL", 401, 404], ["penicillin", "CHEMICAL", 529, 539], ["streptomycin", "CHEMICAL", 554, 566], ["CO2", "CHEMICAL", 401, 404], ["penicillin", "CHEMICAL", 529, 539], ["streptomycin", "CHEMICAL", 554, 566], ["Cell lines", "CELL", 68, 78], ["serum", "ORGANISM_SUBSTANCE", 90, 95], ["Myeloma cell line SP2/0", "CELL", 121, 144], ["baby hamster kidney BHK-21 cells", "CELL", 149, 181], ["CCL-10", "CELL", 183, 189], ["RPMI-1640", "CELL", 242, 251], ["CO2", "SIMPLE_CHEMICAL", 401, 404], ["bovine", "ORGANISM", 493, 499], ["serum", "ORGANISM_SUBSTANCE", 500, 505], ["FBS", "ORGANISM_SUBSTANCE", 507, 510], ["Gibco", "ORGANISM_SUBSTANCE", 512, 517], ["penicillin", "SIMPLE_CHEMICAL", 529, 539], ["streptomycin", "SIMPLE_CHEMICAL", 554, 566], ["Myeloma cell line SP2/0", "CELL_LINE", 121, 144], ["baby hamster kidney BHK-21 cells", "CELL_LINE", 149, 181], ["CCL-10", "CELL_LINE", 183, 189], ["hamster", "SPECIES", 154, 161], ["bovine", "SPECIES", 493, 499], ["hamster", "SPECIES", 154, 161], ["bovine", "SPECIES", 493, 499], ["Materials", "TEST", 100, 109], ["MethodsMyeloma cell line SP2", "TEST", 114, 142], ["baby hamster kidney BHK", "TEST", 149, 172], ["cells", "TEST", 176, 181], ["CCL", "TEST", 183, 186], ["American Type Culture Collection", "TEST", 191, 223], ["RPMI", "TEST", 242, 246], ["Gibco", "TEST", 253, 258], ["Dulbecco", "TEST", 287, 295], ["DMEM", "TEST", 323, 327], ["Gibco", "TEST", 329, 334], ["Invitrogen", "TEST", 336, 346], ["a humidified 5% CO2 atmosphere", "TREATMENT", 385, 415], ["All culture media", "TEST", 425, 442], ["FBS", "TEST", 507, 510], ["Gibco", "TEST", 512, 517], ["penicillin", "TREATMENT", 529, 539], ["streptomycin", "TREATMENT", 554, 566], ["Myeloma cell line", "OBSERVATION", 121, 138], ["kidney", "ANATOMY", 162, 168], ["21 cells", "OBSERVATION_MODIFIER", 173, 181]]], ["The JEV SA14-14-2 strain (GenBank: AF315119) was propagated and titrated on BHK-21 cell monolayers.", [["BHK-21 cell monolayers", "ANATOMY", 76, 98], ["SA14-14-2", "CHEMICAL", 8, 17], ["JEV SA14-14-2 strain", "ORGANISM", 4, 24], ["BHK-21 cell monolayers", "CELL", 76, 98], ["BHK-21 cell monolayers", "CELL_LINE", 76, 98], ["JEV SA14-14-2 strain", "SPECIES", 4, 24], ["The JEV SA14", "TEST", 0, 12], ["BHK", "TEST", 76, 79], ["cell monolayers", "OBSERVATION", 83, 98]]], ["Inactivated WNV, DENV-1, DENV-2, DENV-3 and DENV-4 cell cultures were kindly provided by Dr. Cheng-Feng Qin (Beijing Institute of Microbiology and Epidemiology, Beijing, China).", [["cell cultures", "ANATOMY", 51, 64], ["Inactivated WNV", "ORGANISM", 0, 15], ["DENV-1", "ORGANISM", 17, 23], ["DENV-2", "ORGANISM", 25, 31], ["DENV-3", "ORGANISM", 33, 39], ["DENV-4 cell cultures", "CELL", 44, 64], ["WNV", "SPECIES", 12, 15], ["DENV-1", "SPECIES", 17, 23], ["DENV", "TEST", 17, 21], ["DENV", "PROBLEM", 25, 29], ["DENV", "PROBLEM", 33, 37], ["DENV", "PROBLEM", 44, 48], ["cell cultures", "TEST", 51, 64]]], ["The mouse sera against WNV and DENV were also provided by Dr. Cheng-Feng Qin.Expression of recombinant NS1 ::: Materials and MethodsThe full-length gene of NS1 was PCR amplified from the plasmid pET30-JEV-NS1 [23].", [["sera", "ANATOMY", 10, 14], ["plasmid", "ANATOMY", 187, 194], ["mouse", "ORGANISM", 4, 9], ["sera", "ORGANISM_SUBSTANCE", 10, 14], ["WNV", "ORGANISM", 23, 26], ["DENV", "ORGANISM", 31, 35], ["NS1", "GENE_OR_GENE_PRODUCT", 103, 106], ["NS1", "GENE_OR_GENE_PRODUCT", 156, 159], ["pET30", "GENE_OR_GENE_PRODUCT", 195, 200], ["NS1", "PROTEIN", 103, 106], ["full-length gene", "DNA", 136, 152], ["NS1", "DNA", 156, 159], ["pET30", "DNA", 195, 200], ["mouse", "SPECIES", 4, 9], ["mouse", "SPECIES", 4, 9], ["WNV", "SPECIES", 23, 26], ["DENV", "SPECIES", 31, 35], ["The mouse sera", "TREATMENT", 0, 14], ["WNV", "PROBLEM", 23, 26], ["DENV", "PROBLEM", 31, 35], ["Methods", "TREATMENT", 125, 132], ["NS1", "TEST", 156, 159], ["PCR", "TEST", 164, 167], ["the plasmid pET30", "TEST", 183, 200]]], ["The sequence of the upstream primer is 5\u2032CGCCCATGGACACTGGATGTGCCATTGAC 3\u2032, and that of the downstream primer is 5\u2032TTAGGATCCAGCAGCGACTAGCACCACATACC 3\u2032.", [["upstream primer", "DNA", 20, 35], ["downstream primer", "DNA", 91, 108], ["CGCCCATGGACACTGGATGTGCCATTGAC", "TEST", 41, 70]]], ["Primers were designed according to the sequence of JEV strain SA14-14-2 and contain Nco I and BamH I restriction enzyme site respectively.", [["JEV", "ORGANISM", 51, 54], ["Nco I", "GENE_OR_GENE_PRODUCT", 84, 89], ["BamH I restriction enzyme", "GENE_OR_GENE_PRODUCT", 94, 119], ["JEV strain SA14-14-2", "DNA", 51, 71], ["Nco I", "DNA", 84, 89], ["BamH I restriction enzyme site", "DNA", 94, 124], ["JEV strain SA14", "TEST", 51, 66], ["Nco I and BamH I restriction enzyme site", "TREATMENT", 84, 124]]], ["After agar gel purification and restriction enzyme digestion, the PCR products were cloned into the expression vector pMAL-c5x (NEB, Ipswich, MA, USA).", [["PCR products", "DNA", 66, 78], ["pMAL", "PROTEIN", 118, 122], ["agar gel purification", "TREATMENT", 6, 27], ["restriction enzyme digestion", "PROBLEM", 32, 60], ["the PCR products", "TREATMENT", 62, 78]]], ["The resulting recombinant plasmid was verified by enzyme digestion and DNA sequencing.", [["plasmid", "ANATOMY", 26, 33], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["recombinant plasmid", "DNA", 14, 33], ["The resulting recombinant plasmid", "TREATMENT", 0, 33], ["enzyme digestion", "PROBLEM", 50, 66], ["DNA sequencing", "TEST", 71, 85], ["recombinant plasmid", "OBSERVATION", 14, 33]]], ["Confirmed recombinant plasmids were transformed into E. coli ER2523 (NEB Express, MA, USA) cells for expression.", [["plasmids", "ANATOMY", 22, 30], ["MA, USA) cells", "ANATOMY", 82, 96], ["E. coli", "ORGANISM", 53, 60], ["ER2523", "ORGANISM", 61, 67], ["recombinant plasmids", "DNA", 10, 30], ["E. coli ER2523 (NEB Express, MA, USA) cells", "CELL_LINE", 53, 96], ["E. coli", "SPECIES", 53, 60], ["E. coli", "SPECIES", 53, 60], ["recombinant plasmids", "TREATMENT", 10, 30], ["E. coli", "TEST", 53, 60], ["plasmids", "OBSERVATION", 22, 30], ["E. coli", "OBSERVATION_MODIFIER", 53, 60]]], ["After 1 hour of shaking, isopropyl-D-thiogalactopyranoside (IPTG; Sigma, MO, USA) was added to bacterial cultures in Luria-Bertani broth at a final concentration of 0.3 mM and the cultures were shaken for a further 3 h.", [["cultures", "ANATOMY", 180, 188], ["isopropyl-D-thiogalactopyranoside", "CHEMICAL", 25, 58], ["IPTG", "CHEMICAL", 60, 64], ["isopropyl-D-thiogalactopyranoside", "CHEMICAL", 25, 58], ["IPTG", "CHEMICAL", 60, 64], ["isopropyl-D-thiogalactopyranoside", "SIMPLE_CHEMICAL", 25, 58], ["IPTG", "SIMPLE_CHEMICAL", 60, 64], ["Luria-Bertani", "SPECIES", 117, 130], ["shaking", "PROBLEM", 16, 23], ["isopropyl", "TREATMENT", 25, 34], ["thiogalactopyranoside (IPTG", "TREATMENT", 37, 64], ["bacterial cultures", "TEST", 95, 113], ["the cultures", "TEST", 176, 188]]], ["Then the bacterial cells were pelleted at 5,000 g for 15 min and lysed by sonication in phosphate buffered saline (PBS), and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out to analyze the recombinant protein.", [["cells", "ANATOMY", 19, 24], ["phosphate", "CHEMICAL", 88, 97], ["sodium dodecyl sulfate", "CHEMICAL", 125, 147], ["phosphate", "CHEMICAL", 88, 97], ["sodium dodecyl sulfate", "CHEMICAL", 125, 147], ["polyacrylamide", "CHEMICAL", 148, 162], ["bacterial cells", "CELL", 9, 24], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 88, 113], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 125, 147], ["bacterial cells", "CELL_TYPE", 9, 24], ["recombinant protein", "PROTEIN", 225, 244], ["the bacterial cells", "PROBLEM", 5, 24], ["phosphate buffered saline (PBS", "TREATMENT", 88, 118], ["sodium dodecyl sulfate", "TREATMENT", 125, 147], ["polyacrylamide gel electrophoresis", "TREATMENT", 148, 182], ["bacterial cells", "OBSERVATION", 9, 24]]], ["The recombinant protein MBP-NS1 was purified by MBPTrap HP column affinity chromatography according to the manufacturer's instructions (GE Healthcare Bio-Sciences, MA, USA).Preparation of monoclonal antibodies (MAbs) against NS1 ::: Materials and MethodsThe purified recombinant protein was used as an immunogen in mice.", [["MBP", "GENE_OR_GENE_PRODUCT", 24, 27], ["NS1", "GENE_OR_GENE_PRODUCT", 28, 31], ["NS1", "ORGANISM", 225, 228], ["mice", "ORGANISM", 315, 319], ["MBP", "PROTEIN", 24, 27], ["NS1", "PROTEIN", 28, 31], ["monoclonal antibodies", "PROTEIN", 188, 209], ["MAbs", "PROTEIN", 211, 215], ["NS1", "PROTEIN", 225, 228], ["purified recombinant protein", "PROTEIN", 258, 286], ["mice", "SPECIES", 315, 319], ["mice", "SPECIES", 315, 319], ["The recombinant protein MBP", "TEST", 0, 27], ["NS1", "PROBLEM", 28, 31], ["Methods", "TREATMENT", 247, 254], ["The purified recombinant protein", "TREATMENT", 254, 286], ["an immunogen in mice", "TREATMENT", 299, 319], ["recombinant protein", "OBSERVATION", 267, 286]]], ["Hybridomas secreting anti-NS1 antibodies were generated according to the procedure described previously [24].", [["Hybridomas", "GENE_OR_GENE_PRODUCT", 0, 10], ["anti-NS1 antibodies", "GENE_OR_GENE_PRODUCT", 21, 40], ["anti-NS1 antibodies", "PROTEIN", 21, 40], ["Hybridomas secreting anti-NS1 antibodies", "TEST", 0, 40], ["the procedure", "TREATMENT", 69, 82]]], ["Six-week-old female BALB/c mice were immunized subcutaneously with purified MBP-NS1 protein emulsified with an equal volume of Freund's complete adjuvant (Sigma, St. Louis, MO, USA).", [["subcutaneously", "ANATOMY", 47, 61], ["BALB/c mice", "ORGANISM", 20, 31], ["MBP-NS1", "GENE_OR_GENE_PRODUCT", 76, 83], ["MBP", "PROTEIN", 76, 79], ["NS1 protein", "PROTEIN", 80, 91], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31], ["BALB/c mice", "TREATMENT", 20, 31], ["purified MBP", "TEST", 67, 79], ["NS1 protein emulsified", "TREATMENT", 80, 102]]], ["Two booster injections were given at 2-week intervals with the same immunogen and equal volume of Freund's incomplete adjuvant.", [["Freund", "ORGANISM", 98, 104], ["Two booster injections", "TREATMENT", 0, 22], ["the same immunogen", "TREATMENT", 59, 77], ["Freund's incomplete adjuvant", "TREATMENT", 98, 126]]], ["The soluble recombinant protein was intraperitoneally injected into the mice without adjuvant as a final immunization.", [["mice", "ORGANISM", 72, 76], ["soluble recombinant protein", "PROTEIN", 4, 31], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["The soluble recombinant protein", "TREATMENT", 0, 31], ["adjuvant", "TREATMENT", 85, 93], ["a final immunization", "TREATMENT", 97, 117]]], ["Three days after final administration, the mice were euthanized humanly; spleen cells were harvested and subsequently fused with SP2/0 myeloma cells at 5\u22361 ratio using polyethylene glycol (PEG 4000, Sigma).", [["spleen cells", "ANATOMY", 73, 85], ["SP2/0 myeloma cells", "ANATOMY", 129, 148], ["polyethylene glycol", "CHEMICAL", 168, 187], ["PEG 4000", "CHEMICAL", 189, 197], ["polyethylene glycol", "CHEMICAL", 168, 187], ["PEG", "CHEMICAL", 189, 192], ["mice", "ORGANISM", 43, 47], ["spleen cells", "CELL", 73, 85], ["myeloma cells", "CELL", 135, 148], ["5\u22361", "SIMPLE_CHEMICAL", 152, 155], ["polyethylene glycol", "SIMPLE_CHEMICAL", 168, 187], ["spleen cells", "CELL_TYPE", 73, 85], ["SP2/0 myeloma cells", "CELL_LINE", 129, 148], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["SP2/0 myeloma cells", "PROBLEM", 129, 148], ["polyethylene glycol (PEG", "TREATMENT", 168, 192], ["spleen", "ANATOMY", 73, 79], ["myeloma cells", "OBSERVATION", 135, 148], ["polyethylene glycol", "OBSERVATION", 168, 187]]], ["The hybridoma cells were seeded into ninety-six well plates and selected in HAT medium (RPMI-1640 medium containing 10% fetal bovine serum, 100 \u00b5g/ml streptomycin, 100 IU/ml penicillin, 100 mM hypoxanthine, 16 mM thymidine and 400 mM aminopterin).", [["hybridoma cells", "ANATOMY", 4, 19], ["fetal bovine serum", "ANATOMY", 120, 138], ["RPMI-1640", "CHEMICAL", 88, 97], ["streptomycin", "CHEMICAL", 150, 162], ["penicillin", "CHEMICAL", 174, 184], ["hypoxanthine", "CHEMICAL", 193, 205], ["thymidine", "CHEMICAL", 213, 222], ["aminopterin", "CHEMICAL", 234, 245], ["streptomycin", "CHEMICAL", 150, 162], ["penicillin", "CHEMICAL", 174, 184], ["hypoxanthine", "CHEMICAL", 193, 205], ["thymidine", "CHEMICAL", 213, 222], ["aminopterin", "CHEMICAL", 234, 245], ["hybridoma cells", "CELL", 4, 19], ["bovine", "ORGANISM", 126, 132], ["serum", "ORGANISM_SUBSTANCE", 133, 138], ["streptomycin", "SIMPLE_CHEMICAL", 150, 162], ["penicillin", "SIMPLE_CHEMICAL", 174, 184], ["hypoxanthine", "SIMPLE_CHEMICAL", 193, 205], ["thymidine", "SIMPLE_CHEMICAL", 213, 222], ["aminopterin", "SIMPLE_CHEMICAL", 234, 245], ["hybridoma cells", "CELL_LINE", 4, 19], ["bovine", "SPECIES", 126, 132], ["bovine", "SPECIES", 126, 132], ["The hybridoma cells", "TREATMENT", 0, 19], ["fetal bovine serum", "TREATMENT", 120, 138], ["streptomycin", "TREATMENT", 150, 162], ["penicillin", "TREATMENT", 174, 184], ["hypoxanthine", "TREATMENT", 193, 205], ["16 mM thymidine", "TREATMENT", 207, 222], ["400 mM aminopterin)", "TREATMENT", 227, 246], ["hybridoma cells", "OBSERVATION", 4, 19]]], ["On days 3, 6 and 9, half of this medium was removed and replaced with fresh medium containing HAT.", [["fresh medium containing HAT", "TREATMENT", 70, 97]]], ["After HAT/HT medium selection, culture supernatants of surviving clones were screened for antibody reactivity and specificity by indirect enzyme-linked immunosorbent assay (ELISA) and Western blotting.", [["supernatants", "ANATOMY", 39, 51], ["clones", "ANATOMY", 65, 71], ["HT", "CHEMICAL", 10, 12], ["clones", "CELL", 65, 71], ["surviving clones", "CELL_LINE", 55, 71], ["HAT/HT medium selection", "TREATMENT", 6, 29], ["culture supernatants", "TEST", 31, 51], ["surviving clones", "PROBLEM", 55, 71], ["antibody reactivity", "TEST", 90, 109], ["specificity", "TEST", 114, 125], ["indirect enzyme", "TEST", 129, 144], ["immunosorbent assay", "TEST", 152, 171]]], ["The positive cell clones were subcloned three times by limiting dilution method.", [["cell clones", "ANATOMY", 13, 24], ["cell clones", "CELL", 13, 24], ["positive cell clones", "CELL_LINE", 4, 24], ["The positive cell clones", "PROBLEM", 0, 24], ["positive cell clones", "OBSERVATION", 4, 24]]], ["Selected clones were cultured in the peritoneal cavities of pristane-primed BALB/c mice to obtain ascitic fluid.Preparation of monoclonal antibodies (MAbs) against NS1 ::: Materials and MethodsThe identity of the heavy and light chains of each MAb was determined using Pierce Rapid Isotyping Kit with Kappa and Lambda Mouse (Thermo, Rockford, IL, USA).Expression of short peptide fusion proteins ::: Materials and MethodsIn order to map the epitopes of monoclonal antibodies, a set of 51 16-amino acid partially-overlapping short peptides (NS1-1 to NS1-51; Table 1) covering the entire NS1 protein were designed and expressed as a fusion protein with GST in pGEX-6p-1 plasmids as described previously [23].", [["clones", "ANATOMY", 9, 15], ["peritoneal cavities", "ANATOMY", 37, 56], ["ascitic fluid", "ANATOMY", 98, 111], ["plasmids", "ANATOMY", 668, 676], ["pristane", "CHEMICAL", 60, 68], ["pristane", "CHEMICAL", 60, 68], ["16-amino acid", "CHEMICAL", 488, 501], ["clones", "CELL", 9, 15], ["peritoneal cavities", "MULTI-TISSUE_STRUCTURE", 37, 56], ["pristane", "SIMPLE_CHEMICAL", 60, 68], ["BALB/c mice", "ORGANISM", 76, 87], ["ascitic fluid", "ORGANISM_SUBSTANCE", 98, 111], ["NS1", "ORGANISM", 164, 167], ["MAb", "GENE_OR_GENE_PRODUCT", 244, 247], ["NS1-1", "GENE_OR_GENE_PRODUCT", 540, 545], ["NS1-51", "GENE_OR_GENE_PRODUCT", 549, 555], ["NS1", "GENE_OR_GENE_PRODUCT", 586, 589], ["GST", "GENE_OR_GENE_PRODUCT", 651, 654], ["pGEX-6p-1", "GENE_OR_GENE_PRODUCT", 658, 667], ["monoclonal antibodies", "PROTEIN", 127, 148], ["MAbs", "PROTEIN", 150, 154], ["NS1", "PROTEIN", 164, 167], ["heavy and light chains", "PROTEIN", 213, 235], ["MAb", "PROTEIN", 244, 247], ["short peptide fusion proteins", "PROTEIN", 366, 395], ["epitopes", "PROTEIN", 441, 449], ["monoclonal antibodies", "PROTEIN", 453, 474], ["NS1", "PROTEIN", 540, 543], ["NS1", "PROTEIN", 549, 552], ["NS1 protein", "PROTEIN", 586, 597], ["fusion protein", "PROTEIN", 631, 645], ["GST", "PROTEIN", 651, 654], ["pGEX-6p-1 plasmids", "DNA", 658, 676], ["mice", "SPECIES", 83, 87], ["Mouse", "SPECIES", 318, 323], ["mice", "SPECIES", 83, 87], ["Selected clones", "PROBLEM", 0, 15], ["ascitic fluid", "PROBLEM", 98, 111], ["Methods", "TREATMENT", 186, 193], ["each MAb", "TREATMENT", 239, 247], ["monoclonal antibodies", "TEST", 453, 474], ["a set", "TEST", 476, 481], ["amino acid", "TEST", 491, 501], ["NS1", "TEST", 540, 543], ["NS1", "TEST", 549, 552], ["the entire NS1 protein", "TEST", 575, 597], ["a fusion protein", "TEST", 629, 645], ["GST", "TEST", 651, 654], ["pGEX", "TEST", 658, 662], ["peritoneal", "ANATOMY", 37, 47], ["cavities", "ANATOMY_MODIFIER", 48, 56], ["ascitic", "ANATOMY", 98, 105], ["fluid", "OBSERVATION", 106, 111], ["heavy", "OBSERVATION_MODIFIER", 213, 218]]], ["In fine epitope mapping and specificity identification, all short peptides were expressed as the same way.", [["fine epitope mapping", "TEST", 3, 23], ["specificity identification", "TEST", 28, 54], ["all short peptides", "PROBLEM", 56, 74]]], ["All GST fusion proteins were purified by Glutathione Sepharose 4B RediPack column affinity chromatography according the manufacturer's instructions (Amersham Pharmacia Biotech).Enzyme-linked immunosorbent assay (ELISA) ::: Materials and MethodsNinety-six well microtiter plates were coated with purified fusion protein in 0.1 M carbonate buffer (pH 9.6) at 4\u00b0C overnight and blocked with 5% skimmed milk for 2 h at 37\u00b0C. After washing three times with PBST (PBS plus 0.5% Tween-20), 100 \u00b5L of hybridoma supernatant containing MAbs was added to each well and incubated at 37\u00b0C for 1 h, followed by three washes with PBST.", [["milk", "ANATOMY", 399, 403], ["supernatant", "ANATOMY", 503, 514], ["Glutathione", "CHEMICAL", 41, 52], ["Tween-20", "CHEMICAL", 472, 480], ["Glutathione", "CHEMICAL", 41, 52], ["carbonate", "CHEMICAL", 328, 337], ["Tween-20", "CHEMICAL", 472, 480], ["GST", "GENE_OR_GENE_PRODUCT", 4, 7], ["Glutathione", "SIMPLE_CHEMICAL", 41, 52], ["milk", "ORGANISM_SUBSTANCE", 399, 403], ["Tween-20", "SIMPLE_CHEMICAL", 472, 480], ["GST fusion proteins", "PROTEIN", 4, 23], ["purified fusion protein", "PROTEIN", 295, 318], ["MAbs", "PROTEIN", 526, 530], ["All GST fusion proteins", "TEST", 0, 23], ["Glutathione Sepharose", "TEST", 41, 62], ["affinity chromatography", "TEST", 82, 105], ["Enzyme", "TEST", 177, 183], ["immunosorbent assay", "TEST", 191, 210], ["Materials", "TREATMENT", 223, 232], ["MethodsNinety-six well microtiter plates", "TREATMENT", 237, 277], ["purified fusion protein", "TREATMENT", 295, 318], ["M carbonate buffer", "TREATMENT", 326, 344], ["pH", "TEST", 346, 348], ["5% skimmed milk", "TREATMENT", 388, 403], ["PBST", "TREATMENT", 452, 456], ["PBS", "TEST", 458, 461], ["hybridoma supernatant containing MAbs", "TREATMENT", 493, 530], ["PBST", "TREATMENT", 615, 619]]], ["The bound MAbs were detected with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Zhongshan Biotechnology Co., Ltd Beijing, China).", [["MAbs", "GENE_OR_GENE_PRODUCT", 10, 14], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 34, 56], ["HRP", "SIMPLE_CHEMICAL", 58, 61], ["horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG", "PROTEIN", 34, 93], ["horseradish", "SPECIES", 34, 45], ["goat", "SPECIES", 74, 78], ["anti-mouse", "SPECIES", 79, 89], ["The bound MAbs", "TEST", 0, 14], ["horseradish peroxidase", "TEST", 34, 56]]], ["After a further incubation and thorough washing with PBST, 100 \u00b5L of 3,3\u2032\u20135,5\u2032-tetramethyl benzidine (TMB) was added as a substrate for HRP.", [["3,3\u2032\u20135,5\u2032-tetramethyl benzidine", "CHEMICAL", 69, 100], ["TMB", "CHEMICAL", 102, 105], ["3,3\u2032\u20135,5\u2032-tetramethyl benzidine", "CHEMICAL", 69, 100], ["TMB", "CHEMICAL", 102, 105], ["3,3\u2032\u20135,5\u2032-tetramethyl benzidine", "SIMPLE_CHEMICAL", 69, 100], ["TMB", "SIMPLE_CHEMICAL", 102, 105], ["HRP", "SIMPLE_CHEMICAL", 136, 139], ["HRP", "PROTEIN", 136, 139], ["a further incubation", "TREATMENT", 6, 26], ["PBST", "TREATMENT", 53, 57], ["\u2032-tetramethyl benzidine (TMB)", "TREATMENT", 77, 106]]], ["The reaction was stopped after 15 min with 2 M H2SO4 and the absorbance was measured at 450 nm by an ELISA plate reader (Bio-Rad, Hercules, CA, USA).", [["H2SO4", "CHEMICAL", 47, 52], ["H2SO4", "CHEMICAL", 47, 52], ["The reaction", "PROBLEM", 0, 12], ["2 M H2SO4", "TREATMENT", 43, 52], ["the absorbance", "TEST", 57, 71], ["an ELISA plate", "TEST", 98, 112]]], ["Glutathione S-transferase (GST) and purified MBP-NS1 were used as negative and positive controls, respectively.", [["Glutathione", "CHEMICAL", 0, 11], ["Glutathione", "CHEMICAL", 0, 11], ["Glutathione S-transferase", "GENE_OR_GENE_PRODUCT", 0, 25], ["GST", "GENE_OR_GENE_PRODUCT", 27, 30], ["MBP", "GENE_OR_GENE_PRODUCT", 45, 48], ["NS1", "GENE_OR_GENE_PRODUCT", 49, 52], ["Glutathione S-transferase", "PROTEIN", 0, 25], ["GST", "PROTEIN", 27, 30], ["MBP", "PROTEIN", 45, 48], ["NS1", "PROTEIN", 49, 52], ["Glutathione S-transferase", "TEST", 0, 25], ["GST", "TEST", 27, 30], ["purified MBP-NS1", "TEST", 36, 52]]], ["Results depict the average of duplicate assays.Western blotting ::: Materials and MethodsVirus-infected cell lysates or expressed fusion proteins were subjected to electrophoresis on 12% SDS-PAGE after reduction with dithiothreitol (DTT) at 100\u00b0C for 5 min, then the samples were transferred to a nitrocellulose membrane.", [["cell lysates", "ANATOMY", 104, 116], ["samples", "ANATOMY", 267, 274], ["membrane", "ANATOMY", 312, 320], ["dithiothreitol", "CHEMICAL", 217, 231], ["DTT", "CHEMICAL", 233, 236], ["dithiothreitol", "CHEMICAL", 217, 231], ["DTT", "CHEMICAL", 233, 236], ["nitrocellulose", "CHEMICAL", 297, 311], ["MethodsVirus", "GENE_OR_GENE_PRODUCT", 82, 94], ["cell lysates", "CELL", 104, 116], ["dithiothreitol", "SIMPLE_CHEMICAL", 217, 231], ["DTT", "SIMPLE_CHEMICAL", 233, 236], ["membrane", "CELLULAR_COMPONENT", 312, 320], ["fusion proteins", "PROTEIN", 130, 145], ["duplicate assays", "TEST", 30, 46], ["Materials", "TEST", 68, 77], ["MethodsVirus", "TEST", 82, 94], ["infected cell lysates", "TREATMENT", 95, 116], ["expressed fusion proteins", "PROBLEM", 120, 145], ["electrophoresis", "TEST", 164, 179], ["12% SDS", "TREATMENT", 183, 190], ["dithiothreitol (DTT", "TREATMENT", 217, 236], ["a nitrocellulose membrane", "TREATMENT", 295, 320], ["infected cell lysates", "OBSERVATION", 95, 116]]], ["Nonspecific antibody binding sites were blocked with 5% skimmed milk powder in PBS overnight at 4\u00b0C. The membranes were incubated with MAbs as the primary antibody, after which each blot was washed five times with PBST and treated with IRDye 700-conjugated goat anti-mouse secondary antibodies (LICOR Biosciences, NE, USA).", [["milk", "ANATOMY", 64, 68], ["membranes", "ANATOMY", 105, 114], ["IRDye 700", "CHEMICAL", 236, 245], ["IRDye", "CHEMICAL", 236, 241], ["milk", "ORGANISM_SUBSTANCE", 64, 68], ["membranes", "CELLULAR_COMPONENT", 105, 114], ["IRDye 700", "SIMPLE_CHEMICAL", 236, 245], ["MAbs", "PROTEIN", 135, 139], ["primary antibody", "PROTEIN", 147, 163], ["IRDye 700", "PROTEIN", 236, 245], ["conjugated goat anti-mouse secondary antibodies", "PROTEIN", 246, 293], ["LICOR", "PROTEIN", 295, 300], ["NE", "PROTEIN", 314, 316], ["goat", "SPECIES", 257, 261], ["anti-mouse", "SPECIES", 262, 272], ["goat", "SPECIES", 257, 261], ["Nonspecific antibody binding sites", "PROBLEM", 0, 34], ["5% skimmed milk powder", "TREATMENT", 53, 75], ["MAbs", "TREATMENT", 135, 139], ["PBST", "TREATMENT", 214, 218], ["IRDye", "TREATMENT", 236, 241], ["antibody", "OBSERVATION", 12, 20]]], ["Blots were visualized by scanning the membranes with a LICOR Odyssey infrared image system (LICOR Biosciences).Production of MAbs ::: ResultsRecombinant JEV NS1 was successfully expressed in E. coli ER2523 after induction with IPTG.", [["membranes", "ANATOMY", 38, 47], ["IPTG", "CHEMICAL", 227, 231], ["IPTG", "CHEMICAL", 227, 231], ["membranes", "CELLULAR_COMPONENT", 38, 47], ["MAbs", "GENE_OR_GENE_PRODUCT", 125, 129], ["JEV NS1", "ORGANISM", 153, 160], ["E. coli", "ORGANISM", 191, 198], ["ER2523", "ORGANISM", 199, 205], ["IPTG", "SIMPLE_CHEMICAL", 227, 231], ["MAbs", "PROTEIN", 125, 129], ["ResultsRecombinant JEV NS1", "PROTEIN", 134, 160], ["E. coli", "SPECIES", 191, 198], ["JEV", "SPECIES", 153, 156], ["E. coli", "SPECIES", 191, 198], ["Blots", "TEST", 0, 5], ["ResultsRecombinant JEV NS1", "PROBLEM", 134, 160], ["IPTG", "TREATMENT", 227, 231], ["E. coli", "OBSERVATION_MODIFIER", 191, 198]]], ["Most of the expressed fusion protein MBP-NS1 was soluble in the supernatant of the sonified bacterial cell lysate.", [["supernatant", "ANATOMY", 64, 75], ["cell lysate", "ANATOMY", 102, 113], ["MBP", "GENE_OR_GENE_PRODUCT", 37, 40], ["NS1", "GENE_OR_GENE_PRODUCT", 41, 44], ["bacterial cell", "CELL", 92, 106], ["MBP", "PROTEIN", 37, 40], ["NS1", "PROTEIN", 41, 44], ["the expressed fusion protein MBP", "TREATMENT", 8, 40], ["NS1", "TREATMENT", 41, 44], ["the sonified bacterial cell lysate", "TREATMENT", 79, 113], ["fusion", "OBSERVATION", 22, 28], ["bacterial cell lysate", "OBSERVATION", 92, 113]]], ["The recombinant protein could be recognized by JEV-positive serum from mice (Fig. 1), so purified proteins were used to immunize BALB/c mice.", [["serum", "ANATOMY", 60, 65], ["JEV", "ORGANISM", 47, 50], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["mice", "ORGANISM", 71, 75], ["BALB/c mice", "ORGANISM", 129, 140], ["recombinant protein", "PROTEIN", 4, 23], ["purified proteins", "PROTEIN", 89, 106], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 136, 140], ["JEV", "SPECIES", 47, 50], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 136, 140], ["The recombinant protein", "TEST", 0, 23], ["JEV", "TEST", 47, 50]]], ["After cell fusion and selection, we generated and selected eleven hybridoma cell lines, which produced MAbs that strongly bound recombinant MBP-NS1 and native NS1 of JEV by indirect ELISA and Western blotting.", [["cell", "ANATOMY", 6, 10], ["hybridoma cell lines", "ANATOMY", 66, 86], ["cell", "CELL", 6, 10], ["hybridoma cell lines", "CELL", 66, 86], ["MAbs", "GENE_OR_GENE_PRODUCT", 103, 107], ["MBP-NS1", "GENE_OR_GENE_PRODUCT", 140, 147], ["NS1", "GENE_OR_GENE_PRODUCT", 159, 162], ["JEV", "ORGANISM", 166, 169], ["hybridoma cell lines", "CELL_LINE", 66, 86], ["MAbs", "PROTEIN", 103, 107], ["MBP", "PROTEIN", 140, 143], ["NS1", "PROTEIN", 144, 147], ["NS1", "PROTEIN", 159, 162], ["JEV", "SPECIES", 166, 169], ["cell fusion", "TREATMENT", 6, 17], ["eleven hybridoma cell lines", "TREATMENT", 59, 86], ["MBP", "TEST", 140, 143], ["NS1", "PROBLEM", 144, 147], ["indirect ELISA", "TEST", 173, 187], ["cell fusion", "OBSERVATION", 6, 17], ["hybridoma cell lines", "OBSERVATION", 66, 86]]], ["We further analyzed these MAbs for cross-reactivity with WNV, DENV1, DENV2, DENV3 and DENV4 by Western blotting.", [["MAbs", "GENE_OR_GENE_PRODUCT", 26, 30], ["WNV", "ORGANISM", 57, 60], ["DENV1", "GENE_OR_GENE_PRODUCT", 62, 67], ["DENV2", "ORGANISM", 69, 74], ["DENV3", "GENE_OR_GENE_PRODUCT", 76, 81], ["DENV4", "GENE_OR_GENE_PRODUCT", 86, 91], ["MAbs", "PROTEIN", 26, 30], ["DENV1", "PROTEIN", 62, 67], ["DENV3", "PROTEIN", 76, 81], ["DENV4", "PROTEIN", 86, 91], ["WNV", "SPECIES", 57, 60], ["DENV1", "SPECIES", 62, 67], ["DENV2", "SPECIES", 69, 74], ["DENV3", "SPECIES", 76, 81], ["these MAbs", "TEST", 20, 30], ["WNV", "PROBLEM", 57, 60], ["DENV2", "PROBLEM", 69, 74]]], ["All the MAbs were JEV specific and did not recognize NS1 from WNV or DENV (Table 2).", [["MAbs", "GENE_OR_GENE_PRODUCT", 8, 12], ["JEV", "ORGANISM", 18, 21], ["NS1", "GENE_OR_GENE_PRODUCT", 53, 56], ["WNV", "ORGANISM", 62, 65], ["MAbs", "PROTEIN", 8, 12], ["NS1", "PROTEIN", 53, 56], ["JEV", "SPECIES", 18, 21], ["WNV", "SPECIES", 62, 65], ["DENV", "SPECIES", 69, 73], ["NS1", "PROBLEM", 53, 56], ["DENV", "PROBLEM", 69, 73]]], ["As shown in Table 2, the NS1-specific MAb heavy-chain subclasses were identified as IgG1, IgG2a or IgG2b, while the light chains were all subtype \u03ba.", [["NS1", "GENE_OR_GENE_PRODUCT", 25, 28], ["IgG1", "GENE_OR_GENE_PRODUCT", 84, 88], ["IgG2a", "GENE_OR_GENE_PRODUCT", 90, 95], ["IgG2b", "GENE_OR_GENE_PRODUCT", 99, 104], ["NS1", "PROTEIN", 25, 28], ["MAb heavy-chain subclasses", "PROTEIN", 38, 64], ["IgG1", "PROTEIN", 84, 88], ["IgG2a", "PROTEIN", 90, 95], ["IgG2b", "PROTEIN", 99, 104], ["light chains", "PROTEIN", 116, 128], ["the NS1", "TEST", 21, 28], ["IgG1", "TEST", 84, 88], ["IgG2b", "TEST", 99, 104]]], ["The titers of antibodies secreted into the culture supernatant and ascitic fluid were measured by indirect ELISA.", [["culture supernatant", "ANATOMY", 43, 62], ["ascitic fluid", "ANATOMY", 67, 80], ["ascitic fluid", "ORGANISM_SUBSTANCE", 67, 80], ["antibodies", "PROTEIN", 14, 24], ["The titers of antibodies", "TREATMENT", 0, 24], ["the culture supernatant", "TEST", 39, 62], ["ascitic fluid", "PROBLEM", 67, 80], ["indirect ELISA", "TEST", 98, 112], ["ascitic fluid", "OBSERVATION", 67, 80]]], ["Antibody titers ranged from 32 to 2048.", [["Antibody titers", "TEST", 0, 15]]], ["Antibody titers of ascitic fluid were 204,800 or higher except for 8B5 which was 25,600 (Table 2).Mapping of antigenic epitopes on JEV NS1 ::: ResultsTo map the antigenic epitopes of JEV NS1, 51 short peptides were expressed in a fusion protein with GST and probed by MAbs.", [["ascitic fluid", "ANATOMY", 19, 32], ["ascitic fluid", "ORGANISM_SUBSTANCE", 19, 32], ["JEV", "ORGANISM", 131, 134], ["NS1", "ORGANISM", 135, 138], ["JEV NS1", "ORGANISM", 183, 190], ["GST", "GENE_OR_GENE_PRODUCT", 250, 253], ["antigenic epitopes", "PROTEIN", 109, 127], ["JEV NS1", "PROTEIN", 131, 138], ["antigenic epitopes", "PROTEIN", 161, 179], ["JEV NS1", "PROTEIN", 183, 190], ["fusion protein", "PROTEIN", 230, 244], ["GST", "PROTEIN", 250, 253], ["MAbs", "PROTEIN", 268, 272], ["JEV", "SPECIES", 131, 134], ["JEV NS1", "SPECIES", 183, 190], ["Antibody titers", "TEST", 0, 15], ["ascitic fluid", "TEST", 19, 32], ["JEV NS1", "TEST", 183, 190], ["short peptides", "PROBLEM", 195, 209], ["a fusion protein with GST", "TREATMENT", 228, 253], ["ascitic fluid", "OBSERVATION", 19, 32], ["JEV NS1", "OBSERVATION", 183, 190]]], ["ELISA results showed that five peptide fusion proteins were recognized by eleven MAbs.", [["peptide fusion proteins", "PROTEIN", 31, 54], ["MAbs", "PROTEIN", 81, 85], ["ELISA results", "TEST", 0, 13], ["five peptide fusion proteins", "PROBLEM", 26, 54]]], ["NS1-1, NS1-9 and NS1-32 were recognized by MAb 10F7, 8B5 and 7G1, respectively.", [["NS1-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["NS1-9", "GENE_OR_GENE_PRODUCT", 7, 12], ["NS1-32", "GENE_OR_GENE_PRODUCT", 17, 23], ["7G1", "GENE_OR_GENE_PRODUCT", 61, 64], ["NS1", "PROTEIN", 0, 3], ["NS1", "PROTEIN", 7, 10], ["NS1", "PROTEIN", 17, 20], ["MAb 10F7", "PROTEIN", 43, 51], ["8B5", "PROTEIN", 53, 56], ["7G1", "PROTEIN", 61, 64], ["NS1", "TEST", 0, 3], ["NS1", "TEST", 7, 10], ["NS1", "TEST", 17, 20]]], ["NS1-34 was recognized by three MAbs (7C11, 4E3 and HA12), and NS1-43 was recognized by five MAbs (3H11, 3G11, 4E8, 5C6 and 6D8) (Fig. 2).", [["NS1-34", "GENE_OR_GENE_PRODUCT", 0, 6], ["4E3", "GENE_OR_GENE_PRODUCT", 43, 46], ["HA12", "GENE_OR_GENE_PRODUCT", 51, 55], ["NS1-43", "GENE_OR_GENE_PRODUCT", 62, 68], ["NS1", "PROTEIN", 0, 3], ["MAbs", "PROTEIN", 31, 35], ["7C11", "PROTEIN", 37, 41], ["4E3", "PROTEIN", 43, 46], ["HA12", "PROTEIN", 51, 55], ["NS1", "PROTEIN", 62, 65], ["MAbs", "PROTEIN", 92, 96], ["3H11", "PROTEIN", 98, 102], ["3G11", "PROTEIN", 104, 108], ["4E8", "PROTEIN", 110, 113], ["5C6", "PROTEIN", 115, 118], ["6D8", "PROTEIN", 123, 126], ["NS1", "TEST", 0, 3], ["HA12", "TEST", 51, 55], ["NS1", "TEST", 62, 65]]], ["The results indicate that there are at least five linear epitopes located throughout NS1.Fine mapping of epitopes ::: ResultsTo precisely locate the core sequences of epitopes on NS1, a series of truncated peptides were designed and expressed as a fusion with GST.", [["NS1", "GENE_OR_GENE_PRODUCT", 85, 88], ["NS1", "GENE_OR_GENE_PRODUCT", 179, 182], ["GST", "GENE_OR_GENE_PRODUCT", 260, 263], ["NS1", "PROTEIN", 85, 88], ["epitopes", "PROTEIN", 105, 113], ["epitopes", "PROTEIN", 167, 175], ["NS1", "PROTEIN", 179, 182], ["GST", "PROTEIN", 260, 263], ["truncated peptides", "PROBLEM", 196, 214], ["a fusion with GST", "TREATMENT", 246, 263], ["linear", "OBSERVATION_MODIFIER", 50, 56], ["epitopes", "OBSERVATION", 57, 65]]], ["Firstly, one or two amino acid residues were sequentially removed from the carboxy terminal of the peptide until the minimum peptide was 9 amino acids long.", [["amino acid", "CHEMICAL", 20, 30], ["9 amino acids", "CHEMICAL", 137, 150], ["amino acid", "CHEMICAL", 20, 30], ["carboxy", "CHEMICAL", 75, 82], ["amino acids", "CHEMICAL", 139, 150], ["amino acid", "AMINO_ACID", 20, 30], ["amino acids", "AMINO_ACID", 139, 150], ["carboxy terminal", "PROTEIN", 75, 91], ["two amino acid residues", "TREATMENT", 16, 39], ["the minimum peptide", "TEST", 113, 132], ["acid residues", "OBSERVATION", 26, 39]]], ["The shortened GST-fusion peptides were analyzed by ELISA using specific MAbs.", [["GST", "GENE_OR_GENE_PRODUCT", 14, 17], ["GST", "PROTEIN", 14, 17], ["The shortened GST-fusion peptides", "TREATMENT", 0, 33]]], ["Next, one or two amino acid residues were removed from the amino terminal of the peptide in the same fashion.", [["amino acid", "CHEMICAL", 17, 27], ["amino acid", "CHEMICAL", 17, 27], ["amino", "CHEMICAL", 59, 64], ["amino acid", "AMINO_ACID", 17, 27], ["amino terminal", "AMINO_ACID", 59, 73], ["two amino acid residues", "TREATMENT", 13, 36]]], ["The shortened GST-fusion peptides were also analyzed by ELISA with specific MAbs.", [["GST", "GENE_OR_GENE_PRODUCT", 14, 17], ["GST", "PROTEIN", 14, 17], ["specific MAbs", "PROTEIN", 67, 80], ["The shortened GST-fusion peptides", "TREATMENT", 0, 33]]], ["As Figure 3 indicates, 5AIDITRK11 is the minimal requirement for MAb 10F7 to recognize the linearized epitope NS1-1.", [["5AIDITRK11", "GENE_OR_GENE_PRODUCT", 23, 33], ["MAb 10F7", "GENE_OR_GENE_PRODUCT", 65, 73], ["NS1-1", "GENE_OR_GENE_PRODUCT", 110, 115], ["5AIDITRK11", "PROTEIN", 23, 33], ["MAb 10F7", "PROTEIN", 65, 73], ["linearized epitope NS1-1", "PROTEIN", 91, 115], ["MAb", "TREATMENT", 65, 68], ["the linearized epitope NS1", "TREATMENT", 87, 113]]], ["The minimal linear sequence of epitope NS1-9 for MAb 8B5 is 72RDELNVL78; 251KSKHNRREGY260 for epitope NS1-32 for MAb 7G1; 269DENGIVLD276 for epitope NS1-34 for MAb 7C11 (and MAbs 4E3 and HA12 [data not shown]); 341DETTLVRS348 for epitope NS1-43 for MAb 3H11, 3G11, 4E8, 5C6 and 6D8.Identification of conserved and virus specific B-cell epitopes on NS1 of JEV ::: ResultsTo investigate whether the identified linear epitopes were specific or conserved among viruses of the JEV isolates, NS1 sequences of SA14-14-2 strain were analyzed by Blast in the NCBI Entre protein database (http://blast.ncbi.nlm.nih.gov/Blast.cgi).", [["B-cell", "ANATOMY", 329, 335], ["B-cell", "CELL", 329, 335], ["NS1", "ORGANISM", 348, 351], ["JEV", "ORGANISM", 355, 358], ["JEV", "ORGANISM", 472, 475], ["NS1", "ORGANISM", 486, 489], ["SA14-14-2", "ORGANISM", 503, 512], ["minimal linear sequence", "DNA", 4, 27], ["epitope NS1-9", "PROTEIN", 31, 44], ["MAb 8B5", "PROTEIN", 49, 56], ["NS1", "PROTEIN", 102, 105], ["MAb 7G1", "PROTEIN", 113, 120], ["269DENGIVLD276", "PROTEIN", 122, 136], ["epitope NS1-34", "PROTEIN", 141, 155], ["MAb 7C11", "PROTEIN", 160, 168], ["MAbs 4E3", "PROTEIN", 174, 182], ["HA12", "PROTEIN", 187, 191], ["341DETTLVRS348", "PROTEIN", 211, 225], ["NS1", "PROTEIN", 238, 241], ["3H11", "PROTEIN", 253, 257], ["3G11", "PROTEIN", 259, 263], ["4E8", "PROTEIN", 265, 268], ["5C6", "PROTEIN", 270, 273], ["6D8", "PROTEIN", 278, 281], ["B-cell epitopes", "PROTEIN", 329, 344], ["NS1", "PROTEIN", 348, 351], ["NS1 sequences", "DNA", 486, 499], ["JEV", "SPECIES", 355, 358], ["JEV", "SPECIES", 472, 475], ["epitope NS1", "TEST", 31, 42], ["MAb", "TEST", 49, 52], ["epitope NS1", "TEST", 94, 105], ["MAb", "TEST", 113, 116], ["epitope NS1", "TEST", 141, 152], ["MAb", "TEST", 160, 163], ["MAbs", "TEST", 174, 178], ["HA12", "TEST", 187, 191], ["epitope NS1", "TEST", 230, 241], ["MAb", "TEST", 249, 252], ["the identified linear epitopes", "PROBLEM", 393, 423], ["the JEV isolates", "TEST", 468, 484], ["NS1 sequences", "TEST", 486, 499], ["SA14", "TEST", 503, 507], ["minimal", "OBSERVATION_MODIFIER", 4, 11], ["linear", "OBSERVATION_MODIFIER", 12, 18], ["linear", "OBSERVATION_MODIFIER", 408, 414], ["epitopes", "OBSERVATION", 415, 423]]], ["From this search, 100 JEV NS1 protein or genome polyprotein sequences were selected for sequence alignment.", [["JEV", "ORGANISM", 22, 25], ["NS1", "GENE_OR_GENE_PRODUCT", 26, 29], ["JEV NS1 protein", "PROTEIN", 22, 37], ["genome polyprotein sequences", "DNA", 41, 69], ["JEV", "SPECIES", 22, 25], ["this search", "TEST", 5, 16], ["JEV NS1 protein", "TEST", 22, 37], ["genome polyprotein sequences", "TEST", 41, 69]]], ["Alignment of the five linear epitopes of NS1 from different JEV isolates revealed all five epitopes are highly conserved among JEV isolates.", [["NS1", "GENE_OR_GENE_PRODUCT", 41, 44], ["JEV", "ORGANISM", 60, 63], ["JEV", "ORGANISM", 127, 130], ["NS1", "PROTEIN", 41, 44], ["epitopes", "PROTEIN", 91, 99], ["JEV", "SPECIES", 60, 63], ["JEV", "SPECIES", 127, 130], ["NS1", "PROBLEM", 41, 44], ["different JEV isolates", "TEST", 50, 72], ["all five epitopes", "PROBLEM", 82, 99], ["JEV isolates", "OBSERVATION", 127, 139]]], ["Especially the epitopes NS1-9 72RDELNVL78 and NS1-34 269DENGIVLD276, as 99 of 100 isolates show 100% sequence identity.", [["epitopes", "PROTEIN", 15, 23], ["NS1", "PROTEIN", 24, 27], ["72RDELNVL78", "PROTEIN", 30, 41], ["NS1", "PROTEIN", 46, 49], ["269DENGIVLD276", "PROTEIN", 53, 67], ["the epitopes NS1", "TEST", 11, 27], ["NS1", "TEST", 46, 49]]], ["In the corresponding sequences of all other JEV isolates there is only one amino acid substitution in conserved epitopes (Table 3).Identification of conserved and virus specific B-cell epitopes on NS1 of JEV ::: ResultsSequence alignment was also performed between these five B-cell epitopes with homologous sequences from other flaviviruses including WNV, MVEV and DENV (Fig. 4, right panels).", [["B-cell", "ANATOMY", 178, 184], ["B-cell", "ANATOMY", 276, 282], ["JEV", "DISEASE", 44, 47], ["amino acid", "CHEMICAL", 75, 85], ["amino acid", "CHEMICAL", 75, 85], ["JEV", "ORGANISM", 44, 47], ["amino acid", "AMINO_ACID", 75, 85], ["B-cell", "CELL", 178, 184], ["NS1", "ORGANISM", 197, 200], ["JEV", "ORGANISM", 204, 207], ["B-cell", "CELL", 276, 282], ["WNV", "ORGANISM", 352, 355], ["conserved epitopes", "PROTEIN", 102, 120], ["Table 3", "PROTEIN", 122, 129], ["B-cell epitopes", "PROTEIN", 178, 193], ["NS1", "PROTEIN", 197, 200], ["B-cell epitopes", "PROTEIN", 276, 291], ["JEV", "SPECIES", 44, 47], ["JEV", "SPECIES", 204, 207], ["WNV", "SPECIES", 352, 355], ["MVEV", "SPECIES", 357, 361], ["DENV", "SPECIES", 366, 370], ["one amino acid substitution", "TREATMENT", 71, 98], ["homologous sequences", "TEST", 297, 317], ["WNV", "PROBLEM", 352, 355], ["MVEV", "TEST", 357, 361], ["DENV (Fig.", "TEST", 366, 376], ["JEV isolates", "OBSERVATION", 44, 56], ["acid substitution", "OBSERVATION", 81, 98]]], ["Alignment results showed that all five identified epitopes have less than 50% identity with DENV (1\u20134) NS1 sequences.", [["NS1", "ORGANISM", 103, 106], ["epitopes", "PROTEIN", 50, 58], ["DENV (1\u20134) NS1 sequences", "DNA", 92, 116], ["DENV (1\u20134) NS1 sequences", "TEST", 92, 116]]], ["After the corresponding peptides for epitopes NS1-1, NS1-32 and NS1-34 were expressed and tested by ELISA, no positive reaction with MAbs and mouse sera against JEV NS1 was found for the homologous sequences from WNV and MVEV (Fig. 4, left panels).", [["sera", "ANATOMY", 148, 152], ["NS1-1", "GENE_OR_GENE_PRODUCT", 46, 51], ["NS1-32", "GENE_OR_GENE_PRODUCT", 53, 59], ["NS1-34", "GENE_OR_GENE_PRODUCT", 64, 70], ["MAbs", "GENE_OR_GENE_PRODUCT", 133, 137], ["mouse", "ORGANISM", 142, 147], ["sera", "ORGANISM_SUBSTANCE", 148, 152], ["JEV", "ORGANISM", 161, 164], ["NS1", "ORGANISM", 165, 168], ["WNV", "ORGANISM", 213, 216], ["epitopes", "PROTEIN", 37, 45], ["NS1", "PROTEIN", 46, 49], ["NS1", "PROTEIN", 53, 56], ["NS1", "PROTEIN", 64, 67], ["MAbs", "PROTEIN", 133, 137], ["JEV NS1", "PROTEIN", 161, 168], ["mouse", "SPECIES", 142, 147], ["mouse", "SPECIES", 142, 147], ["JEV", "SPECIES", 161, 164], ["WNV", "SPECIES", 213, 216], ["MVEV", "SPECIES", 221, 225], ["the corresponding peptides", "TEST", 6, 32], ["epitopes", "TEST", 37, 45], ["NS1", "TEST", 46, 49], ["NS1", "TEST", 53, 56], ["NS1", "TEST", 64, 67], ["ELISA", "TEST", 100, 105], ["positive reaction", "PROBLEM", 110, 127], ["MAbs", "TEST", 133, 137], ["mouse sera", "TEST", 142, 152], ["JEV NS1", "PROBLEM", 161, 168], ["the homologous sequences", "TEST", 183, 207], ["WNV", "TEST", 213, 216], ["MVEV", "TEST", 221, 225], ["left panels", "TEST", 235, 246], ["left", "ANATOMY_MODIFIER", 235, 239]]], ["Further, no epitope-specific MAbs could recognize the corresponding peptides from WNV epitopes.Identification of conserved and virus specific B-cell epitopes on NS1 of JEV ::: ResultsWe then determined the reactivity of sera against WNV and DENV with the identified epitope-derived peptides.", [["B-cell", "ANATOMY", 142, 148], ["sera", "ANATOMY", 220, 224], ["MAbs", "GENE_OR_GENE_PRODUCT", 29, 33], ["WNV", "ORGANISM", 82, 85], ["B-cell", "CELL", 142, 148], ["NS1", "ORGANISM", 161, 164], ["JEV", "ORGANISM", 168, 171], ["sera", "ORGANISM_SUBSTANCE", 220, 224], ["WNV", "ORGANISM", 233, 236], ["DENV", "ORGANISM", 241, 245], ["epitope", "PROTEIN", 12, 19], ["MAbs", "PROTEIN", 29, 33], ["WNV epitopes", "PROTEIN", 82, 94], ["B-cell epitopes", "PROTEIN", 142, 157], ["NS1", "PROTEIN", 161, 164], ["epitope", "PROTEIN", 266, 273], ["JEV", "SPECIES", 168, 171], ["WNV", "SPECIES", 233, 236], ["DENV", "SPECIES", 241, 245], ["epitope", "PROBLEM", 12, 19], ["WNV epitopes", "PROBLEM", 82, 94], ["WNV", "PROBLEM", 233, 236], ["DENV", "PROBLEM", 241, 245], ["no", "UNCERTAINTY", 9, 11]]], ["The results showed that neither sera against WNV nor DENV reacted with the five JEV NS1 epitopes (Fig. 5).DiscussionFlaviviral NS1 protein is involved in virus replication [25], [26] and induces a protective immune response against lethal virus infections though it does not induce neutralizing antibodies [27].", [["sera", "ANATOMY", 32, 36], ["lethal virus infections", "DISEASE", 232, 255], ["sera", "ORGANISM_SUBSTANCE", 32, 36], ["WNV", "ORGANISM", 45, 48], ["DENV", "ORGANISM", 53, 57], ["JEV", "ORGANISM", 80, 83], ["NS1", "GENE_OR_GENE_PRODUCT", 127, 130], ["JEV NS1 epitopes", "PROTEIN", 80, 96], ["Flaviviral NS1 protein", "PROTEIN", 116, 138], ["neutralizing antibodies", "PROTEIN", 282, 305], ["WNV", "SPECIES", 45, 48], ["DENV", "SPECIES", 53, 57], ["JEV", "SPECIES", 80, 83], ["WNV", "PROBLEM", 45, 48], ["DENV", "PROBLEM", 53, 57], ["Flaviviral NS1 protein", "TREATMENT", 116, 138], ["a protective immune response", "TREATMENT", 195, 223], ["lethal virus infections", "PROBLEM", 232, 255], ["neutralizing antibodies", "PROBLEM", 282, 305]]], ["Passive administration of MAbs against NS1 or active immunization with NS1 gene/proteins confirmed protection from a lethal JEV challenge [5], [6], [28].", [["JEV", "DISEASE", 124, 127], ["NS1", "GENE_OR_GENE_PRODUCT", 39, 42], ["NS1", "GENE_OR_GENE_PRODUCT", 71, 74], ["JEV", "ORGANISM", 124, 127], ["MAbs", "PROTEIN", 26, 30], ["NS1", "PROTEIN", 39, 42], ["NS1 gene", "DNA", 71, 79], ["JEV", "SPECIES", 124, 127], ["Passive administration of MAbs", "TREATMENT", 0, 30], ["NS1", "TREATMENT", 39, 42], ["active immunization", "TREATMENT", 46, 65], ["NS1 gene/proteins", "TREATMENT", 71, 88], ["a lethal JEV challenge", "TREATMENT", 115, 137]]], ["Serological cross-reactivity among members of the JEV serocomplex and other flaviviruses could confound detection results [29], especially in regions where two or more flaviviruses co-exist [30].", [["flaviviruses", "DISEASE", 168, 180], ["JEV serocomplex", "ORGANISM", 50, 65], ["JEV serocomplex", "SPECIES", 50, 65], ["JEV serocomplex", "SPECIES", 50, 65], ["Serological cross-reactivity", "TEST", 0, 28], ["the JEV serocomplex", "PROBLEM", 46, 65], ["other flaviviruses", "PROBLEM", 70, 88]]], ["It was difficult to differentiate between viruses using ELISA or even by neutralization tests or other serological methods.", [["viruses", "PROBLEM", 42, 49], ["ELISA", "TEST", 56, 61], ["neutralization tests", "TEST", 73, 93]]], ["The cross-reactivity among flaviviruses is primarily caused by the E glycoprotein [31].", [["flaviviruses", "DISEASE", 27, 39], ["E glycoprotein", "PROTEIN", 67, 81], ["The cross-reactivity among flaviviruses", "PROBLEM", 0, 39], ["flaviviruses", "OBSERVATION", 27, 39]]], ["Though NS1 is thought to contain more virus-specific epitopes than E protein [32], there are epitopes on NS1 of WNV cross-reacted with antibody against JEV-serocomplex virus [33]\u2013[36].", [["NS1", "GENE_OR_GENE_PRODUCT", 7, 10], ["NS1", "GENE_OR_GENE_PRODUCT", 105, 108], ["WNV", "ORGANISM", 112, 115], ["JEV-serocomplex virus", "ORGANISM", 152, 173], ["NS1", "PROTEIN", 7, 10], ["epitopes", "PROTEIN", 53, 61], ["E protein", "PROTEIN", 67, 76], ["epitopes", "PROTEIN", 93, 101], ["NS1", "PROTEIN", 105, 108], ["JEV-serocomplex virus", "SPECIES", 152, 173], ["WNV", "SPECIES", 112, 115], ["JEV-serocomplex virus", "SPECIES", 152, 173], ["NS1", "PROBLEM", 7, 10], ["more virus", "PROBLEM", 33, 43], ["E protein", "TEST", 67, 76], ["epitopes", "PROBLEM", 93, 101], ["NS1", "TEST", 105, 108], ["WNV cross-", "TEST", 112, 122], ["antibody", "TEST", 135, 143], ["JEV-serocomplex virus", "TEST", 152, 173]]], ["Therefore, identification of epitopes on NS1 is important for subunit vaccine design and for developing serological tests that can differentiate between infections caused by flaviviruses of the JEV serocomplex and other flaviviruses.DiscussionIn this study, we constructed a panel of JEV NS1-specific MAbs with 6\u00d7His-tagged and MBP-tagged recombinant JEV NS1 protein.", [["infections", "DISEASE", 153, 163], ["JEV serocomplex", "DISEASE", 194, 209], ["flaviviruses", "DISEASE", 220, 232], ["NS1", "GENE_OR_GENE_PRODUCT", 41, 44], ["JEV serocomplex", "ORGANISM", 194, 209], ["JEV", "ORGANISM", 284, 287], ["NS1", "GENE_OR_GENE_PRODUCT", 288, 291], ["MBP", "GENE_OR_GENE_PRODUCT", 328, 331], ["JEV", "ORGANISM", 351, 354], ["NS1", "ORGANISM", 355, 358], ["epitopes", "PROTEIN", 29, 37], ["NS1", "PROTEIN", 41, 44], ["JEV NS1-specific MAbs", "PROTEIN", 284, 305], ["6\u00d7His-tagged and MBP-tagged recombinant JEV NS1 protein", "PROTEIN", 311, 366], ["JEV serocomplex", "SPECIES", 194, 209], ["JEV serocomplex", "SPECIES", 194, 209], ["JEV", "SPECIES", 284, 287], ["JEV", "SPECIES", 351, 354], ["epitopes", "PROBLEM", 29, 37], ["NS1", "TREATMENT", 41, 44], ["subunit vaccine design", "TREATMENT", 62, 84], ["developing serological tests", "TEST", 93, 121], ["infections", "PROBLEM", 153, 163], ["flaviviruses", "PROBLEM", 174, 186], ["the JEV serocomplex", "TREATMENT", 190, 209], ["other flaviviruses", "PROBLEM", 214, 232], ["this study", "TEST", 246, 256], ["JEV NS1", "TEST", 284, 291], ["MBP", "TEST", 328, 331], ["flaviviruses", "OBSERVATION", 174, 186]]], ["After testing NS1-derived short fusion peptides against MAbs, five peptides were identified by eleven MAbs.", [["NS1", "GENE_OR_GENE_PRODUCT", 14, 17], ["NS1", "PROTEIN", 14, 17], ["MAbs", "PROTEIN", 56, 60], ["MAbs", "PROTEIN", 102, 106], ["testing", "TEST", 6, 13], ["NS1", "TEST", 14, 17], ["short fusion peptides", "TREATMENT", 26, 47], ["MAbs", "TEST", 56, 60], ["five peptides", "TEST", 62, 75]]], ["These peptides correspond to JEV NS1 residues 1\u201316, 65\u201380, 249\u2013264, 265\u2013280 and 337\u2013352, respectively, and are referred to as peptides NS1-1, -9, -32, -34 and -43.", [["JEV", "ORGANISM", 29, 32], ["NS1", "GENE_OR_GENE_PRODUCT", 33, 36], ["NS1-1", "GENE_OR_GENE_PRODUCT", 135, 140], ["JEV NS1 residues", "PROTEIN", 29, 45], ["NS1", "PROTEIN", 135, 138], ["These peptides", "TEST", 0, 14], ["JEV NS1 residues", "TEST", 29, 45], ["NS1", "TEST", 135, 138], ["JEV NS1 residues", "OBSERVATION", 29, 45]]], ["The peptides NS1-1, NS1-9 and NS1-32 were recognized by only one MAb; however, peptide NS1-34 was recognized by three MAbs, and peptide NS1-43 was recognized by five MAbs.", [["NS1-1", "GENE_OR_GENE_PRODUCT", 13, 18], ["NS1-9", "GENE_OR_GENE_PRODUCT", 20, 25], ["NS1-32", "GENE_OR_GENE_PRODUCT", 30, 36], ["NS1-43", "GENE_OR_GENE_PRODUCT", 136, 142], ["NS1", "PROTEIN", 13, 16], ["NS1", "PROTEIN", 20, 23], ["NS1", "PROTEIN", 30, 33], ["MAb", "PROTEIN", 65, 68], ["NS1", "PROTEIN", 87, 90], ["MAbs", "PROTEIN", 118, 122], ["NS1", "PROTEIN", 136, 139], ["MAbs", "PROTEIN", 166, 170], ["The peptides NS1", "TEST", 0, 16], ["NS1", "TEST", 20, 23], ["NS1", "TEST", 30, 33], ["peptide NS1", "TEST", 79, 90], ["peptide NS1", "TEST", 128, 139], ["NS1", "OBSERVATION", 13, 16]]], ["Peptide NS1-34 and peptide NS1-43 may therefore contain more than one epitope respectively.", [["NS1-34", "GENE_OR_GENE_PRODUCT", 8, 14], ["NS1", "PROTEIN", 8, 11], ["NS1", "PROTEIN", 27, 30], ["Peptide NS1", "TEST", 0, 11], ["peptide NS1", "TEST", 19, 30]]], ["In order finely map the epitopes, we designed and expressed sets of shortened fusion peptides for each of the above-mentioned peptides.", [["epitopes", "PROTEIN", 24, 32], ["shortened fusion peptides", "TREATMENT", 68, 93], ["the above-mentioned peptides", "TREATMENT", 106, 134]]], ["After probing the shortened fusion peptides with MAbs, we confirmed five linear epitopes and deduced that the minimal units of epitopes of NS1-1, -9, -32, -34, -43 were 5AIDITRK11, 72RDELNVL78, 251KSKHNRREGY260, 269DENGIVLD276, 341DETTLVRS348, respectively.DiscussionSequence alignment showed that the epitopes are highly conserved among JEV strains.", [["NS1-1", "GENE_OR_GENE_PRODUCT", 139, 144], ["JEV", "ORGANISM", 338, 341], ["MAbs", "PROTEIN", 49, 53], ["epitopes", "PROTEIN", 127, 135], ["NS1", "PROTEIN", 139, 142], ["epitopes", "PROTEIN", 302, 310], ["JEV", "SPECIES", 338, 341], ["the shortened fusion peptides", "TREATMENT", 14, 43], ["MAbs", "TREATMENT", 49, 53], ["five linear epitopes", "PROBLEM", 68, 88], ["NS1", "TEST", 139, 142], ["KSKHNRREGY260", "TEST", 197, 210], ["Sequence alignment", "TEST", 267, 285], ["the epitopes", "PROBLEM", 298, 310], ["minimal", "OBSERVATION_MODIFIER", 110, 117]]], ["Notably, epitopes NS1-9 and NS1-34 have 99% identity among 100 JEV strains, and there was only one amino acid substitution in all of the heterologous peptides corresponding to the respective epitope.", [["amino acid", "CHEMICAL", 99, 109], ["amino acid", "CHEMICAL", 99, 109], ["NS1-9", "GENE_OR_GENE_PRODUCT", 18, 23], ["NS1-34", "GENE_OR_GENE_PRODUCT", 28, 34], ["JEV", "ORGANISM", 63, 66], ["amino acid", "AMINO_ACID", 99, 109], ["epitopes", "PROTEIN", 9, 17], ["NS1", "PROTEIN", 18, 21], ["NS1", "PROTEIN", 28, 31], ["epitope", "PROTEIN", 191, 198], ["JEV", "SPECIES", 63, 66], ["epitopes NS1", "TEST", 9, 21], ["NS1", "TEST", 28, 31], ["JEV strains", "TEST", 63, 74], ["one amino acid substitution", "PROBLEM", 95, 122], ["the heterologous peptides", "TREATMENT", 133, 158], ["the respective epitope", "PROBLEM", 176, 198], ["JEV strains", "OBSERVATION", 63, 74], ["amino acid substitution", "OBSERVATION", 99, 122], ["heterologous peptides", "OBSERVATION", 137, 158], ["respective epitope", "OBSERVATION", 180, 198]]], ["The highly conserved nature of the epitopes we identified is beneficial for the application of epitopes in vaccine design and epitope-based diagnosis.", [["epitopes", "PROTEIN", 35, 43], ["epitopes", "PROTEIN", 95, 103], ["epitopes in vaccine", "TREATMENT", 95, 114]]], ["We then compared the JEV NS1 protein sequence with the NS1 sequences of WNV, MVEV and DENV.", [["JEV", "ORGANISM", 21, 24], ["NS1", "GENE_OR_GENE_PRODUCT", 25, 28], ["NS1", "GENE_OR_GENE_PRODUCT", 55, 58], ["WNV", "ORGANISM", 72, 75], ["MVEV", "CANCER", 77, 81], ["DENV", "ORGANISM", 86, 90], ["JEV NS1 protein sequence", "DNA", 21, 45], ["NS1 sequences", "DNA", 55, 68], ["JEV", "SPECIES", 21, 24], ["WNV", "SPECIES", 72, 75], ["MVEV", "SPECIES", 77, 81], ["DENV", "SPECIES", 86, 90], ["the JEV NS1 protein sequence", "TEST", 17, 45], ["the NS1 sequences", "TEST", 51, 68], ["WNV", "PROBLEM", 72, 75], ["DENV", "PROBLEM", 86, 90], ["DENV", "OBSERVATION", 86, 90]]], ["Among the JEV-serocomplex, JEV has the highest NS1 sequence similarity with MVEV.", [["JEV-serocomplex", "ORGANISM", 10, 25], ["JEV", "ORGANISM", 27, 30], ["NS1", "GENE_OR_GENE_PRODUCT", 47, 50], ["NS1", "PROTEIN", 47, 50], ["MVEV", "DNA", 76, 80], ["JEV", "SPECIES", 27, 30], ["JEV", "PROBLEM", 27, 30]]], ["JEV and DENV co-circulate in Southeast Asia [12], and JEV and WNV co-circulate in India [15], so there is an urgent need for differential diagnoses between JEV, WNV and DENV.", [["JEV", "DISEASE", 54, 57], ["JEV, WNV and DENV", "DISEASE", 156, 173], ["JEV", "ORGANISM", 0, 3], ["DENV", "ORGANISM", 8, 12], ["JEV", "ORGANISM", 54, 57], ["WNV", "ORGANISM", 62, 65], ["JEV", "ORGANISM", 156, 159], ["WNV", "ORGANISM", 161, 164], ["DENV", "ORGANISM", 169, 173], ["JEV", "SPECIES", 0, 3], ["DENV", "SPECIES", 8, 12], ["JEV", "SPECIES", 54, 57], ["WNV", "SPECIES", 62, 65], ["JEV", "SPECIES", 156, 159], ["WNV", "SPECIES", 161, 164], ["DENV", "SPECIES", 169, 173], ["JEV", "PROBLEM", 0, 3], ["DENV", "PROBLEM", 8, 12], ["JEV", "PROBLEM", 54, 57], ["JEV", "PROBLEM", 156, 159], ["WNV", "PROBLEM", 161, 164], ["DENV", "PROBLEM", 169, 173], ["DENV", "OBSERVATION", 8, 12], ["DENV", "OBSERVATION", 169, 173]]], ["None of the MAbs in this study reacted to WNV or DENV whole virus antigens or the corresponding NS1 sequences.", [["WNV", "ORGANISM", 42, 45], ["DENV whole virus antigens", "ORGANISM", 49, 74], ["NS1", "GENE_OR_GENE_PRODUCT", 96, 99], ["MAbs", "PROTEIN", 12, 16], ["DENV whole virus antigens", "PROTEIN", 49, 74], ["NS1 sequences", "DNA", 96, 109], ["WNV", "SPECIES", 42, 45], ["DENV whole virus", "SPECIES", 49, 65], ["the MAbs", "TEST", 8, 16], ["this study", "TEST", 20, 30], ["WNV", "PROBLEM", 42, 45], ["DENV whole virus antigens", "TEST", 49, 74], ["the corresponding NS1 sequences", "TEST", 78, 109]]], ["Furthermore, none of the five JEV NS1 epitopes were recognized by anti-sera against WNV and DENV.", [["JEV", "ORGANISM", 30, 33], ["NS1", "ORGANISM", 34, 37], ["anti-sera", "GENE_OR_GENE_PRODUCT", 66, 75], ["WNV", "ORGANISM", 84, 87], ["DENV", "ORGANISM", 92, 96], ["JEV NS1 epitopes", "PROTEIN", 30, 46], ["anti-sera", "PROTEIN", 66, 75], ["JEV", "SPECIES", 30, 33], ["WNV", "SPECIES", 84, 87], ["DENV", "SPECIES", 92, 96], ["WNV", "PROBLEM", 84, 87], ["DENV", "PROBLEM", 92, 96], ["DENV", "OBSERVATION", 92, 96]]], ["Although the corresponding epitopes NS1-9 and NS1-43 of MVEV have weak reactivity with JEV NS1-specific MAbs and mouse antisera, there is no report of JEV and MVEV co-circulating in any region, and epitopes NS1-1, -32 and -34 did not cross-react with MVEV.", [["NS1-9", "GENE_OR_GENE_PRODUCT", 36, 41], ["NS1-43", "GENE_OR_GENE_PRODUCT", 46, 52], ["MVEV", "GENE_OR_GENE_PRODUCT", 56, 60], ["JEV NS1", "ORGANISM", 87, 94], ["mouse", "ORGANISM", 113, 118], ["JEV", "ORGANISM", 151, 154], ["MVEV", "GENE_OR_GENE_PRODUCT", 159, 163], ["NS1-1", "GENE_OR_GENE_PRODUCT", 207, 212], ["MVEV", "CANCER", 251, 255], ["epitopes", "PROTEIN", 27, 35], ["NS1", "PROTEIN", 36, 39], ["NS1", "PROTEIN", 46, 49], ["MVEV", "PROTEIN", 56, 60], ["JEV NS1-specific MAbs", "PROTEIN", 87, 108], ["epitopes", "PROTEIN", 198, 206], ["NS1", "PROTEIN", 207, 210], ["MVEV", "PROTEIN", 251, 255], ["mouse", "SPECIES", 113, 118], ["JEV", "SPECIES", 87, 90], ["mouse", "SPECIES", 113, 118], ["JEV", "SPECIES", 151, 154], ["MVEV", "SPECIES", 159, 163], ["the corresponding epitopes NS1", "TEST", 9, 39], ["NS1", "TEST", 46, 49], ["MVEV", "TEST", 56, 60], ["weak reactivity", "PROBLEM", 66, 81], ["JEV NS1", "TEST", 87, 94], ["mouse antisera", "TEST", 113, 127], ["JEV", "PROBLEM", 151, 154], ["MVEV", "PROBLEM", 159, 163], ["epitopes NS1", "TEST", 198, 210], ["no report of", "UNCERTAINTY", 138, 150], ["JEV", "OBSERVATION", 151, 154]]], ["This finding may indicate that these NS1 epitopes have the potential to be of use in serological monitoring and differential diagnosis.DiscussionIn summary, we precisely identified five JEV-specific and highly conserved B-cell epitopes on JEV NS1.", [["B-cell", "ANATOMY", 220, 226], ["NS1", "GENE_OR_GENE_PRODUCT", 37, 40], ["JEV", "ORGANISM", 186, 189], ["B-cell", "CELL", 220, 226], ["JEV", "ORGANISM", 239, 242], ["NS1", "ORGANISM", 243, 246], ["NS1 epitopes", "PROTEIN", 37, 49], ["B-cell epitopes", "PROTEIN", 220, 235], ["JEV NS1", "PROTEIN", 239, 246], ["JEV", "SPECIES", 186, 189], ["JEV NS1", "SPECIES", 239, 246], ["these NS1 epitopes", "PROBLEM", 31, 49], ["serological monitoring", "TEST", 85, 107], ["JEV NS1", "TREATMENT", 239, 246], ["may indicate", "UNCERTAINTY", 13, 25], ["cell epitopes", "OBSERVATION", 222, 235]]], ["The data described in this work could provide a foundation for further understanding of the antigenic structure of NS1 and the potential clinical application of epitope-based methods.", [["NS1", "GENE_OR_GENE_PRODUCT", 115, 118], ["NS1", "PROTEIN", 115, 118], ["NS1", "PROBLEM", 115, 118], ["epitope-based methods", "TREATMENT", 161, 182]]]], "PMC7382409": [["POSSIBLE MECHANISMS OF TASTE DYSFUNCTION IN COVID-19The molecular mechanisms leading to the gustatory dysfunctions in COVID-19 are still unclear.", [["gustatory", "ANATOMY", 92, 101], ["gustatory dysfunctions", "DISEASE", 92, 114], ["COVID-19", "CHEMICAL", 118, 126], ["COVID-19", "GENE_OR_GENE_PRODUCT", 118, 126], ["TASTE DYSFUNCTION", "PROBLEM", 23, 40], ["COVID", "TEST", 44, 49], ["The molecular mechanisms", "PROBLEM", 52, 76], ["the gustatory dysfunctions", "PROBLEM", 88, 114], ["COVID", "TEST", 118, 123], ["TASTE DYSFUNCTION", "OBSERVATION", 23, 40], ["gustatory dysfunctions", "OBSERVATION", 92, 114]]], ["But it is suggested that angiotensin-converting enzyme-2 (ACE2) receptor expressing cells may act as target cells for SARS-CoV-2 entry.9 The results from single cell RNA-seq profiles shows that the ACE2 is expressed in the epithelial cells of the oral cavity and is higher in the tongue epithelium than that of buccal and gingival tissues.10 This indicates that oral cavity being a high risk route of SARS-CoV-2 entry and involvement of tongue epithelium may contribute to taste disturbances.POSSIBLE MECHANISMS OF TASTE DYSFUNCTION IN COVID-19Another common possibility is the simultaneous presence of olfactory disturbances which prevents the taste sensation, because of the intimate functional correlation between these 2 chemosensory systems.11 However, isolated taste dysfunctions are reported in COVID-19 which shows other mechanisms are involved.", [["cells", "ANATOMY", 84, 89], ["cells", "ANATOMY", 108, 113], ["cell", "ANATOMY", 161, 165], ["epithelial cells", "ANATOMY", 223, 239], ["oral cavity", "ANATOMY", 247, 258], ["tongue epithelium", "ANATOMY", 280, 297], ["buccal", "ANATOMY", 311, 317], ["gingival tissues", "ANATOMY", 322, 338], ["oral cavity", "ANATOMY", 362, 373], ["tongue epithelium", "ANATOMY", 437, 454], ["olfactory", "ANATOMY", 603, 612], ["angiotensin", "CHEMICAL", 25, 36], ["SARS", "DISEASE", 401, 405], ["taste disturbances", "DISEASE", 473, 491], ["olfactory disturbances", "DISEASE", 603, 625], ["taste dysfunctions", "DISEASE", 767, 785], ["angiotensin-converting enzyme-2", "GENE_OR_GENE_PRODUCT", 25, 56], ["ACE2", "GENE_OR_GENE_PRODUCT", 58, 62], ["cells", "CELL", 84, 89], ["cells", "CELL", 108, 113], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 118, 128], ["cell", "CELL", 161, 165], ["ACE2", "GENE_OR_GENE_PRODUCT", 198, 202], ["epithelial cells", "CELL", 223, 239], ["oral cavity", "ORGAN", 247, 258], ["tongue epithelium", "TISSUE", 280, 297], ["buccal", "TISSUE", 311, 317], ["gingival tissues", "TISSUE", 322, 338], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 362, 373], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 401, 411], ["tongue epithelium", "TISSUE", 437, 454], ["taste", "ORGANISM_SUBDIVISION", 473, 478], ["olfactory", "ORGAN", 603, 612], ["taste", "ORGANISM_SUBDIVISION", 767, 772], ["angiotensin-converting enzyme-2 (ACE2) receptor", "PROTEIN", 25, 72], ["target cells", "CELL_TYPE", 101, 113], ["ACE2", "PROTEIN", 198, 202], ["epithelial cells", "CELL_TYPE", 223, 239], ["angiotensin-converting enzyme-2 (ACE2) receptor expressing cells", "TREATMENT", 25, 89], ["SARS", "TEST", 118, 122], ["CoV", "TEST", 123, 126], ["single cell RNA", "TEST", 154, 169], ["the ACE2", "TEST", 194, 202], ["oral cavity", "PROBLEM", 362, 373], ["SARS", "PROBLEM", 401, 405], ["CoV", "TEST", 406, 409], ["tongue epithelium", "PROBLEM", 437, 454], ["taste disturbances", "PROBLEM", 473, 491], ["TASTE DYSFUNCTION", "PROBLEM", 515, 532], ["olfactory disturbances", "PROBLEM", 603, 625], ["the taste sensation", "PROBLEM", 641, 660], ["isolated taste dysfunctions", "PROBLEM", 758, 785], ["COVID", "TEST", 802, 807], ["epithelial cells", "OBSERVATION", 223, 239], ["oral cavity", "ANATOMY", 247, 258], ["higher", "OBSERVATION_MODIFIER", 266, 272], ["tongue", "ANATOMY", 280, 286], ["epithelium", "ANATOMY_MODIFIER", 287, 297], ["buccal", "ANATOMY_MODIFIER", 311, 317], ["gingival tissues", "ANATOMY", 322, 338], ["oral cavity", "ANATOMY", 362, 373], ["tongue epithelium", "ANATOMY", 437, 454], ["TASTE DYSFUNCTION", "OBSERVATION", 515, 532], ["olfactory disturbances", "OBSERVATION", 603, 625], ["taste dysfunctions", "OBSERVATION", 767, 785]]], ["Coronaviruses are known to be neurotropic and neuroinvasive.", [["Coronaviruses", "PROBLEM", 0, 13], ["known to be", "UNCERTAINTY", 18, 29]]], ["This might lead to alteration in smell or taste sensation through the cranial nerves, but still lacks enough evidence.12 We hope that prospective histopathologic analysis from COVID-19 autopsies will give us the understanding of pathogenesis of these chemosensitive disorders.PREVALENCE OF TASTE DISTURBANCES IN COVID-19One of the initial study from China by Mao et al, analyzed the neurologic manifestations in SARS-CoV-2 infected 214 patients and reported ageusia in 5.6% of patients.13 In contrary to this, the first European clinical series showed a high frequency of chemosensitive disorders ranging between 19.4% and 88%.", [["cranial nerves", "ANATOMY", 70, 84], ["neurologic", "ANATOMY", 383, 393], ["chemosensitive disorders", "DISEASE", 251, 275], ["SARS-CoV-2 infected", "DISEASE", 412, 431], ["ageusia", "DISEASE", 458, 465], ["chemosensitive disorders", "DISEASE", 572, 596], ["taste", "ORGANISM_SUBDIVISION", 42, 47], ["cranial nerves", "MULTI-TISSUE_STRUCTURE", 70, 84], ["SARS-CoV-2", "ORGANISM", 412, 422], ["patients", "ORGANISM", 436, 444], ["patients", "ORGANISM", 477, 485], ["patients", "SPECIES", 436, 444], ["patients", "SPECIES", 477, 485], ["SARS-CoV-2", "SPECIES", 412, 422], ["alteration in smell or taste sensation through the cranial nerves", "PROBLEM", 19, 84], ["prospective histopathologic analysis", "TEST", 134, 170], ["COVID", "TEST", 176, 181], ["these chemosensitive disorders", "PROBLEM", 245, 275], ["the initial study", "TEST", 327, 344], ["the neurologic manifestations", "PROBLEM", 379, 408], ["SARS", "PROBLEM", 412, 416], ["CoV", "TEST", 417, 420], ["ageusia", "TEST", 458, 465], ["the first European clinical series", "TEST", 510, 544], ["chemosensitive disorders", "PROBLEM", 572, 596], ["smell", "OBSERVATION", 33, 38], ["cranial nerves", "ANATOMY", 70, 84], ["chemosensitive disorders", "OBSERVATION", 251, 275]]], ["They also found that the gustatory changes were frequent in the initial stages of the infection and in paucisymptomatic patients.14\u201316PREVALENCE OF TASTE DISTURBANCES IN COVID-19Giacomelli et al collected data on olfactory and taste dysfunctions, and their type and time of onset respective to hospital admission from 59 COVID-19 hospitalized patients by a questionnaire interview.", [["gustatory", "ANATOMY", 25, 34], ["olfactory", "ANATOMY", 213, 222], ["infection", "DISEASE", 86, 95], ["olfactory and taste dysfunctions", "DISEASE", 213, 245], ["patients", "ORGANISM", 120, 128], ["olfactory", "ANATOMICAL_SYSTEM", 213, 222], ["taste", "ORGANISM_SUBDIVISION", 227, 232], ["patients", "ORGANISM", 343, 351], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 343, 351], ["the gustatory changes", "PROBLEM", 21, 42], ["the infection", "PROBLEM", 82, 95], ["TASTE DISTURBANCES", "PROBLEM", 148, 166], ["taste dysfunctions", "PROBLEM", 227, 245], ["frequent", "OBSERVATION_MODIFIER", 48, 56], ["infection", "OBSERVATION", 86, 95]]], ["Out of these, 33.9% patients reported either a taste or odor disorder and 18.6% had both.", [["taste or odor disorder", "DISEASE", 47, 69], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["odor disorder", "PROBLEM", 56, 69]]], ["Symptoms before hospitalization was present in 20.3% patients and 13.5% patients experienced during the hospital stay.", [["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 72, 80], ["Symptoms", "PROBLEM", 0, 8]]], ["Taste disturbances were present in 91% before hospitalization, whereas after hospitalization the symptoms appeared with equal frequency.", [["Taste disturbances", "DISEASE", 0, 18], ["Taste disturbances", "PROBLEM", 0, 18], ["the symptoms", "PROBLEM", 93, 105]]], ["Females (52.6%) reported symptoms more frequently than males (25%).17PREVALENCE OF TASTE DISTURBANCES IN COVID-19A multicentric study was conducted by Vaira et al in Italy on 300 COVID-19 positive patients and reported that 80% patients commonly had chemosensitive disorders typically 2 days after the onset of the fever in the early stages of the disease.", [["chemosensitive disorders", "DISEASE", 250, 274], ["fever", "DISEASE", 315, 320], ["patients", "ORGANISM", 197, 205], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 197, 205], ["patients", "SPECIES", 228, 236], ["symptoms", "PROBLEM", 25, 33], ["multicentric study", "TEST", 115, 133], ["chemosensitive disorders", "PROBLEM", 250, 274], ["the fever", "PROBLEM", 311, 320], ["the disease", "PROBLEM", 344, 355], ["fever", "OBSERVATION", 315, 320], ["disease", "OBSERVATION", 348, 355]]], ["Interestingly, 15.3% patients manifested only temporary smell and/or taste alterations.", [["taste alterations", "DISEASE", 69, 86], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["temporary smell", "PROBLEM", 46, 61], ["taste alterations", "PROBLEM", 69, 86], ["temporary smell", "OBSERVATION", 46, 61]]], ["In 67.5% of patients, there is spontaneous regression of these symptoms in few days.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["these symptoms", "PROBLEM", 57, 71], ["spontaneous", "OBSERVATION_MODIFIER", 31, 42], ["regression", "OBSERVATION_MODIFIER", 43, 53]]], ["They reported that those patients who had the chemosensitive disorders for more than 10 days, had 2.4 times greater risk of developing a severe pulmonary damage.18 This implies that chemosensitive disorders can be used to predict the severity of the disease to a certain level.PREVALENCE OF TASTE DISTURBANCES IN COVID-19Spinato et al surveyed positive and mild symptomatic SARS-CoV-2 outpatients in Italy and found that 64.4% had some degree of taste or smell alterations.", [["pulmonary", "ANATOMY", 144, 153], ["chemosensitive disorders", "DISEASE", 46, 70], ["pulmonary damage", "DISEASE", 144, 160], ["chemosensitive disorders", "DISEASE", 182, 206], ["SARS", "DISEASE", 374, 378], ["taste or smell alterations", "DISEASE", 446, 472], ["patients", "ORGANISM", 25, 33], ["pulmonary", "ORGAN", 144, 153], ["outpatients", "ORGANISM", 385, 396], ["patients", "SPECIES", 25, 33], ["outpatients", "SPECIES", 385, 396], ["the chemosensitive disorders", "PROBLEM", 42, 70], ["a severe pulmonary damage", "PROBLEM", 135, 160], ["chemosensitive disorders", "PROBLEM", 182, 206], ["the disease", "PROBLEM", 246, 257], ["TASTE DISTURBANCES", "PROBLEM", 291, 309], ["mild symptomatic SARS", "PROBLEM", 357, 378], ["smell alterations", "PROBLEM", 455, 472], ["severe", "OBSERVATION_MODIFIER", 137, 143], ["pulmonary", "ANATOMY", 144, 153], ["damage", "OBSERVATION", 154, 160], ["disease", "OBSERVATION", 250, 257], ["mild", "OBSERVATION_MODIFIER", 357, 361], ["symptomatic", "OBSERVATION_MODIFIER", 362, 373], ["SARS", "OBSERVATION", 374, 378], ["smell alterations", "OBSERVATION", 455, 472]]], ["The timing of the onset of this symptom was analyzed and found that 11.9% had it before other symptoms, 22.8% had along with other symptoms, 26.7% had afterwards, and 3% had it as their only symptom.", [["this symptom", "PROBLEM", 27, 39], ["other symptoms", "PROBLEM", 88, 102], ["other symptoms", "PROBLEM", 125, 139]]], ["Women (72.4%) presented more frequently with an altered sense of smell or taste than men (55.7%).19PREVALENCE OF TASTE DISTURBANCES IN COVID-19An European multicentric study was conducted by Lechien et al in hospitals from Belgium, France, Spain, and Italy.", [["Women", "ORGANISM", 0, 5], ["men", "ORGANISM", 85, 88], ["Women", "SPECIES", 0, 5], ["men", "SPECIES", 85, 88], ["an altered sense of smell or taste", "PROBLEM", 45, 79], ["European multicentric study", "TEST", 146, 173]]], ["Clinical features data were collected through a questionnaire from 417 mild to moderate test-confirmed COVID-19 patients.", [["patients", "ORGANISM", 112, 120], ["patients", "SPECIES", 112, 120], ["Clinical features data", "TEST", 0, 22], ["moderate test", "TEST", 79, 92], ["COVID", "TEST", 103, 108]]], ["16 The questionnaire was based on the smell and taste component of the National Health and Nutrition Examination Survey.20 Gustatory disorders were found in 88.0% of patients out of which 78.9% had hypogeusia and 21.1% had distorted ability to taste flavors.", [["Gustatory disorders", "DISEASE", 123, 142], ["hypogeusia", "DISEASE", 198, 208], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["Nutrition Examination", "TEST", 91, 112], ["Gustatory disorders", "PROBLEM", 123, 142], ["hypogeusia", "PROBLEM", 198, 208]]], ["There was a significant association between olfactory and gustatory disorders (P < 0.001).", [["olfactory", "ANATOMY", 44, 53], ["gustatory", "ANATOMY", 58, 67], ["olfactory and gustatory disorders", "DISEASE", 44, 77], ["olfactory", "ORGAN", 44, 53], ["a significant association between olfactory and gustatory disorders", "PROBLEM", 10, 77], ["significant", "OBSERVATION_MODIFIER", 12, 23]]], ["The chemosensitive disorders were constant in 72.8% and fluctuated in 23.4% of patients over the days.", [["chemosensitive disorders", "DISEASE", 4, 28], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["The chemosensitive disorders", "PROBLEM", 0, 28], ["chemosensitive disorders", "OBSERVATION", 4, 28]]], ["Among the recovered patients, who had residual chemosensitive disorders: isolated smell disorder was in 53.9%, isolated taste disorder in 22.5% and both in 23.6%.", [["chemosensitive disorders", "DISEASE", 47, 71], ["smell disorder", "DISEASE", 82, 96], ["taste disorder", "DISEASE", 120, 134], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["residual chemosensitive disorders", "PROBLEM", 38, 71], ["isolated smell disorder", "PROBLEM", 73, 96], ["isolated taste disorder", "PROBLEM", 111, 134], ["chemosensitive disorders", "OBSERVATION", 47, 71], ["smell disorder", "OBSERVATION", 82, 96]]], ["In this study also, females were more affected by these symptoms than males.", [["this study", "TEST", 3, 13], ["these symptoms", "PROBLEM", 50, 64]]], ["There was no significant association between the comorbidities and the presence of these symptoms.16PREVALENCE OF TASTE DISTURBANCES IN COVID-19Most studies were based on subjective evaluation of the patients.", [["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 200, 208], ["the comorbidities", "PROBLEM", 45, 62], ["these symptoms", "PROBLEM", 83, 97], ["COVID", "TEST", 136, 141], ["Most studies", "TEST", 144, 156], ["subjective evaluation", "TEST", 171, 192], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24]]], ["The first study to objectively evaluate these symptoms was conducted extensively by Vaira et al on 72 COVID-19 positive patients in the University Hospital of Sassari, Italy.21 The patients were requested to provide the timeline of the onset, duration and the regression of the chemosensitive symptoms.", [["patients", "ORGANISM", 120, 128], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 181, 189], ["The first study", "TEST", 0, 15], ["these symptoms", "PROBLEM", 40, 54], ["COVID", "TEST", 102, 107], ["the chemosensitive symptoms", "PROBLEM", 274, 301]]], ["About 73.6% of patients reported chemosensory dysfunctions during the course of the infection.", [["chemosensory dysfunctions", "DISEASE", 33, 58], ["infection", "DISEASE", 84, 93], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["chemosensory dysfunctions", "PROBLEM", 33, 58], ["the infection", "PROBLEM", 80, 93], ["chemosensory dysfunctions", "OBSERVATION", 33, 58], ["infection", "OBSERVATION", 84, 93]]], ["Gustatory function was evaluated by the ability to identify sweet, salt, sour, and bitter tastes.", [["sweet", "ORGANISM_SUBDIVISION", 60, 65]]], ["The most affected sensitivities were those for sweet and sour with no clear predominance to a specific taste.", [["sweet", "ORGANISM_SUBDIVISION", 47, 52], ["The most affected sensitivities", "PROBLEM", 0, 31]]], ["Taste scoring was carried out and found as normal in 51.4%, mild hypogeusia in 22.2%, moderate hypogeusia in 15.3%, severe hypogeusia in 9.7%, and ageusia in 1.4% of patients.", [["hypogeusia", "DISEASE", 65, 75], ["hypogeusia", "DISEASE", 95, 105], ["hypogeusia", "DISEASE", 123, 133], ["ageusia", "DISEASE", 147, 154], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["Taste scoring", "TEST", 0, 13], ["mild hypogeusia", "PROBLEM", 60, 75], ["moderate hypogeusia", "PROBLEM", 86, 105], ["severe hypogeusia", "PROBLEM", 116, 133], ["ageusia", "TEST", 147, 154], ["normal", "OBSERVATION", 43, 49], ["mild", "OBSERVATION_MODIFIER", 60, 64], ["hypogeusia", "OBSERVATION", 65, 75], ["moderate", "OBSERVATION_MODIFIER", 86, 94], ["hypogeusia", "OBSERVATION", 95, 105], ["15.3%", "OBSERVATION_MODIFIER", 109, 114], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["hypogeusia", "OBSERVATION", 123, 133], ["9.7%", "OBSERVATION_MODIFIER", 137, 141]]], ["Isolated taste and smell disorders were reported in 12.5% and 14.4% of patients, respectively, and both in 41.7% of patients.", [["taste and smell disorders", "DISEASE", 9, 34], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 116, 124], ["Isolated taste", "PROBLEM", 0, 14], ["smell disorders", "PROBLEM", 19, 34], ["smell disorders", "OBSERVATION", 19, 34]]], ["Complete recovery of chemosensitive symptoms was reported in 66% of patients, in which 54.3% recovered in <5 days and 45.7% in >5 days, meanwhile 34% had persistence of smell and taste alterations.", [["taste alterations", "DISEASE", 179, 196], ["chemosensitive", "CANCER", 21, 35], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["chemosensitive symptoms", "PROBLEM", 21, 44], ["smell and taste alterations", "PROBLEM", 169, 196]]], ["Infact, 18.1% of this series presented smell and taste alterations as the first clinical manifestation of the disease.", [["taste alterations", "DISEASE", 49, 66], ["taste alterations", "PROBLEM", 49, 66], ["the disease", "PROBLEM", 106, 117], ["18.1%", "OBSERVATION_MODIFIER", 8, 13], ["disease", "OBSERVATION", 110, 117]]], ["This implies that clinicians should suspect SARS-CoV-2 infection in the differential diagnosis of such nonspecific chemosensory dysfunction.PREVALENCE OF TASTE DISTURBANCES IN COVID-19Also, it is noted that anosmia, with or without dysgeusia, manifests either early in the disease process or in patients with mild or no constitutional symptoms.17 Still, it is commented that more evidence is needed to establish these chemosensitive changes as COVID-19 symptoms.22VARIATIONS IN THE PREVALENCE OF TASTE DISTURBANCESGustatory dysfunctions are reported more in European studies and there is absence of such symptom in Asian studies.", [["infection", "DISEASE", 55, 64], ["chemosensory dysfunction", "DISEASE", 115, 139], ["anosmia", "DISEASE", 207, 214], ["dysgeusia", "DISEASE", 232, 241], ["SARS-CoV-2", "ORGANISM", 44, 54], ["patients", "ORGANISM", 295, 303], ["patients", "SPECIES", 295, 303], ["SARS", "PROBLEM", 44, 48], ["CoV", "PROBLEM", 49, 52], ["2 infection", "PROBLEM", 53, 64], ["such nonspecific chemosensory dysfunction", "PROBLEM", 98, 139], ["anosmia", "PROBLEM", 207, 214], ["dysgeusia", "PROBLEM", 232, 241], ["the disease process", "PROBLEM", 269, 288], ["constitutional symptoms", "PROBLEM", 320, 343], ["these chemosensitive changes", "PROBLEM", 412, 440], ["COVID", "TEST", 444, 449], ["symptoms", "PROBLEM", 453, 461], ["TASTE DISTURBANCESGustatory dysfunctions", "PROBLEM", 496, 536], ["European studies", "TEST", 558, 574], ["such symptom", "PROBLEM", 599, 611], ["Asian studies", "TEST", 615, 628], ["infection", "OBSERVATION", 55, 64], ["nonspecific", "OBSERVATION_MODIFIER", 103, 114], ["chemosensory dysfunction", "OBSERVATION", 115, 139], ["disease", "OBSERVATION", 273, 280]]], ["This might be due to the lack of assessment of these symptom or the Chinese patients really had insignificant taste disorders.", [["taste disorders", "DISEASE", 110, 125], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["assessment", "TEST", 33, 43], ["these symptom", "PROBLEM", 47, 60], ["insignificant taste disorders", "PROBLEM", 96, 125]]], ["This high regional variation might be due to the mutations of surface proteins (spike-S-protein and nucleocapsid-N protein) in SARS-Cov-2 or due to the ACE2 polymorphisms and ACE2 expression levels between Asian and European populations.23,24 There is also a high susceptibility of females to develop these chemosensitive symptoms than males.", [["surface", "ANATOMY", 62, 69], ["spike-S-protein", "GENE_OR_GENE_PRODUCT", 80, 95], ["nucleocapsid-N protein", "GENE_OR_GENE_PRODUCT", 100, 122], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 127, 137], ["ACE2", "GENE_OR_GENE_PRODUCT", 152, 156], ["ACE2", "GENE_OR_GENE_PRODUCT", 175, 179], ["surface proteins", "PROTEIN", 62, 78], ["spike-S-protein", "PROTEIN", 80, 95], ["nucleocapsid", "PROTEIN", 100, 112], ["N protein", "PROTEIN", 113, 122], ["ACE2", "PROTEIN", 152, 156], ["ACE2", "PROTEIN", 175, 179], ["This high regional variation", "PROBLEM", 0, 28], ["the mutations of surface proteins", "PROBLEM", 45, 78], ["spike", "TEST", 80, 85], ["protein", "TEST", 88, 95], ["nucleocapsid", "TEST", 100, 112], ["SARS", "PROBLEM", 127, 131], ["Cov", "TEST", 132, 135], ["the ACE2 polymorphisms", "PROBLEM", 148, 170], ["ACE2 expression levels", "TEST", 175, 197], ["a high susceptibility of females", "PROBLEM", 257, 289], ["these chemosensitive symptoms", "PROBLEM", 301, 330], ["high susceptibility", "OBSERVATION_MODIFIER", 259, 278]]], ["This gender-related differences would be related to the variation in the inflammatory reaction process.25CONCLUSIONGustatory dysfunction symptoms are more prevalent symptoms in European COVID-19 patients as part of the chemosensory dysfunction.", [["chemosensory dysfunction", "DISEASE", 219, 243], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203], ["the variation", "PROBLEM", 52, 65], ["the inflammatory reaction", "PROBLEM", 69, 94], ["dysfunction symptoms", "PROBLEM", 125, 145], ["prevalent symptoms", "PROBLEM", 155, 173], ["the chemosensory dysfunction", "PROBLEM", 215, 243], ["inflammatory", "OBSERVATION_MODIFIER", 73, 85], ["chemosensory dysfunction", "OBSERVATION", 219, 243]]], ["The sudden onset of taste disorders without any oral or systemic cause needs to be recognized by the physicians, oral-maxillofacial surgeons, craniofacial surgeons, and otorhinolaryngologists as an important suspicion for COVID-19.", [["oral", "ANATOMY", 48, 52], ["oral", "ANATOMY", 113, 117], ["taste disorders", "DISEASE", 20, 35], ["oral", "ORGANISM_SUBDIVISION", 48, 52], ["oral", "ORGANISM_SUBDIVISION", 113, 117], ["taste disorders", "PROBLEM", 20, 35], ["any oral or systemic cause", "PROBLEM", 44, 70], ["COVID", "TEST", 222, 227], ["maxillofacial", "ANATOMY", 118, 131]]], ["The relationship between the duration of the gustatory symptoms and the severity of COVID-19 disease might be associated with the viral load in the oral cavity.", [["gustatory", "ANATOMY", 45, 54], ["oral cavity", "ANATOMY", 148, 159], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 148, 159], ["the gustatory symptoms", "PROBLEM", 41, 63], ["COVID-19 disease", "PROBLEM", 84, 100], ["the viral load in the oral cavity", "PROBLEM", 126, 159], ["viral load", "OBSERVATION", 130, 140], ["oral cavity", "ANATOMY", 148, 159]]], ["Future studies correlating the symptomatic condition to the viral loads from the swabs or saliva will help to verify this hypothesis.", [["swabs", "ANATOMY", 81, 86], ["saliva", "ORGANISM_SUBSTANCE", 90, 96], ["Future studies", "TEST", 0, 14], ["the symptomatic condition", "PROBLEM", 27, 52], ["the viral loads", "TEST", 56, 71], ["the swabs", "TEST", 77, 86], ["saliva", "TREATMENT", 90, 96], ["this hypothesis", "PROBLEM", 117, 132]]], ["Thus, the available studies clearly show that the gustatory functions may be impaired in COVID-19 patients and would be a reliable early symptom which could be used for screening, testing and for self-isolation in this pandemic keeping in mind the regional variations.", [["gustatory", "ANATOMY", 50, 59], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["the available studies", "TEST", 6, 27], ["a reliable early symptom", "PROBLEM", 120, 144], ["screening", "TEST", 169, 178], ["testing", "TEST", 180, 187], ["self-isolation", "TREATMENT", 196, 210], ["regional variations", "OBSERVATION", 248, 267]]]], "e99c9402431a63d5b8cfd41127737327e858f0a0": [["2 These hopes and fears were expressed for example in a conference held on the GJ in 2019 attended by notable figures of the European left.", [["the GJ", "TREATMENT", 75, 81], ["left", "ANATOMY_MODIFIER", 134, 138]]], ["In that event, Etienne Balibar enunciated the more fearful view while Antonio Negri posited a view which cast the GJ's as participants in building an optimistic future as a people's movement that contests capitalism.", [["people", "ORGANISM", 173, 179], ["participants", "SPECIES", 122, 134], ["people", "SPECIES", 173, 179], ["GJ", "ANATOMY", 114, 116]]], ["See Susser, (forthcoming) These notes are based on observation, but not participation in the mobilizations of the GJ in Paris in 2019.", [["GJ", "ANATOMY", 114, 116]]], ["While I chatted with some participants in the GJ movement, my conversations during fieldwork were undertaken mostly with those who have not been part of it and in fact who seem to disavow this militancy.", [["participants", "SPECIES", 26, 38]]], ["Emerging from this research are reflections in these notes on how the contradictions in contemporary capitalism are refracted through the disparate aims of a militancy that builds social solidarities on the one hand while fostering divisions.", [["hand", "ANATOMY", 211, 215], ["hand", "ORGANISM_SUBDIVISION", 211, 215]]], ["I also ask the focus on the question of the relationship between the conjunctural forces in France and the emergence of movements that are populist in orientationObservations on the gilets jaunesTo think through some facets of a mobilization that many suggest is unprecedented in many ways, I address 3 questions.", [["a mobilization", "TREATMENT", 227, 241]]], ["I look into the past and ask what aspects of the GJ mobilization are shared with collective struggles that have erupted in France.", [["GJ", "MULTI-TISSUE_STRUCTURE", 49, 51], ["the GJ mobilization", "TREATMENT", 45, 64]]], ["It also provoked me to reflect on the problems of the system of representational democracy that the eruption of the GJ exposes.", [["GJ", "MULTI-TISSUE_STRUCTURE", 116, 118], ["the GJ exposes", "TREATMENT", 112, 126], ["democracy", "OBSERVATION", 81, 90], ["GJ", "ANATOMY", 116, 118]]], ["The third is concerned with how the objectives that animate GJ struggles might suggest that grievances may be resolved.", [["GJ", "MULTI-TISSUE_STRUCTURE", 60, 62]]], ["Here, I am especially interested in the nature of the challenges that are posed by the GJ on the capitalist state and state capitalism.", [["GJ", "MULTI-TISSUE_STRUCTURE", 87, 89], ["capitalism", "OBSERVATION", 124, 134]]], ["For the sake of convenience, I have ordered reflections on these questions, in terms of 3 Rs-retrospection, representation, and resolution.", [["Rs", "PROTEIN", 90, 92]]], ["I begin first with a brief review of what we might know about the GJ by highlighting a few of its distinctive characteristics and then will move to address the 3Rs.What we might knowThe movement of the GJ is distinguished by its scale, scope, and persistence.", [["GJ", "MULTI-TISSUE_STRUCTURE", 66, 68], ["GJ", "MULTI-TISSUE_STRUCTURE", 202, 204], ["3Rs", "DNA", 160, 163], ["the GJ", "TREATMENT", 62, 68], ["movement", "OBSERVATION_MODIFIER", 186, 194], ["GJ", "ANATOMY", 202, 204], ["persistence", "OBSERVATION_MODIFIER", 247, 258]]], ["It has involved the longest series of public and mass protests in French history, having endured from November 2018 until March 2020.", [["mass", "OBSERVATION", 49, 53]]], ["Its origins are dated to May 2018, when an online petition was posted by a woman who ran a small business in a southeastern suburb of Paris.", [["woman", "ORGANISM", 75, 80], ["woman", "SPECIES", 75, 80], ["small", "OBSERVATION_MODIFIER", 91, 96]]], ["In October 2018, calls to oppose the rise in taxes on car fuel introduced by the government of Emmanuel Macron were added to these demands.", [["Macron", "CHEMICAL", 104, 110], ["Macron", "SIMPLE_CHEMICAL", 104, 110], ["Emmanuel Macron", "TREATMENT", 95, 110]]], ["This sparked the transformation of what began as an online protest in a digital forum into a series of collective actions that also unfolded in physical spaces.", [["collective actions", "TREATMENT", 103, 121], ["unfolded", "OBSERVATION_MODIFIER", 132, 140]]], ["The first mass demonstrations took place on November 17 and attracted over 300,000 people across France, although the figures vary depending on the source and the week, the GJ actions mobilized from 90,000 to 1.3 million.", [["people", "ORGANISM", 83, 89], ["people", "SPECIES", 83, 89], ["the GJ actions", "TREATMENT", 169, 183], ["mass", "OBSERVATION", 10, 14]]], ["It included participants in most of the 96 departments in metropolitan France and 5 overseas departments (Guardian Sat 9 Feb 2019).", [["participants", "SPECIES", 12, 24]]], ["Though still very active, the number of participants started to dwindle in late 2019, and in 2020, the last mobilization was staged on March 14, 2020.", [["participants", "SPECIES", 40, 52], ["very", "OBSERVATION_MODIFIER", 13, 17], ["active", "OBSERVATION", 18, 24]]], ["This was in defiance of government ban issued on the previous day that prohibited gatherings of more than 100 people in public places in response to the COVID pandemic.", [["people", "ORGANISM", 110, 116], ["people", "SPECIES", 110, 116]]], ["While public and the mass gatherings have been suspended, their activities continue on various social media platforms, including one that supports the online GJ magazine.", [["the mass gatherings", "PROBLEM", 17, 36], ["mass", "OBSERVATION", 21, 25]]], ["3 Social media has been the main means through which information about GJ activities have been organized.", [["GJ", "MULTI-TISSUE_STRUCTURE", 71, 73]]], ["Information is also disseminated through local social networks through many and varied means, including by word of mouth (de bouche \u00e0 oreille).", [["social networks", "MULTI-TISSUE_STRUCTURE", 47, 62], ["mouth", "ORGANISM_SUBDIVISION", 115, 120], ["mouth", "ANATOMY", 115, 120]]], ["There are two main forms of mass, collective action and both involve the occupation of public spaces.", [["mass", "PROBLEM", 28, 32], ["two", "OBSERVATION_MODIFIER", 10, 13], ["main", "OBSERVATION_MODIFIER", 14, 18], ["mass", "OBSERVATION", 28, 32], ["public spaces", "ANATOMY", 87, 100]]], ["One involves marches, known as Acts, which involve weekly marches held on Saturdays.", [["marches", "OBSERVATION", 13, 20]]], ["In Paris, participants in the marches rally at a meeting point then march along city streets through different neighborhoods.What we might knowThe routes of the marches are pre-determined, announced publicly, and vary from week to week.", [["participants", "SPECIES", 10, 22]]], ["The marches often end in a square, park, or field where participants rally again, socialize, debate, argue or disperse.", [["participants", "SPECIES", 56, 68]]], ["Also included are many spin-off initiatives such as the establishment of the journal of the GJ as well as the short-lived jogging jaunes on Sundays in Paris that was launched in early spring 2019.", [["GJ", "ANATOMY", 92, 94]]], ["Curious to see how the Sunday event would unfold, I followed the joggers on their inaugural run which was attended by a very small group of roughly 20 women and men of varying ages and abilities.", [["women", "ORGANISM", 151, 156], ["men", "ORGANISM", 161, 164], ["women", "SPECIES", 151, 156], ["men", "SPECIES", 161, 164]]], ["It also included one runner who pushed a participant in a wheelchair.", [["participant", "SPECIES", 41, 52]]], ["The presence of a participant in a wheelchair was significant symbolically in terms of the composition of participants in GJ activities.What we might knowParticipants in protests consist of a heterogeneous collection of people that have been difficult to define in terms of any single prevailing sociological category.What we might knowIn terms of class, they have been referred to as members of the popular classes, incorporating different strata of the working and non-working poor.", [["GJ", "MULTI-TISSUE_STRUCTURE", 122, 124], ["people", "ORGANISM", 220, 226], ["participant", "SPECIES", 18, 29], ["participants", "SPECIES", 106, 118], ["people", "SPECIES", 220, 226], ["heterogeneous", "OBSERVATION_MODIFIER", 192, 205], ["collection", "OBSERVATION", 206, 216]]], ["The non-working poor include pensioners, retirees, persons on social assistance, or with disabilities as the wheelchair participant in the jogging jaunes signaled, as well as many unemployed.", [["persons", "ORGANISM", 51, 58], ["persons", "SPECIES", 51, 58]]], ["But the GJ also include members of the petty bourgeoisie who own and operate businesses in France.", [["GJ", "ANATOMY", 8, 10]]], ["For those GJ who are engaged in paid work, the core participants seem to be those who hold positions situated at the lower end of the occupational hierarchy in a very diverse labor market.", [["participants", "SPECIES", 52, 64], ["lower", "ANATOMY_MODIFIER", 117, 122]]], ["With wages that are commensurate with low status, the GJ also encompass many who work as part of the contingent labor force in the \"gig\" economy.", [["GJ", "ANATOMY", 54, 56]]], ["In contrast, other participants who are engaged in paid work are employed in white collar jobs as mid-level managers in such organizations as insurance companies, real estate agencies, and pharmacies.", [["participants", "SPECIES", 19, 31]]], ["In terms of sociodemographics, observers have noted the uncommon age and gender composition of participants in such mass mobilizations.", [["participants", "SPECIES", 95, 107], ["such mass mobilizations", "PROBLEM", 111, 134], ["mass", "OBSERVATION", 116, 120]]], ["The average age of the participants seems to be between 45 and 60 and roughly 45% are women.What we might knowWhile there is considerable heterogeneity, one unifying feature is that many participants have never participated in popular protests and generally tended to eschew collective action.", [["participants", "ORGANISM", 23, 35], ["women", "ORGANISM", 86, 91], ["participants", "SPECIES", 23, 35], ["women", "SPECIES", 86, 91], ["participants", "SPECIES", 187, 199]]], ["This is particularly the case amongst owners and operators of small businesses or members of the petty bourgeoisie.", [["small", "OBSERVATION_MODIFIER", 62, 67], ["businesses", "OBSERVATION", 68, 78]]], ["Another significant unifying feature is that they position themselves as peripheral in sociopolitical, economic, and also geographic landscape of France.", [["significant", "OBSERVATION_MODIFIER", 8, 19], ["peripheral", "OBSERVATION_MODIFIER", 73, 83], ["sociopolitical", "OBSERVATION_MODIFIER", 87, 101], ["geographic", "OBSERVATION_MODIFIER", 122, 132], ["landscape", "OBSERVATION_MODIFIER", 133, 142]]], ["Many participants in the Paris Acts actually live and work outside the city, in surrounding suburbs, as well as small towns, rural, and peri-urban settlements.", [["participants", "SPECIES", 5, 17]]], ["These participants make a weekly drive into the center of cities such as Paris to join in the marches and rallies.", [["participants", "SPECIES", 6, 18]]], ["Beyond Paris, of course, the GJ have a strong presence in the small towns and villages in France provinces.", [["GJ", "ANATOMY", 29, 31], ["small", "OBSERVATION_MODIFIER", 62, 67]]], ["I will return to this later in these notes.What we might knowAmongst some of its participants are that many and varied supporters that include and national and international cohort of intellectuals, academics, activists, and university students.", [["participants", "SPECIES", 81, 93]]], ["Many of the latter of course are undertaking research for scholarly papers and theses about the mobilization.", [["the mobilization", "TREATMENT", 92, 108]]], ["In Paris and in many of the cities in the provinces, the GJ have also gathered up some controversial figures.", [["the GJ", "TREATMENT", 53, 59], ["GJ", "ANATOMY", 57, 59]]], ["Some of these are provocateurs, mostly young men dressed in black clothing masks and hoodies, generally thought to be members of the Black Bloc.", [["men", "ORGANISM", 45, 48], ["Black Bloc", "PROTEIN", 133, 143], ["men", "SPECIES", 45, 48], ["provocateurs", "OBSERVATION", 18, 30], ["Bloc", "OBSERVATION", 139, 143]]], ["The symbolism of such acts of course was not very subtle.", [["symbolism", "OBSERVATION", 4, 13]]], ["In many of the rallies that took place in squares such as the Place de la R\u00e9publique in Paris, many of these young men clustered to form a cohort that would taunt the police who responded by hurling tear gas and stun grenades.", [["men", "ORGANISM", 115, 118], ["men", "SPECIES", 115, 118]]], ["Many of these provocateurs were suspected to be undercover cops and indeed many plainclothes police are interspersed amongst the protesters.", [["provocateurs", "CANCER", 14, 26]]], ["They often moved freely and openly between the protestors and police, stepping in and out of vans that block roads and intersections.What we might knowThe mobilization of the GJ is further distinguished by two other related features.", [["GJ", "MULTI-TISSUE_STRUCTURE", 175, 177], ["the GJ", "TREATMENT", 171, 177], ["GJ", "ANATOMY", 175, 177]]], ["There is a lack of commitment to any single ideology or political philosophy and this is combined with a deep commitment to horizontalism.", [["horizontalism", "DISEASE", 124, 137], ["a deep commitment to horizontalism", "PROBLEM", 103, 137], ["political philosophy", "OBSERVATION", 56, 76], ["deep", "ANATOMY_MODIFIER", 105, 109]]], ["There is a general abhorrence of hierarchy, and the GJ have made much effort to create an impression that any structure that required leadership and hierarchy is anathema.", [["anathema", "DISEASE", 162, 170], ["the GJ", "TREATMENT", 48, 54], ["anathema", "PROBLEM", 162, 170], ["hierarchy", "OBSERVATION", 33, 42], ["GJ", "ANATOMY", 52, 54]]], ["So it has no set leader and the movement is not supported by any formal organization.", [["no", "UNCERTAINTY", 10, 12], ["set leader", "OBSERVATION_MODIFIER", 13, 23], ["not supported", "UNCERTAINTY", 44, 57]]], ["Local and regional committees are struck to organize gatherings, assembles and there is also a federation of assemblies.", [["regional", "ANATOMY", 10, 18]]], ["\"Assemblies of assemblies\" have been organized by a central committee of GJ and these meetings have resulted in the creation of the official charter of the GJ (la Charter Oficielle des Gilets Jaunes) (Image 1).What we might knowThe charter contains a set of demands that are as heterogeneous as their participants, extending from banning speed cameras to withdrawing France from NATO.", [["participants", "SPECIES", 301, 313], ["central", "ANATOMY_MODIFIER", 52, 59], ["GJ", "ANATOMY", 73, 75], ["GJ", "ANATOMY", 156, 158], ["heterogeneous", "OBSERVATION_MODIFIER", 278, 291]]], ["However, the core of their claims focuses on economic justice in the light of the injustices and grievances that are experienced by those who constitute themselves as marginalized, underprivileged, impoverished \"people.\"", [["people", "ORGANISM", 212, 218], ["people", "SPECIES", 212, 218]]], ["Such people stand in contrast to a privileged monied and powerful \"\u00e9lite.\"", [["people", "ORGANISM", 5, 11], ["people", "SPECIES", 5, 11]]], ["Indeed, their manifestos and proclamations, the lines of opposition are drawn in dyadic terms as the people vs the \u00e9lite.", [["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107]]], ["Also, the common people are venerated while \u00e9lites are vilified Image 1 Official charter of the gilets jaunes (source https://www.lelibrepenseur.org/giletsjaunes-charter-of-25claims-of-yellow-vests/) 4 This valorization of the people and denigrating the \u00e9lite have translated into a demand to create a citizen's referendum as a forum for popular sovereignty.", [["people", "ORGANISM", 17, 23], ["people", "ORGANISM", 227, 233], ["people", "SPECIES", 17, 23], ["people", "SPECIES", 227, 233]]], ["With an oppositional politics that has these features, the GJ mobilization is the embodiment of a militancy that is populist in orientation 5 Militant populism is not unprecedented in the extensive history of collective protest amongst the notoriously \"contentious\" French (Tilly 1986 ).RetrospectionIn looking into the past the GJ mobilization resonates in several respects with a populist movement that emanated in the 1950s from France's regions and small towns.", [["the GJ mobilization", "TREATMENT", 55, 74], ["RetrospectionIn", "TREATMENT", 287, 302], ["the GJ mobilization", "TREATMENT", 325, 344], ["oppositional", "OBSERVATION_MODIFIER", 8, 20], ["politics", "OBSERVATION", 21, 29], ["GJ mobilization", "OBSERVATION", 59, 74], ["GJ", "ANATOMY", 329, 331], ["mobilization", "OBSERVATION", 332, 344], ["small", "OBSERVATION_MODIFIER", 453, 458], ["towns", "OBSERVATION", 459, 464]]], ["The movement came to be known as Poujadism named after Pierre Poujade, a small business owner, who initiated a tax revolt in 1953 in a small town in the department of the Lot in southwestern France.", [["small", "OBSERVATION_MODIFIER", 73, 78]]], ["6 This revolt began as Poujade, and a small group of people prevented government tax inspectors, whom they called \"le Gestapo fiscal\" from investigating tax fraud in small businesses.", [["people", "ORGANISM", 53, 59], ["tax", "PROTEIN", 153, 156], ["people", "SPECIES", 53, 59], ["small", "OBSERVATION_MODIFIER", 38, 43], ["small businesses", "OBSERVATION", 166, 182]]], ["7 Called by some, a movement of the petty bourgeoisie, Poujadism eventually spread throughout France.", [["Poujadism", "PROBLEM", 55, 64], ["spread", "OBSERVATION_MODIFIER", 76, 82]]], ["This revolt galvanized the support of artisans and small shopkeepers whose ire was directed initially toward the tax system, particularly the income tax system, and then grew to focus on the French state and its visions for economic development and modernization in the Postwar era.", [["tax", "PROTEIN", 113, 116], ["artisans", "TREATMENT", 38, 46], ["small", "OBSERVATION_MODIFIER", 51, 56]]], ["Support for Poujadism was so strong that Poujade created a political party, the UDCA (Union of for the Defense of Shopkeepers and Craftsmen) in 1953.", [["UDCA", "CHEMICAL", 80, 84], ["UDCA", "CHEMICAL", 80, 84], ["UDCA", "SIMPLE_CHEMICAL", 80, 84], ["Poujadism", "PROBLEM", 12, 21]]], ["It mounted a list of candidates in the French elections in 1956 and secured 52 seats in parliament.RetrospectionThe GJ mobilization was also ignited by a protest against taxes, sparked by a fuel tax introduced by the French government as part of a general effort to reform the tax structure.", [["fuel tax", "PROTEIN", 190, 198], ["tax structure", "PROTEIN", 277, 290], ["The GJ mobilization", "TREATMENT", 112, 131], ["a fuel tax", "TREATMENT", 188, 198], ["GJ mobilization", "OBSERVATION", 116, 131]]], ["This tax was seen to have an adverse effect on the middle and working-class strata of the French population as well as people in the peri-urban, suburbs, and rural regions who relied on motor transportation for work and access to consumer goods.", [["people", "ORGANISM", 119, 125], ["tax", "PROTEIN", 5, 8], ["people", "SPECIES", 119, 125], ["an adverse effect", "PROBLEM", 26, 43], ["adverse effect", "OBSERVATION", 29, 43], ["middle", "ANATOMY_MODIFIER", 51, 57]]], ["The tax was withdrawn in December 2018 but not before the protests became widespread and grievances expanded to other facets reform programs pursued by the French government.", [["tax", "PROTEIN", 4, 7]]], ["However, unlike the Poujadists, the GJ have not formed a party or at least not yet, and it reject attempts by individuals who emerge and claim to represent them.", [["GJ", "ANATOMY", 36, 38]]], ["Yet, despite this commitment to horizontalism, several key figures have emerged and were elected to act as spokespersons for the GJ.", [["horizontalism", "DISEASE", 32, 45], ["GJ", "MULTI-TISSUE_STRUCTURE", 129, 131], ["the GJ", "TREATMENT", 125, 131], ["GJ", "ANATOMY", 129, 131]]], ["Moreover, several individuals have appointed themselves as representatives of the GJ and ran for seats in the European parliament.", [["GJ", "CELL", 82, 84], ["the GJ", "TREATMENT", 78, 84], ["GJ", "ANATOMY", 82, 84]]], ["They mounted campaigns amidst much opposition from the ranks of the GJ and were resoundingly defeated in the EU election in May of 2019.RetrospectionThe GJ and the Poujadists both emerged at conjunctures characterized by much political turbulence and economic uncertainty.", [["Retrospection", "TREATMENT", 136, 149], ["The GJ", "TREATMENT", 149, 155], ["the Poujadists", "TREATMENT", 160, 174], ["GJ", "ANATOMY", 68, 70], ["GJ", "ANATOMY", 153, 155], ["political turbulence", "OBSERVATION", 226, 246], ["economic uncertainty", "OBSERVATION", 251, 271]]], ["Poujadism arose as France was emerging from Vichy rule and 23 governments had risen and fallen since 1945 and the end of WW2.", [["Poujadism", "CHEMICAL", 0, 9], ["WW2", "PROTEIN", 121, 124]]], ["The nation had also suffered many major humiliations on the global stage.", [["major", "OBSERVATION_MODIFIER", 34, 39], ["humiliations", "OBSERVATION", 40, 52], ["global stage", "OBSERVATION_MODIFIER", 60, 72]]], ["It lost its colonial possessions in South East Asia after its defeat in 1940, Dien Bien Phu, and France also failed to regain control of Suez from Egypt late 1956.", [["colonial", "OBSERVATION_MODIFIER", 12, 20], ["possessions", "OBSERVATION_MODIFIER", 21, 32]]], ["6 The GJ have been described derisively as a Poujadist movement especially by some segments of the left. instabilities of a war-torn economy.", [["GJ", "MULTI-TISSUE_STRUCTURE", 6, 8], ["GJ", "PROTEIN", 6, 8], ["The GJ", "TREATMENT", 2, 8], ["a Poujadist movement", "TREATMENT", 43, 63], ["GJ", "OBSERVATION", 6, 8], ["segments", "ANATOMY_MODIFIER", 83, 91], ["left", "ANATOMY_MODIFIER", 99, 103], ["torn", "OBSERVATION_MODIFIER", 128, 132], ["economy", "OBSERVATION", 133, 140]]], ["To regain stability and to stave off the appeal of Soviet socialism, transnational capital was pumped into France though the Marshall plan for restructuring the French economy, which added to the turmoil and chaos.", [["restructuring the French economy", "TREATMENT", 143, 175], ["stability", "OBSERVATION", 10, 19]]], ["It was far from obvious that in the mid-1950s, France was on the cusp of the 30-year period of economic growth from 1950 to 1980 that later to be known as \"les trente glorieuses,\" during which a welfare state based on Keynesian economic principles would be constructed.", [["economic growth", "PROBLEM", 95, 110], ["Keynesian economic principles", "TREATMENT", 218, 247]]], ["8 The GJ have also appeared at a tumultuous time in France that has extended from the 1980s and continues into the 2000s.", [["The GJ", "TREATMENT", 2, 8], ["GJ", "ANATOMY", 6, 8]]], ["This is a period of time that some have called the 30 pitiful years (les trente pitieuses) (Bavarez 1998) when programs of neo-liberalization based on Hayekian economic principles provoked a political and economic shift \"state-managed capitalism\" to \"financialized capitalism.\" 9 Such programs were rolled out to stabilize an economy suffering the crises of slow growth provoked in part by the oil crisis in 1973 and the efforts by governments who worked in league with international financial institutions to create globally integrated economies.", [["oil", "ORGANISM_SUBSTANCE", 394, 397], ["neo-liberalization", "TREATMENT", 123, 141], ["the crises", "PROBLEM", 344, 354], ["slow growth", "PROBLEM", 358, 369], ["slow growth", "OBSERVATION_MODIFIER", 358, 369]]], ["In France, neoliberal reforms were initiated in the 1970s with a moderate approach to the privatization of public services, industry, and sales of public assets.", [["neoliberal reforms", "TREATMENT", 11, 29]]], ["But it became more aggressive as the twenty-first century approached.", [["more", "OBSERVATION_MODIFIER", 14, 18], ["aggressive", "OBSERVATION_MODIFIER", 19, 29]]], ["Privatizations became deeper and more extensive.", [["Privatizations", "TREATMENT", 0, 14], ["deeper", "OBSERVATION_MODIFIER", 22, 28], ["more extensive", "OBSERVATION_MODIFIER", 33, 47]]], ["Meanwhile, tax cuts were extended to private corporations and those who run them.", [["tax", "PROTEIN", 11, 14]]], ["The tax on fuel was introduced in this context, which was perceived by the GJ and furthering and assault on the disadvantaged.", [["tax", "PROTEIN", 4, 7], ["GJ", "ANATOMY", 75, 77]]], ["Introduced to remediate some facet of a climate crisis, it is an example of neo-liberalization in its ecological variant.", [["a climate crisis", "PROBLEM", 38, 54], ["facet", "OBSERVATION_MODIFIER", 29, 34], ["climate crisis", "OBSERVATION", 40, 54], ["ecological variant", "OBSERVATION", 102, 120]]], ["10 Introduced to remediate some facet of a climate crisis, it is an example of neo-liberalization in its ecological variant.", [["a climate crisis", "PROBLEM", 41, 57], ["facet", "OBSERVATION_MODIFIER", 32, 37], ["climate crisis", "OBSERVATION", 43, 57], ["ecological variant", "OBSERVATION", 105, 123]]], ["The rise of the GJ underscores the fallacies that are embedded in a strategy of socializing solutions to problems that have been created by private and corporate capital.", [["socializing solutions", "TREATMENT", 80, 101], ["rise", "OBSERVATION_MODIFIER", 4, 8], ["GJ", "ANATOMY", 16, 18], ["fallacies", "OBSERVATION", 35, 44]]], ["For the reforms and programs of austerity that have been applied in France were first tested in the context of the debt crisis of the 1980s in nations of the global south.", [["austerity", "TREATMENT", 32, 41]]], ["Referred to as structural adjustment programs imposed by international financial institutions (IFIs) upon developing countries, governments in Africa and Latin America implemented privatizations, deregulations, the termination of protectionism and subsidies in social provision and food production.", [["structural adjustment programs", "TREATMENT", 15, 45], ["IFIs", "PROBLEM", 95, 99], ["deregulations", "TREATMENT", 196, 209]]], ["The population at large, then, bore the brunt for crises of slow growth and of servicing sovereign debt and were drawn into IFI's agendas of creating a liberalized global economic order.RetrospectionThe foundation of this global order was of course was initiated in the aftermath of World War 2 when institutions such as the World Bank and the International Monetary Fund were formed largely under the aegis of the USA to facilitate international financial transfers for economic development.", [["crises", "PROBLEM", 50, 56], ["slow growth", "PROBLEM", 60, 71], ["international financial transfers", "TREATMENT", 433, 466], ["population", "OBSERVATION_MODIFIER", 4, 14], ["large", "OBSERVATION_MODIFIER", 18, 23]]], ["This was also a period of the reconstruction of European nations and the financial infusion that came to France from the US-backed Marshall Plan was combined with the Monnet Plan to direct the course of a program of modernization.", [["European nations", "TREATMENT", 48, 64], ["the financial infusion", "TREATMENT", 69, 91], ["a program of modernization", "TREATMENT", 203, 229]]], ["9 Fraser, Nancy (2017) 10 The French approach of \"pragmatic neoliberalism\" stood in contrast to the American or British approach of aggressive cuts in social spending, tax cuts, and rapid deregulation of industry.", [["neoliberalism", "DISEASE", 60, 73], ["The French approach of \"pragmatic neoliberalism", "TREATMENT", 26, 73]]], ["These segments included many small farmers in regions such as Languedoc where I undertook my first field research on agrarian change and regional nationalism 11 (Image 2).", [["regional nationalism", "TEST", 137, 157], ["segments", "OBSERVATION_MODIFIER", 6, 14], ["many", "OBSERVATION_MODIFIER", 24, 28], ["small", "OBSERVATION_MODIFIER", 29, 34], ["farmers", "OBSERVATION", 35, 42]]], ["Indeed, in the legislative elections of 1956, support for the UCDA party was very high in Languedoc (Image 3).RetrospectionLanguedoc is a region of mono-crop viticulture dominated by small-scale owner-operated family farms.", [["mono-crop viticulture", "PROBLEM", 148, 169], ["small", "OBSERVATION_MODIFIER", 183, 188]]], ["Some of the small farmers were fervent advocates of regional autonomy and separatism citing centuries' cultural, economic, and political domination of the north over the south and of the center over the periphery.", [["small", "OBSERVATION_MODIFIER", 12, 17], ["farmers", "OBSERVATION", 18, 25], ["regional autonomy", "OBSERVATION", 52, 69], ["economic", "OBSERVATION_MODIFIER", 113, 121], ["political domination", "OBSERVATION", 127, 147], ["north", "ANATOMY_MODIFIER", 155, 160], ["south", "ANATOMY_MODIFIER", 170, 175], ["periphery", "ANATOMY_MODIFIER", 203, 212]]], ["This was articulated as the domination of the people of the langue d' o\u00efl over the people of the langue d'oc, who inhabited the cultural and vague physical space of Occitania (l'Occitanie).", [["people", "ORGANISM", 46, 52], ["people", "ORGANISM", 83, 89], ["people", "SPECIES", 46, 52], ["people", "SPECIES", 83, 89], ["vague", "OBSERVATION_MODIFIER", 141, 146]]], ["12 Many of the small farmers who own and operated such holdings were also firmly embedded in the politics of agrarian populism.", [["small", "OBSERVATION_MODIFIER", 15, 20], ["farmers", "OBSERVATION", 21, 28], ["agrarian populism", "OBSERVATION", 109, 126]]], ["This form of populism valorized notions of small-scale, local, artisanal production, and vilified large-scale modern industrial farming.", [["populism", "PROBLEM", 13, 21], ["small-scale", "PROBLEM", 43, 54], ["small", "OBSERVATION_MODIFIER", 43, 48], ["-scale", "OBSERVATION_MODIFIER", 48, 54], ["artisanal production", "OBSERVATION", 63, 83], ["large", "OBSERVATION_MODIFIER", 98, 103], ["industrial farming", "OBSERVATION", 117, 135]]], ["In the post World War 2 era, this vilification was manifested in much opposition to the plans to modernize the agricultural economy.RetrospectionI suspect that many such farmers were very likely sympathetic to Poujadism, for the Poujadists were very much opposed to modernization, as well as industrialization and urbanization.", [["agricultural economy", "OBSERVATION", 111, 131]]], ["13 They also displayed a propensity to be anti-American and nationalistic adhering to the view that modernization American style ran counter to French national interests and identity 14 A form of nationalism that emerged amongst the Poujadists translated into xenophobic tendencies which particularly targeted France's Jewish population.", [["anti-American", "TREATMENT", 42, 55]]], ["Such xenophobic tendencies brought the Poujadists into alignment with the remnants of the Vichy regime that had broken up by 1950 and its supporters dispersed.", [["Such xenophobic tendencies", "PROBLEM", 0, 26], ["the Vichy regime", "TREATMENT", 86, 102]]], ["So, Poujadism also gathered up the likes of Jean Marie le Pen (the founder of the extreme-right National Front in France) and in fact launched Le Pen into politics.", [["right", "ANATOMY_MODIFIER", 90, 95]]], ["He was a member of the youth wing of the UDCA, and in the 1956 parliamentary election, he secured one of the 52 seats won by the Poujadist party.RetrospectionIt is noteworthy that in the Languedoc region of France is one of the areas where support for the FN has grown over the course of the past few decade (Image 4).RetrospectionIssues of xenophobia and nationalism bring me to the questions of representation and perhaps more at issue, the failures of representation in the movement, and in the wider polity.RepresentationIn principle and practice, whoever dons a Yellow Vest is considered to belong to the GJ movement.", [["UDCA", "CHEMICAL", 41, 45], ["xenophobia", "DISEASE", 341, 351], ["UDCA", "CHEMICAL", 41, 45], ["UDCA", "SIMPLE_CHEMICAL", 41, 45], ["FN", "GENE_OR_GENE_PRODUCT", 256, 258], ["FN", "PROTEIN", 256, 258], ["the FN", "PROBLEM", 252, 258], ["xenophobia", "PROBLEM", 341, 351], ["UDCA", "ANATOMY", 41, 45], ["France", "OBSERVATION_MODIFIER", 207, 213], ["one", "OBSERVATION_MODIFIER", 217, 220], ["grown", "OBSERVATION_MODIFIER", 263, 268]]], ["The line the divides speakers of the langue d'o\u00efl from the langue d'oc is blurry but generally thought to run from Grenoble to Bordeaux.", [["The line", "TREATMENT", 0, 8], ["the langue d'o\u00efl", "TREATMENT", 33, 49], ["blurry", "PROBLEM", 74, 80], ["line", "OBSERVATION_MODIFIER", 4, 8]]], ["13 Fitzgerald, S. (1970) 14 My trailing of the GJ and observations of participants in the marches also prompted me to ponder the valences of the \"we,\" in the light of how two mobilizations unfolded in the streets of Paris.RepresentationOne was the march through the neighborhoods on the Blvd. de Strasbourg on the right bank of Paris.", [["participants", "SPECIES", 70, 82], ["the GJ", "TREATMENT", 43, 49], ["GJ", "ANATOMY", 47, 49], ["right", "ANATOMY_MODIFIER", 314, 319], ["Paris", "ANATOMY", 328, 333]]], ["This is a neighborhood filled with businesses run by the Franco African population of Paris.RepresentationThe other was the march through Ave. de Choisie, in one of Paris's Chinatowns on the left bank.", [["left bank", "ANATOMY", 191, 200], ["left", "ANATOMY_MODIFIER", 191, 195], ["bank", "ANATOMY", 196, 200]]], ["The valences of \"we\" became abundantly clear in the spatial politics of the marches and evoked the insights of Lefebvre (2003) and David Harvey's (2012) on spatiality in urban politics and the patterns of who moved through the city and how.", [["clear", "OBSERVATION", 39, 44]]], ["In both marches, I noted how the different social divides and cleavages that prevail in urban France are refracted through the patterns of occupation and movement through the public spaces of roads and sidewalks.", [["both", "ANATOMY_MODIFIER", 3, 7], ["marches", "ANATOMY", 8, 15]]], ["The roads were a central conduit for a population of mostly white participants.", [["participants", "SPECIES", 66, 78], ["a central conduit", "TREATMENT", 15, 32], ["central conduit", "OBSERVATION", 17, 32]]], ["People of color either stood on the sidewalks and watched or simply ignored the GJ and went about their daily business.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["GJ", "ANATOMY", 80, 82]]], ["Many smiled rather uncomfortably as some amongst the GJ protesters beckoned bystanders to join with a hand wave.", [["hand", "ANATOMY", 102, 106], ["hand", "ORGANISM_SUBDIVISION", 102, 106]]], ["I asked one bystander why he was rejecting the gesture from the GJ.", [["GJ", "MULTI-TISSUE_STRUCTURE", 64, 66], ["GJ", "ANATOMY", 64, 66]]], ["The gist of his reply was that he did not see himself reflected in the GJ.RepresentationAnother person who stood on the sidewalk remarked on the marchers saying: Tout ce que je vois, c'est une vague de visages blancs avec quelques points de couleur (All I see is a wave of white faces with few dots of color).RepresentationIn another march through the Chinatown on the Avenue de Choisy, Asian business owners hastily locked doors and barricaded their windows as soon as the police vehicles appeared announcing the imminent arrival of the GJ.", [["person", "SPECIES", 96, 102], ["c'est une vague", "PROBLEM", 183, 198], ["a wave of white faces", "PROBLEM", 263, 284], ["gist", "OBSERVATION", 4, 8], ["GJ", "ANATOMY", 71, 73], ["GJ", "ANATOMY", 538, 540]]], ["Most Franco-Asians on this avenue, like the Franco Africans on the Blvd de Strasbourg, simply let them GJ pass by, did not respond to invitations to join in the march, and simply carried on with their daily activities.RepresentationMy fieldwork on the occupation background of many of Paris' Asians population seems to suggest an affinity between their concerns and the concerns of the GJ.", [["GJ", "MULTI-TISSUE_STRUCTURE", 386, 388], ["an affinity", "PROBLEM", 327, 338], ["GJ", "ANATOMY", 386, 388]]], ["Many of Paris's Asian population are small business owners, truck drivers, care workers, pharmacists, artisans, and taxi drivers Also, a good number of Asians live and work in the urban peripheries and outer Image 5 The GJ March-Blvd de Strasbourg suburbs of Paris.", [["small", "OBSERVATION_MODIFIER", 37, 42], ["good", "OBSERVATION_MODIFIER", 137, 141], ["number", "OBSERVATION_MODIFIER", 142, 148], ["GJ", "ANATOMY", 220, 222]]], ["Yet, on the whole, they seem to reject the GJ.", [["GJ", "OBSERVATION", 43, 45]]], ["Most recently, Franco Asians have been mobilized to contest the predictable rise of anti-Asian hostility due to COVID 19 and the re-emergence of the heinous language of the \"yellow peril\" at least in taking forms of digital activism.RepresentationIn talking about the GJ, I have joked with some of my colleagues in France as well as some Asian informants, who stood on the sidelines\u2026, \"o\u00f9 sont les jaunes dans les gilets jaunes?\"", [["hostility", "DISEASE", 95, 104]]], ["Roughly translated: \"where are the yellows (yellow people) in gilets jaunes?\"RepresentationThe joke sounds better in French.", [["yellows", "DISEASE", 35, 42], ["yellow people", "ORGANISM", 44, 57], ["people", "SPECIES", 51, 57], ["better", "OBSERVATION_MODIFIER", 107, 113]]], ["The jaunes appeared during Chinese New Year in February 2019 (Image 6).", [["jaunes", "ANATOMY", 4, 10]]], ["Two men who donned a yellow dragon costume danced their way into the march and created a spectacle by taunting the riot police.", [["men", "ORGANISM", 4, 7], ["men", "SPECIES", 4, 7]]], ["This spectacle was that proverbial exception to the rule.RepresentationIt is a source of bemusement to many of my informants that the GJ mobilizations have arrogated the color yellow and have been referred to as the new \"Yellow Peril\" in several articles and commentaries in the press.", [["the GJ mobilizations", "TREATMENT", 130, 150], ["the color yellow", "PROBLEM", 166, 182]]], ["17 While in the protests, many demonstrators carried anti-racist and pro-immigrant signs and placards, many members of France's ethnic minority and migrant populations seem to disavow the GJ.", [["GJ", "MULTI-TISSUE_STRUCTURE", 188, 190], ["GJ", "ANATOMY", 188, 190]]], ["So very few sported the yellow vest.", [["very", "OBSERVATION_MODIFIER", 3, 7], ["few", "OBSERVATION_MODIFIER", 8, 11], ["yellow vest", "OBSERVATION", 24, 35]]], ["In my chats with some members of the migrant and ethnic minority populations, there were worries about the xenophobic proclivities amongst some of the participants and ideological ambiguity around the question of migration.", [["participants", "SPECIES", 151, 163], ["the xenophobic proclivities", "PROBLEM", 103, 130], ["ideological ambiguity", "PROBLEM", 168, 189], ["migration", "PROBLEM", 213, 222], ["migration", "OBSERVATION", 213, 222]]], ["This ambiguity is reflected in the widely publicized GJ charter which contains a demand to \"prevent migratory flows that cannot be accommodated or integrated, given the profound civilizational crisis we are experiencing.\"", [["migratory flows", "PROBLEM", 100, 115], ["the profound civilizational crisis", "PROBLEM", 165, 199], ["GJ charter", "OBSERVATION", 53, 63]]], ["The coupling of migrants with the profound civilizational crisis reinforces the suspicion held by many migrants that xenophobic currents prevail amongst the GJ and this has been reinforced by the widespread reportage of anti-Semitist attacks attributed to its members.", [["the profound civilizational crisis", "PROBLEM", 30, 64], ["xenophobic currents", "TREATMENT", 117, 136], ["the GJ", "TREATMENT", 153, 159]]], ["18 Such worries about racism, so some migrants with whom I chatted have suggested the GJ appears to be \"a white people's protest.\"", [["people", "SPECIES", 112, 118]]], ["Such white people are often referred to as the \"Fran\u00e7ais de souche\" (people of French stock), an invidious term often used assert the boundaries between \"the French\" and the \"non-French\" or \"us\" and \"them\" in the fraught politics of belonging.", [["people", "ORGANISM", 11, 17], ["people", "ORGANISM", 69, 75], ["people", "SPECIES", 11, 17], ["people", "SPECIES", 69, 75]]], ["This view amongst informants that the GJ seem to be a protest largely of the \"Fran\u00e7ais de souche\" is prevalent despite anti-racism placards that are evident and disclaimers made by many GJ in the press that run counter this view.", [["GJ", "MULTI-TISSUE_STRUCTURE", 186, 188], ["anti-racism placards", "TREATMENT", 119, 139]]], ["These divisions have condensed into specters of color through which larger ideologies and practices of belonging under the strain of neo-liberalization are refracted.", [["larger", "OBSERVATION_MODIFIER", 68, 74], ["ideologies", "OBSERVATION", 75, 85]]], ["19 Such specters and 16 See Harvey, D., & Williams, R. (1995) 17 Wilkin, P. (2020) 18 A study produced by the Fondation Jean Jaures showed that 50% of those who participated in Yellow Vest p r o t e s t s s a i d t h e y b e l i e v e d i n a \" g l o b a l Z i o n i s t c o n s p i r a c y . \" h t t p s : / / j e a n -j a u r e s . org/sites/default/files/redac/commun/productions/2019/0220/rapport_complot.pdf 19 Although xenophobia and anti-immigration attitudes and values have been around for a long time they have reactivated or leveraged into greater salience by the economic strains that neoliberal globalization has imposed on different segments of the population.", [["A study", "TEST", 86, 93], ["a c y", "TEST", 285, 290], ["h", "PROBLEM", 295, 296], ["p s", "TEST", 301, 304], ["j e", "TEST", 311, 314], ["redac", "PROBLEM", 358, 363], ["xenophobia", "PROBLEM", 425, 435], ["neoliberal globalization", "TREATMENT", 597, 621], ["neoliberal globalization", "OBSERVATION", 597, 621]]], ["Amongst these political shifts, perhaps the most painful is the rise in social status of the very groups to whom poor whites once felt superior and the conviction that these groups are rising because of favoritism from national government.", [["political shifts", "OBSERVATION", 14, 30], ["rise", "OBSERVATION_MODIFIER", 64, 68]]], ["(See Berger 2017) their resonances have been made evident in the spatial politics in the GJ mobilizations.", [["the GJ mobilizations", "TREATMENT", 85, 105], ["GJ mobilizations", "OBSERVATION", 89, 105]]], ["These specters suggest that rather than building important solidarities, the GJ seem to reinforce the migrant non-migrant divide and to emphasize divisions by color.RepresentationThe specter of color is indeed very much embedded into the GJ insurgency and the mobilizations that have grown around them.", [["GJ", "MULTI-TISSUE_STRUCTURE", 77, 79], ["the GJ", "TREATMENT", 73, 79], ["the GJ insurgency", "PROBLEM", 234, 251], ["GJ", "ANATOMY", 238, 240]]], ["Collective actions that have arisen to repudiate the GJ have also adopted a color.", [["GJ", "MULTI-TISSUE_STRUCTURE", 53, 55], ["Collective actions", "TREATMENT", 0, 18], ["GJ", "ANATOMY", 53, 55]]], ["The foulards rouges (red scarf) movement, emerged as a counterfoil to the GJ.", [["GJ", "ANATOMY", 74, 76]]], ["It consisted of a quite disparate collection of people and at its height, the mobilization drew only 10,000.", [["people", "ORGANISM", 48, 54], ["people", "SPECIES", 48, 54], ["disparate", "OBSERVATION_MODIFIER", 24, 33], ["collection", "OBSERVATION", 34, 44], ["mobilization", "OBSERVATION_MODIFIER", 78, 90]]], ["The GJ have also spawned a parallel militancy-the Gilets Noirs.", [["GJ", "ANATOMY", 4, 6], ["parallel", "OBSERVATION_MODIFIER", 27, 35], ["militancy", "OBSERVATION", 36, 45]]], ["20 The GN are a collective of undocumented migrants in France whose slogan is \"black with anger.\"", [["GN", "OBSERVATION", 7, 9]]], ["It is a mobilization that has emerged to protest the repression of undocumented migrants, detention centers, the emergence of a deportation state, and the conditions of work for migrants in Paris who face racism, terrible living, and working conditions.", [["mobilization", "OBSERVATION", 8, 20]]], ["These are not issues addressed by the GJ.RepresentationWhile nationalist and xenophobic elements seem to be present amongst the GJ, the GJ themselves have also rejected any attempts by the far-right and all political parties to represent them.", [["nationalist and xenophobic elements", "DNA", 61, 96], ["xenophobic elements", "PROBLEM", 77, 96], ["GJ", "ANATOMY", 38, 40], ["GJ", "ANATOMY", 128, 130], ["right", "ANATOMY_MODIFIER", 193, 198]]], ["The ideological programs of the far-right often ranged from the conservative corporatists to outright fascism as well as anti-Republican, anti-parliamentary, and anti-liberal sentiments.", [["the conservative corporatists", "TREATMENT", 60, 89], ["outright fascism", "TREATMENT", 93, 109], ["anti-Republican", "TREATMENT", 121, 136], ["anti-parliamentary", "TREATMENT", 138, 156], ["right", "ANATOMY_MODIFIER", 36, 41]]], ["However, like the Poujadists before them, the GJ seem to lack an ideological paradigm.", [["the GJ", "TREATMENT", 42, 48], ["ideological paradigm", "OBSERVATION", 65, 85]]], ["Also, like the Poujadists, the GJ simply and viscerally focus their attacks on the \u00e9lites that controlled the Republic.", [["the GJ", "TREATMENT", 27, 33]]], ["The \u00e9lites under attack by the Poujadists were a vague assemblage of French Third and Fourth Republic politicians, capitalists, and left-wing intellectuals (Berger 2017) .", [["vague", "OBSERVATION_MODIFIER", 49, 54], ["assemblage", "OBSERVATION_MODIFIER", 55, 65], ["left", "ANATOMY_MODIFIER", 132, 136]]], ["In a similar vein, the GJ focus their attacks on \"the \u00e9lite\" that is understood to include the rich, well-educated professionals, banks and insurance companies and globally connected big business, transnational companies who have done well out of the forces of neoliberal restructuring of economies.", [["vein", "ANATOMY", 13, 17], ["vein", "MULTI-TISSUE_STRUCTURE", 13, 17], ["similar vein", "ANATOMY", 5, 17], ["GJ", "ANATOMY", 23, 25], ["neoliberal restructuring", "OBSERVATION", 261, 285], ["economies", "OBSERVATION", 289, 298]]], ["The emergence of the GJ underscores the flaws of a democracy that operates in a world divided by a social and political class and in which the state operates in league with capital to ensure the power and wealth of the \u00e9lite.RepresentationThis path toward strengthening the position of an economic \u00e9lite is paved by a selfreproducing political \u00e9lite.", [["an economic \u00e9lite", "TREATMENT", 286, 303], ["a selfreproducing political \u00e9lite", "TREATMENT", 316, 349], ["democracy", "OBSERVATION", 51, 60], ["position", "OBSERVATION_MODIFIER", 274, 282], ["economic \u00e9lite", "OBSERVATION", 289, 303]]], ["Such institutions select and set the rules for ensuring the ruling class sustains its power and in a system of representative democracy.", [["democracy", "OBSERVATION", 126, 135]]], ["Wearing a jacket that is yellow and fluorescent is apposite, not only because it is a militancy that was ignited by an issue related to motor transport, but these jackets are mandatory for motorists to carry in their cars to be worn as a safety measure to make motorists visible on the roads in case of accidents.", [["accidents", "DISEASE", 303, 312], ["a jacket", "TREATMENT", 8, 16], ["yellow", "PROBLEM", 25, 31], ["yellow", "OBSERVATION", 25, 31]]], ["Worn by participants in the mobilization, the yellow renders visible a segment of French society that has felt itself to be invisible to the gaze of state and their mobilization signal the failure of the state and its institutions to represent them.", [["participants", "SPECIES", 8, 20], ["the mobilization", "TREATMENT", 24, 40]]], ["So in the view of the GJ, this political system and its economic model have not only generated wealth for the \u00e9lite but also failed to represent the interests of those sidelined by the current economic and political system.", [["the GJ", "TREATMENT", 18, 24], ["GJ", "ANATOMY", 22, 24]]], ["The GJ are persistent in their opposition to the rule of \u00e9lites, and their attacks and grievances are focused on the injustices that this political system generates.", [["\u00e9lites", "PROBLEM", 57, 63], ["GJ", "ANATOMY", 4, 6], ["persistent", "OBSERVATION_MODIFIER", 11, 21]]], ["This raises the question of the aims of the GJ and how they foresee that their grievances might be resolved.ResolutionIn focusing on the questions of resolution, my interests lie in asking what are the desired ends of this militancy and what might they tell us about the movement.", [["the GJ", "TREATMENT", 40, 46], ["GJ", "ANATOMY", 44, 46]]], ["The first is the issue of the mobilization and tactics of the GJ itself in relation to the economy of capitalism.", [["GJ", "MULTI-TISSUE_STRUCTURE", 62, 64], ["the mobilization", "TREATMENT", 26, 42], ["tactics of the GJ", "TREATMENT", 47, 64], ["mobilization", "OBSERVATION", 30, 42], ["GJ", "ANATOMY", 62, 64], ["capitalism", "OBSERVATION", 102, 112]]], ["The second focuses on the endpoint GJ agency whether its aims are to reproduce the capitalist state and indeed state capitalism or challenge it.ResolutionThe grievances of the GJ are focused overall on economic injustice and their rage emerges from the difficulties that are experienced in the attempt to reproduce human life.", [["GJ", "MULTI-TISSUE_STRUCTURE", 176, 178], ["human", "ORGANISM", 315, 320], ["human", "SPECIES", 315, 320], ["human", "SPECIES", 315, 320], ["GJ", "ANATOMY", 176, 178]]], ["Such difficulties have been exacerbated by the programs of neoliberal restructuring.", [["Such difficulties", "PROBLEM", 0, 17], ["neoliberal restructuring", "TREATMENT", 59, 83], ["neoliberal restructuring", "OBSERVATION", 59, 83]]], ["This suggests to me that they are engaged in a struggle for social reproduction and their contestation focuses on the production of people and not the production of things (Katz 2001; Harris and Young 1981) .", [["people", "ORGANISM", 132, 138], ["people", "SPECIES", 132, 138]]], ["The mobilizations of the GJ are clearly not organized around sites of where the production of things is located in the circuits of capitalism.", [["GJ", "MULTI-TISSUE_STRUCTURE", 25, 27], ["The mobilizations of the GJ", "TREATMENT", 0, 27], ["GJ", "ANATOMY", 25, 27], ["capitalism", "OBSERVATION", 131, 141]]], ["They also occur outside of workplaces and working hours, mostly on the weekend at traffic circles, organizing blockades that alter and slow down the circulation of goods and people.", [["people", "ORGANISM", 174, 180], ["people", "SPECIES", 174, 180], ["blockades", "OBSERVATION", 110, 119]]], ["The GJ mobilization then may be differentiated from those that focus on the direct wage and the conditions for exploiting the labor force within the workplace (Paye 2019) .ResolutionThis division was evident in the spatialities of the Mayday March held in Paris in 2019.", [["The GJ mobilization", "TREATMENT", 0, 19], ["GJ mobilization", "OBSERVATION", 4, 19]]], ["The GJ participated in this annual parade which is organized by the major unions in France such as the Force Ouvriere and the General Confederation of Labor (Conf\u00e9d\u00e9ration G\u00e9n\u00e9rale du Travail).", [["Labor (Conf\u00e9d\u00e9ration G\u00e9n\u00e9rale du Travail", "TREATMENT", 151, 191], ["GJ", "ANATOMY", 4, 6]]], ["The GJ marched as a cohort in front of the unions and the union marshals carried rope to maintain a physical distance that separated the union participants from the GJ.", [["participants", "SPECIES", 143, 155], ["The GJ marched", "TREATMENT", 0, 14], ["GJ", "ANATOMY", 4, 6], ["marched", "OBSERVATION", 7, 14], ["GJ", "ANATOMY", 165, 167]]], ["Also, the march is usually peaceful, but in 2019, it took a violent turn when GJ clashed with the polices.", [["GJ", "TREATMENT", 78, 80]]], ["So against the optimistic view held by some members of the left that the GJ is a form of class struggle, it is a militancy that cannot be seen in a very clear sense as a struggle of labor against capital.", [["GJ", "MULTI-TISSUE_STRUCTURE", 73, 75], ["left", "ANATOMY_MODIFIER", 59, 63], ["GJ", "ANATOMY", 73, 75]]], ["Their demands target the state and not employers.ResolutionThe GJ then are not opposed to the republic, the state, and capitalism but are agitating to reform the capitalist economy in ways that serve the interests of people within the borders of the French nation who have been marginalized.", [["people", "ORGANISM", 217, 223], ["people", "SPECIES", 217, 223], ["GJ", "ANATOMY", 63, 65]]], ["As a struggle for economic justice, the goal is to ensure that a moral economy will prevail.", [["a moral economy", "TREATMENT", 63, 78]]], ["The GJ do not take issue with an economy based on the accumulation of capital, but they argue that the gains of accumulation should be distributed and not hoarded.", [["The GJ", "TREATMENT", 0, 6], ["an economy", "TREATMENT", 30, 40]]], ["The GJ have argued that gains in the current economic system must be used to compensate those who have been thrown out of jobs or that to ensure that those who have been ejected from one industry can be absorbed into employment in other more promising sectors of the economy.", [["The GJ", "TREATMENT", 0, 6], ["GJ", "ANATOMY", 4, 6]]], ["To enable this form of economic justice, they propose a form of direct democracy R\u00e9f\u00e9rendum d'initiative Citoyenne (RIC) citizen's referendum which is a proposal for a constitutional amendment to permit the consultation of the citizenry to limit the power of political bodies to propose or abrogate legislations.", [["direct democracy R\u00e9f\u00e9rendum d'initiative Citoyenne (RIC) citizen's referendum", "TREATMENT", 64, 141], ["a constitutional amendment", "TREATMENT", 166, 192], ["the citizenry", "TREATMENT", 223, 236]]], ["21 While this poses a limitation on representational democracy, the focus on popular sovereignty through a form of direct democracy does not replace it.ResolutionRedistribution, then, is the economic endpoint of struggles, and such an endpoint would enhance the ability of people to sustain life for at minimum; purchasing power in a commodified economy will be increased.", [["people", "ORGANISM", 273, 279], ["people", "SPECIES", 273, 279], ["ResolutionRedistribution", "PROBLEM", 152, 176], ["a commodified economy", "TREATMENT", 332, 353], ["democracy", "OBSERVATION", 53, 62], ["democracy", "OBSERVATION", 122, 131], ["increased", "OBSERVATION_MODIFIER", 362, 371]]], ["The struggles of the GJ are focused on reproduction, not only of people but are also linked to the reproduction of \"the people\" as a nation.", [["people", "ORGANISM", 65, 71], ["people", "ORGANISM", 120, 126], ["people", "SPECIES", 65, 71], ["people", "SPECIES", 120, 126], ["GJ", "ANATOMY", 21, 23]]], ["The reproduction of human life is achievable if France withdraws from the European Union and so an emphasis that is placed on FREXIT, the French version of BREXIT which will enable a renewed emphasis on the national economy for the nation and its people.", [["human", "ORGANISM", 20, 25], ["people", "ORGANISM", 247, 253], ["human", "SPECIES", 20, 25], ["people", "SPECIES", 247, 253], ["human", "SPECIES", 20, 25], ["FREXIT", "TREATMENT", 126, 132]]], ["Globalization has exacerbated the problems of reproduction, and so in the agendas of the GJ, there is opposition to global integration and a renewed emphasis on the galvanizing and reproducing the nation and its 21 Zoe Lauwereys (10 December 2018) people.", [["people", "ORGANISM", 248, 254], ["people", "SPECIES", 248, 254], ["the galvanizing", "TREATMENT", 161, 176], ["GJ", "ANATOMY", 89, 91], ["global integration", "OBSERVATION", 116, 134]]], ["The obscurities contained in the rhetoric of \"we\" and \"the people\" combined with the ambiguities of the GJ position on ethnicity and migration, juxtaposed against the demand to end the \"civilization crisis\" has raised concerns about what such a struggle for reproduction means for people of color, racialized populations, and migrants.", [["people", "ORGANISM", 59, 65], ["people", "ORGANISM", 281, 287], ["people", "SPECIES", 59, 65], ["people", "SPECIES", 281, 287], ["rhetoric", "OBSERVATION_MODIFIER", 33, 41]]], ["This is of course not insignificant at a particular moment of history in 2020 when struggles to end racism have proliferated around the globe.ResolutionFinal reflections In much of the literature that has emerged on the GJ, it is almost de rigueur to add a speculative note that considers outcomes, effects, and the future of the movement itself.", [["globe", "ANATOMY", 136, 141], ["Final reflections", "OBSERVATION", 152, 169]]], ["There are those who have looked back at collective struggles in France's past and have made comparisons between the GJ and Jacqueries that took place in medieval Franc 22 In these jacqueries, peasants rose up often violently in protests against tax offices and local landowners.", [["GJ", "ANATOMY", 116, 118]]], ["Others have suggested that the GJ resonates with the 1789 Revolution, in which struggles were initiated between those who favored direct democracy and those who favored representational democracy led by elites in the formation of the new republic.", [["the GJ resonates", "TREATMENT", 27, 43], ["democracy", "OBSERVATION", 186, 195], ["new", "OBSERVATION_MODIFIER", 234, 237], ["republic", "OBSERVATION", 238, 246]]], ["23 Still others have forged a link between the GJ to movements outside France, and the GJ have been likened to the Chartists.", [["the GJ", "TREATMENT", 83, 89]]], ["Chartism was a transclass movement that arose in England in with the publication a people's charter, in May 1838.", [["Chartism", "DISEASE", 0, 8], ["people", "ORGANISM", 83, 89], ["people", "SPECIES", 83, 89]]], ["The chartists included artisans, traders, managers, and small shop keepers close to the working classes, and their charter, petitions, and collective actions led to parliamentary reforms that allowed unpropertied men to vote.", [["men", "ORGANISM", 213, 216], ["men", "SPECIES", 213, 216]]], ["There is a striking absence of an ideology, program, doctrine, or even a notion of utopia.", [["utopia", "DISEASE", 83, 89], ["utopia", "CANCER", 83, 89], ["doctrine", "TREATMENT", 53, 61]]], ["The participants inhabit an affective world that is negative and seem to subscribe to a world view that is reductionist in its adherence to a Manicheanism which sees systems institutions, practices, and people in terms of a dualistic division between good and evil.", [["people", "ORGANISM", 203, 209], ["participants", "SPECIES", 4, 16], ["people", "SPECIES", 203, 209]]], ["While anger and a sense of injustice fuels most social movements, the participants inhabit an affective world that is particularly negative.", [["participants", "SPECIES", 70, 82]]], ["Such negativity, reductionism, and anger render such movement particularly prone to xenophobia and an ethno-nationalist outlook.", [["xenophobia", "DISEASE", 84, 94], ["reductionism", "PROBLEM", 17, 29], ["xenophobia", "PROBLEM", 84, 94]]], ["So, if some speculation is in order, the negativity, Manicheanism, and lack of vision and more significantly lack of a coherent ideology will likely be the undoing the GJ like the Poujadist before them.", [["lack of vision", "PROBLEM", 71, 85]]], ["For Poujadism disintegrated in 1958, and its participants were gathered up into movements, organizations, and parties with more coherent ideologies, programs as well as institutional support.ResolutionI have also referred to the movement of the GJ as militancy that is populist in orientation.", [["GJ", "MULTI-TISSUE_STRUCTURE", 245, 247], ["participants", "SPECIES", 45, 57], ["Poujadism", "PROBLEM", 4, 13], ["institutional support", "TREATMENT", 169, 190], ["GJ", "ANATOMY", 245, 247]]], ["It is protean in nature and often difficult to define.", [["protean", "OBSERVATION_MODIFIER", 6, 13]]], ["This leaves open the possibility that the GJ might be both more and maybe less than a movement of militant populism.", [["GJ", "MULTI-TISSUE_STRUCTURE", 42, 44], ["the GJ", "TREATMENT", 38, 44], ["GJ", "OBSERVATION", 42, 44]]], ["For the moment, the rise of the GJ presents one case in the many collective struggles that have emerged at a political and economic conjuncture when savage capitalism prevails.", [["the GJ", "TREATMENT", 28, 34], ["GJ", "ANATOMY", 32, 34]]]], "PMC7453202": [], "PMC7510210": [["IntroductionThe pandemic triggered after the massive spread of SARS-CoV-2 from Wuhan (1) is hitting most countries with varying degrees of virulence, striking particularly hard in Spain.", [["SARS", "DISEASE", 63, 67], ["SARS-CoV-2", "ORGANISM", 63, 73], ["SARS-CoV-2", "SPECIES", 63, 73], ["SARS", "PROBLEM", 63, 67], ["virulence", "PROBLEM", 139, 148], ["massive", "OBSERVATION_MODIFIER", 45, 52], ["spread", "OBSERVATION_MODIFIER", 53, 59]]], ["A pandemic without precedent, and of a magnitude and severity unknown to this century.", [["A pandemic", "PROBLEM", 0, 10], ["pandemic", "OBSERVATION", 2, 10]]], ["Let's contrast and compare some recent data on other seasonal respiratory viruses with serious health consequences.", [["respiratory viruses", "DISEASE", 62, 81], ["Let", "GENE_OR_GENE_PRODUCT", 0, 3], ["Let's contrast", "TEST", 0, 14], ["other seasonal respiratory viruses", "PROBLEM", 47, 81], ["serious health consequences", "PROBLEM", 87, 114], ["respiratory", "ANATOMY", 62, 73], ["viruses", "OBSERVATION", 74, 81]]], ["During the 2018\u20132019 influenza epidemic in Spain, there were 490,000 non-serious cases, 35,300 hospitalizations, 2,500 patients were admitted to the intensive care units (ICU) and 6,300 died (https://vacunasaep.org).", [["influenza", "DISEASE", 21, 30], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["influenza", "PROBLEM", 21, 30]]], ["Concerning SARS-CoV-2 infection, on May 15, 2020, the Spanish Ministry of Health (https://www.mscbs.gob.es) had reported 230,183 cases, 124,571 hospitalizations, 11,493 ICU admissions, and 27,459 deaths.", [["SARS-CoV-2 infection", "DISEASE", 11, 31], ["deaths", "DISEASE", 196, 202], ["CoV-2", "ORGANISM", 16, 21], ["SARS-CoV", "SPECIES", 11, 19], ["SARS", "PROBLEM", 11, 15], ["CoV", "PROBLEM", 16, 19], ["2 infection", "PROBLEM", 20, 31], ["SARS", "OBSERVATION", 11, 15], ["CoV", "OBSERVATION_MODIFIER", 16, 19], ["infection", "OBSERVATION", 22, 31]]], ["Therefore, the numbers speak for themselves when both infections were compared.IntroductionIt is true that the Spanish Healthcare System has some peculiarities that may have made initial control of the pandemic difficult.", [["infections", "DISEASE", 54, 64], ["both infections", "PROBLEM", 49, 64], ["infections", "OBSERVATION", 54, 64]]], ["These include the system fragmentation into 17 health regions and the absence of a proactive strategy to tracing contacts or search for potential cases, coupled with an absence of preventive measures to foresee the supply chain shortages for personal protection equipment and diagnostics tests (RNA extraction reagents and RT-PCR kits).", [["the system fragmentation into 17 health regions", "PROBLEM", 14, 61], ["preventive measures", "TREATMENT", 180, 199], ["personal protection equipment", "TREATMENT", 242, 271], ["diagnostics tests", "TEST", 276, 293], ["RNA extraction reagents", "TREATMENT", 295, 318], ["RT-PCR kits", "TEST", 323, 334]]], ["Nevertheless, the Spanish Healthcare System has demonstrated great flexibility and adaptability during pandemics.", [["pandemics", "PROBLEM", 103, 112], ["great flexibility", "OBSERVATION", 61, 78]]], ["In fact, hospital beds and intensive care facilities have increased, even external hospitalization centers such as the IFEMA in Madrid with up to 5,000 beds (an ~39% increase in the number of hospital beds in one of the most affected regions in Spain) have been set up in record time to attend COVID-19 patients, and a number of research laboratories (24 laboratories accreditated by the National Research Institute Carlos III) got ready to do RT-PCR diagnostics test across the country.", [["patients", "ORGANISM", 303, 311], ["patients", "SPECIES", 303, 311], ["research laboratories", "TEST", 329, 350], ["PCR diagnostics test", "TEST", 447, 467]]], ["Besides, our knowledge of the best therapeutic measures to fight against coronavirus is rapidly increasing.", [["coronavirus", "DISEASE", 73, 84], ["coronavirus", "ORGANISM", 73, 84], ["coronavirus", "PROBLEM", 73, 84], ["rapidly", "OBSERVATION_MODIFIER", 88, 95], ["increasing", "OBSERVATION_MODIFIER", 96, 106]]], ["Therefore, there is likely to be room for hope even in the case of a second SARS-CoV-2 wave in our country.IntroductionWithout a doubt, the economic impact in a system highly dependent on the tourism and service sectors will be enormous, with the consequent impoverishment and added difficulty in taking public health actions.", [["SARS", "DISEASE", 76, 80]]], ["These actions are accompanied by increased SARS-CoV-2 testing to know the degree of immunization in the general population (2).", [["CoV-2", "GENE_OR_GENE_PRODUCT", 48, 53], ["increased SARS", "PROBLEM", 33, 47], ["CoV-2 testing", "TEST", 48, 61], ["immunization", "TREATMENT", 84, 96]]], ["However, within the first weeks of \u201cnormal activity\u201d we are seeing an ever increasing number of traceable outbreaks and, in some cases, they are at risk of developing as community epidemics in a second wave.Will the Sanitary Passport Clear all our Doubts?Due to several reasons, we deem that classifying the individuals into immunized and non-immunized groups will not solve all our troubles as most people believe:Will the Sanitary Passport Clear all our Doubts?(a) At present, not only do we not know the real prevalence of the viral infection, but more importantly, we do not know what the progression of the pandemic will be.", [["viral infection", "DISEASE", 530, 545], ["people", "ORGANISM", 400, 406], ["people", "SPECIES", 400, 406], ["the viral infection", "PROBLEM", 526, 545], ["traceable", "OBSERVATION_MODIFIER", 96, 105], ["outbreaks", "OBSERVATION", 106, 115], ["viral", "OBSERVATION_MODIFIER", 530, 535], ["infection", "OBSERVATION", 536, 545]]], ["We also do not know whether subjects who have had COVID19 will be immune in a possible future SARS-CoV-2 wave, probably next winter (3).", [["SARS", "DISEASE", 94, 98], ["COVID19", "GENE_OR_GENE_PRODUCT", 50, 57], ["COVID19", "PROTEIN", 50, 57], ["CoV", "TEST", 99, 102]]], ["Besides, we still do not appreciate the mutation capacity of SARS-CoV-2 and its impact on infectivity and lethality.", [["SARS", "DISEASE", 61, 65], ["SARS-CoV-2", "ORGANISM", 61, 71], ["SARS-CoV", "SPECIES", 61, 69], ["the mutation capacity", "PROBLEM", 36, 57], ["SARS", "PROBLEM", 61, 65], ["CoV", "TEST", 66, 69], ["lethality", "PROBLEM", 106, 115]]], ["Preliminary data from Spain big survey on seroprevalence indicates 5.2% overall humoral immunity (4).Will the Sanitary Passport Clear all our Doubts?(b) There are some doubts about the sensitivity and specificity of SARS-CoV-2 serological tests, as well as about the SARS-CoV-2 epitopes they include.", [["SARS-CoV-2 epitopes", "PROTEIN", 267, 286], ["SARS-CoV", "SPECIES", 216, 224], ["Preliminary data", "TEST", 0, 16], ["seroprevalence", "TEST", 42, 56], ["the sensitivity", "TEST", 181, 196], ["SARS", "TEST", 216, 220], ["CoV", "TEST", 221, 224], ["serological tests", "TEST", 227, 244], ["the SARS", "TEST", 263, 271]]], ["Thus, these tests should be interpreted with caution, especially in the case of lateral flow rapid tests (5).Will the Sanitary Passport Clear all our Doubts?(c) Although the original intention is on massive population-wide testing, the impossibility of carrying out this measure in the entire Spanish population is clear.", [["these tests", "TEST", 6, 17], ["lateral flow rapid tests", "TEST", 80, 104], ["wide testing", "TEST", 218, 230], ["clear", "OBSERVATION", 315, 320]]], ["From the outset, it seems reasonable to select the high-risk groups for testing: elderly people (especially nursing homes residents), immunosuppressed patients, health care workers, etc. (6).", [["people", "ORGANISM", 89, 95], ["patients", "ORGANISM", 151, 159], ["people", "SPECIES", 89, 95], ["patients", "SPECIES", 151, 159]]], ["Are we going to test all the children or youth people?", [["children", "ORGANISM", 29, 37], ["people", "ORGANISM", 47, 53], ["children", "SPECIES", 29, 37], ["people", "SPECIES", 47, 53]]], ["In fact, although there is little information (7) they are probably the main asymptomatic groups and potentially spreaders of the disease to high-risk individuals.", [["the disease", "PROBLEM", 126, 137]]], ["Besides, some experts consider that summer is a season with a lower incidence of viral infections not only because of climatic factors but also because, with schools closed, viruses have much less ability to spread, as it has happened with other viral outbreaks.Will the Sanitary Passport Clear all our Doubts?(d) Therefore, not only are there factors dependent on the virus, but we also ought to take into account host factors.", [["viral infections", "DISEASE", 81, 97], ["host factors", "PROTEIN", 415, 427], ["viral infections", "PROBLEM", 81, 97], ["viruses", "PROBLEM", 174, 181], ["other viral outbreaks", "PROBLEM", 240, 261], ["the virus", "PROBLEM", 365, 374], ["viral", "OBSERVATION_MODIFIER", 81, 86], ["infections", "OBSERVATION", 87, 97]]], ["Not everyone may be capable of developing an effective immune response against the infection.", [["infection", "DISEASE", 83, 92], ["the infection", "PROBLEM", 79, 92], ["infection", "OBSERVATION", 83, 92]]], ["It is also unclear what level of antibodies one should reach, or whether this level could protect against a second encounter with the virus or any of its variants (8).", [["antibodies", "PROTEIN", 33, 43], ["the virus", "PROBLEM", 130, 139]]], ["If the outbreak becomes endemic-seasonal, the possibility of response might also decrease over time.", [["endemic", "PROBLEM", 24, 31], ["decrease", "OBSERVATION_MODIFIER", 81, 89]]], ["On the other hand, recent evidences point to the protective role of cellular immunity, which has not been taken into account until very recently, either cross-reactive with seasonal coronavirus (9) or after SARS-CoV-2 infection (10).Will the Sanitary Passport Clear all our Doubts?(e) Something very similar would happen if we hopefully had an effective vaccine.", [["cellular", "ANATOMY", 68, 76], ["SARS-CoV-2 infection", "DISEASE", 207, 227], ["cellular", "CELL", 68, 76], ["seasonal coronavirus", "ORGANISM", 173, 193], ["SARS-CoV-2", "ORGANISM", 207, 217], ["seasonal coronavirus", "SPECIES", 173, 193], ["SARS-CoV-2", "SPECIES", 207, 217], ["seasonal coronavirus", "PROBLEM", 173, 193], ["SARS", "PROBLEM", 207, 211], ["CoV-2 infection", "PROBLEM", 212, 227], ["an effective vaccine", "TREATMENT", 341, 361]]], ["Furthermore, the duration of a proper immunization is also unknown.", [["a proper immunization", "TREATMENT", 29, 50]]], ["Therefore, until we increase our knowledge about immunity generated by SARS-CoV2, continuing to work on general preventive actions and antiviral treatments seems to be the key to success against this infection.", [["SARS", "DISEASE", 71, 75], ["infection", "DISEASE", 200, 209], ["SARS-CoV2", "ORGANISM", 71, 80], ["general preventive actions", "TREATMENT", 104, 130], ["antiviral treatments", "TREATMENT", 135, 155], ["this infection", "PROBLEM", 195, 209], ["infection", "OBSERVATION", 200, 209]]], ["The use of facial mask and hand washing, together with social distancing, will remain the main actions in counteracting the pandemic.DiscussionGiven the current uncertainty derived from the lack of knowledge of the natural history of the viral disease, we can anticipate two extreme scenarios:DiscussionIt is crucial to bear in mind that it is extremely complicated for all the favorable conditions to eradicate COVID19.", [["facial", "ANATOMY", 11, 17], ["hand", "ANATOMY", 27, 31], ["viral disease", "DISEASE", 238, 251], ["COVID19", "SIMPLE_CHEMICAL", 412, 419], ["COVID19", "PROTEIN", 412, 419], ["facial mask", "TREATMENT", 11, 22], ["hand washing", "TREATMENT", 27, 39], ["the viral disease", "PROBLEM", 234, 251], ["COVID19", "TREATMENT", 412, 419], ["facial", "ANATOMY", 11, 17], ["viral disease", "OBSERVATION", 238, 251]]], ["Nonetheless, the presence of a single unfavorable condition can be critical in the general outcome of the pandemic.DiscussionSo far in Spain, only those patients with moderate-severe symptoms have been tested for coronavirus with PCR tests.", [["patients", "ORGANISM", 153, 161], ["coronavirus", "ORGANISM", 213, 224], ["patients", "SPECIES", 153, 161], ["a single unfavorable condition", "PROBLEM", 29, 59], ["moderate-severe symptoms", "PROBLEM", 167, 191], ["coronavirus", "PROBLEM", 213, 224], ["PCR tests", "TEST", 230, 239]]], ["The health system has made a heroic effort to treat those patients with serious COVID19, and several drugs have been used with a rational pathophysiological principle, despite the lack of solid scientific evidence to date (11).", [["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["serious COVID19", "PROBLEM", 72, 87], ["several drugs", "TREATMENT", 93, 106]]], ["On the other hand, not only in Spain but in the rest of the world, numerous well-designed studies have been launched in a short period of time, to demonstrate whether the different therapeutic agents we are currently using can really be effective in treating COVID19.", [["COVID19", "TREATMENT", 259, 266]]], ["It stands to reason that knowing the real efficacy of these therapeutic agents will help patients who become infected in the future to overcome their disease and design treatment protocols according to its severity, although today none of these agents seems to have a curative role.", [["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["these therapeutic agents", "TREATMENT", 54, 78], ["infected", "PROBLEM", 109, 117], ["their disease", "PROBLEM", 144, 157], ["design treatment protocols", "TREATMENT", 162, 188], ["infected", "OBSERVATION", 109, 117]]], ["Only the collective effort of the international scientific community, through the careful study of SARS-CoV-2 characteristics, the intimate pathogenic mechanisms of the disease, the pattern of the different responses of the host to infection, and the protective health measures against it, would help to control this pandemic promptly.DiscussionThe possibilities that we are going to face and the different clinical scenarios in which we have to fight to overcome COVID19 are shown in the Table 1.", [["SARS", "DISEASE", 99, 103], ["infection", "DISEASE", 232, 241], ["COVID19", "GENE_OR_GENE_PRODUCT", 464, 471], ["COVID19", "PROTEIN", 464, 471], ["the careful study", "TEST", 78, 95], ["SARS", "TEST", 99, 103], ["the disease", "PROBLEM", 165, 176], ["infection", "PROBLEM", 232, 241], ["disease", "OBSERVATION", 169, 176], ["infection", "OBSERVATION", 232, 241]]], ["The war against this serious disease, as previously discussed, is still being waged without truce.", [["this serious disease", "PROBLEM", 16, 36], ["serious", "OBSERVATION_MODIFIER", 21, 28], ["disease", "OBSERVATION", 29, 36]]], ["This fight will provide relevant information for new patients with severe COVID19 manifestations: identifying prognostic factors for disease severity and progression to ARDS (12, 13), and determine the real efficacy of therapeutic options through well-designed clinical trials (14).", [["ARDS", "DISEASE", 169, 173], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["severe COVID19 manifestations", "PROBLEM", 67, 96], ["disease severity", "PROBLEM", 133, 149], ["ARDS", "PROBLEM", 169, 173], ["ARDS", "OBSERVATION", 169, 173]]], ["The study of mild cases of the disease and the asymptomatic carriers might help us answer other relevant questions, such as the duration of the contagious period, the characteristics of the non-severe disease or even the type, intensity and duration of immunization (8).", [["The study", "TEST", 0, 9], ["the disease", "PROBLEM", 27, 38], ["the asymptomatic carriers", "PROBLEM", 43, 68], ["the non-severe disease", "PROBLEM", 186, 208], ["immunization", "TREATMENT", 253, 265], ["mild", "OBSERVATION_MODIFIER", 13, 17], ["disease", "OBSERVATION", 31, 38], ["non-severe", "OBSERVATION_MODIFIER", 190, 200], ["disease", "OBSERVATION", 201, 208]]], ["The issue of immunization is relevant in the development of vaccination strategies once they are ready to be used.DiscussionA critical part of the fight against SARS-CoV-2 is the improvement in diagnostic tests, not only during the acute phase of the disease, but also in the sensitivity and specificity of serological tests (6, 15).", [["SARS", "DISEASE", 161, 165], ["SARS-CoV-2", "ORGANISM", 161, 171], ["SARS-CoV", "SPECIES", 161, 169], ["immunization", "TREATMENT", 13, 25], ["vaccination strategies", "TREATMENT", 60, 82], ["SARS", "PROBLEM", 161, 165], ["diagnostic tests", "TEST", 194, 210], ["the disease", "PROBLEM", 247, 258], ["the sensitivity", "TEST", 272, 287], ["serological tests", "TEST", 307, 324], ["disease", "OBSERVATION", 251, 258]]], ["Furthermore, the development of more suitable tests to determine the cellular immunity against the virus, will improve the knowledge of the disease and the opportunities for intervention.", [["cellular", "ANATOMY", 69, 77], ["cellular", "CELL", 69, 77], ["more suitable tests", "TEST", 32, 51], ["the virus", "PROBLEM", 95, 104], ["the disease", "PROBLEM", 136, 147], ["intervention", "TREATMENT", 174, 186]]], ["This is a key aspect, especially in high risk groups, where in the absence of curative treatments for the infection, establishing appropriate prophylaxis measures is crucial.", [["infection", "DISEASE", 106, 115], ["curative treatments", "TREATMENT", 78, 97], ["the infection", "PROBLEM", 102, 115], ["appropriate prophylaxis measures", "TREATMENT", 130, 162], ["infection", "OBSERVATION", 106, 115]]], ["Nowadays, and pending the results of appropriate studies (antimalarial drugs, vitamin D, trained immunity, etc.) (16\u201319), the only preventive measures that have been proven effective are the implementation of precautions and hygienic measures to minimize human transmission of the virus, especially in high-risk populations.DiscussionThe investigation focused on \u201chealthy\u201d people who have contacted the virus and did not develop the disease, or those who have been cured without problems (including the asymptomatic carriers) is a crucial issue (9).", [["vitamin D", "CHEMICAL", 78, 87], ["vitamin D", "CHEMICAL", 78, 87], ["vitamin D", "SIMPLE_CHEMICAL", 78, 87], ["human", "ORGANISM", 255, 260], ["people", "ORGANISM", 373, 379], ["human", "SPECIES", 255, 260], ["people", "SPECIES", 373, 379], ["human", "SPECIES", 255, 260], ["appropriate studies", "TEST", 37, 56], ["antimalarial drugs", "TREATMENT", 58, 76], ["vitamin D", "TREATMENT", 78, 87], ["precautions", "TREATMENT", 209, 220], ["hygienic measures", "TREATMENT", 225, 242], ["the virus", "PROBLEM", 277, 286], ["the disease", "PROBLEM", 429, 440], ["disease", "OBSERVATION", 433, 440]]], ["Probably, this may be the key to identifying new therapeutic or preventive interventions.", [["preventive interventions", "TREATMENT", 64, 88]]], ["Perhaps, we ought to go for strategies that combine the study of the \u201csick\u201d and the \u201chealthy\u201d individual.", [["the study", "TEST", 52, 61]]], ["In the meantime, it is probably utopian to reach the entire population with an appropriate diagnostic test, but we must prepare ourselves to reach the maximum number of people, with a logistical and economic effort of unprecedented dimensions.", [["people", "ORGANISM", 169, 175], ["people", "SPECIES", 169, 175], ["an appropriate diagnostic test", "TEST", 76, 106]]], ["At this moment, probably the most cost-effective approach will rely in the urgent identification of cases and outbreaks by RT-PCR together with searching of contacts to trace any focus (20).", [["PCR", "TEST", 126, 129]]], ["VM-T, JH, ML-H, JC, and PC wrote the manuscript.", [["VM-T", "CELL", 0, 4], ["VM", "TEST", 0, 2]]]], "8d9b3ffff649f964c0d5f41c99eecb1dac7fb036": [["IntroductionHolmium laser enucleation of the prostate (HoLEP) is a highly effective, minimally invasive surgical procedure for benign prostatic hyperplasia (BPH).", [["prostate", "ANATOMY", 45, 53], ["benign prostatic hyperplasia", "ANATOMY", 127, 155], ["BPH", "ANATOMY", 157, 160], ["Holmium", "CHEMICAL", 12, 19], ["benign prostatic hyperplasia", "DISEASE", 127, 155], ["BPH", "DISEASE", 157, 160], ["prostate", "ORGAN", 45, 53], ["benign prostatic hyperplasia", "CANCER", 127, 155], ["BPH", "CANCER", 157, 160], ["IntroductionHolmium laser enucleation of the prostate (HoLEP", "TREATMENT", 0, 60], ["minimally invasive surgical procedure", "TREATMENT", 85, 122], ["benign prostatic hyperplasia", "PROBLEM", 127, 155], ["BPH", "PROBLEM", 157, 160], ["Holmium", "OBSERVATION_MODIFIER", 12, 19], ["laser", "OBSERVATION_MODIFIER", 20, 25], ["enucleation", "OBSERVATION", 26, 37], ["prostate", "ANATOMY", 45, 53], ["minimally", "OBSERVATION_MODIFIER", 85, 94], ["invasive", "OBSERVATION_MODIFIER", 95, 103], ["surgical", "OBSERVATION", 104, 112], ["benign", "OBSERVATION_MODIFIER", 127, 133], ["prostatic", "ANATOMY", 134, 143], ["hyperplasia", "OBSERVATION", 144, 155], ["BPH", "OBSERVATION", 157, 160]]], ["HoLEP is a size independent procedure, 1 but has had the strongest impact in the management of large (>80 grams) prostates 2 by preventing the need for more invasive therapies such as open or robotic simple prostatectomy.", [["prostates", "ANATOMY", 113, 122], ["HoLEP", "TREATMENT", 0, 5], ["a size independent procedure", "TREATMENT", 9, 37], ["the management", "TREATMENT", 77, 91], ["large (>80 grams) prostates", "TREATMENT", 95, 122], ["more invasive therapies", "TREATMENT", 152, 175], ["open or robotic simple prostatectomy", "TREATMENT", 184, 220], ["size", "OBSERVATION_MODIFIER", 11, 15], ["large", "OBSERVATION_MODIFIER", 95, 100], ["prostates", "ANATOMY", 113, 122], ["prostatectomy", "OBSERVATION", 207, 220]]], ["Compared to the \"gold standard\" transurethral resection of prostate (TURP), HoLEP has a lower hospital stay, transfusion rate, retreatment rate and equivalent if not superior postoperative outcomes.", [["prostate", "ANATOMY", 59, 67], ["prostate", "ORGAN", 59, 67], ["the \"gold standard\" transurethral resection of prostate (TURP", "TREATMENT", 12, 73], ["HoLEP", "TREATMENT", 76, 81], ["transfusion rate", "TREATMENT", 109, 125], ["retreatment rate", "TREATMENT", 127, 143], ["resection", "OBSERVATION", 46, 55], ["prostate", "ANATOMY", 59, 67], ["TURP", "OBSERVATION", 69, 73]]], ["3 Surgical BPH treatments are often associated with inpatient hospital stays.IntroductionTURP, photovaporization of the prostate (PVP) and HoLEP are all traditionally associated with at least overnight hospital stays.", [["BPH", "ANATOMY", 11, 14], ["prostate", "ANATOMY", 120, 128], ["BPH", "DISEASE", 11, 14], ["PVP", "CHEMICAL", 130, 133], ["BPH", "MULTI-TISSUE_STRUCTURE", 11, 14], ["prostate", "MULTI-TISSUE_STRUCTURE", 120, 128], ["HoLEP", "SIMPLE_CHEMICAL", 139, 144], ["Surgical BPH treatments", "TREATMENT", 2, 25], ["IntroductionTURP", "TREATMENT", 77, 93], ["photovaporization of the prostate (PVP", "TREATMENT", 95, 133], ["HoLEP", "TREATMENT", 139, 144], ["BPH", "OBSERVATION", 11, 14], ["prostate", "ANATOMY", 120, 128], ["HoLEP", "OBSERVATION", 139, 144]]], ["3, 4 Newer technologies such as bipolar TURP and 180W PVP have allowed those procedures to be more conducive to same day discharge.", [["bipolar", "DISEASE", 32, 39], ["PVP", "CHEMICAL", 54, 57], ["bipolar TURP", "TREATMENT", 32, 44], ["180W PVP", "TREATMENT", 49, 57], ["those procedures", "TREATMENT", 71, 87]]], ["In an attempt to reduce morbidity of BPH treatment, new therapies have emerged, such as convective water thermal therapy and prostatic urethral lift, 5 with the goal of same day procedure discharge, minimal morbidity and reduced duration of indwelling catheter dwell time.IntroductionIn light of goals to reduce morbidity of HoLEP, investigators have explored ways for HoLEP to be performed as an outpatient procedure.", [["BPH", "ANATOMY", 37, 40], ["prostatic urethral", "ANATOMY", 125, 143], ["BPH", "DISEASE", 37, 40], ["BPH", "CANCER", 37, 40], ["prostatic urethral", "MULTI-TISSUE_STRUCTURE", 125, 143], ["BPH treatment", "TREATMENT", 37, 50], ["new therapies", "TREATMENT", 52, 65], ["convective water thermal therapy", "TREATMENT", 88, 120], ["prostatic urethral lift", "TREATMENT", 125, 148], ["same day procedure", "TREATMENT", 169, 187], ["minimal morbidity", "PROBLEM", 199, 216], ["indwelling catheter dwell time", "TREATMENT", 241, 271], ["HoLEP", "TREATMENT", 325, 330], ["HoLEP", "TREATMENT", 369, 374], ["an outpatient procedure", "TREATMENT", 394, 417], ["BPH", "OBSERVATION", 37, 40], ["prostatic urethral", "ANATOMY", 125, 143], ["minimal", "OBSERVATION_MODIFIER", 199, 206], ["morbidity", "OBSERVATION", 207, 216], ["indwelling catheter", "OBSERVATION", 241, 260]]], ["Multiple series have demonstrated HoLEP can be done as outpatient procedure in selected patient populations.", [["HoLEP", "SIMPLE_CHEMICAL", 34, 39], ["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["HoLEP", "TREATMENT", 34, 39], ["outpatient procedure", "TREATMENT", 55, 75], ["HoLEP", "OBSERVATION", 34, 39]]], ["[6] [7] [8] [9] [10] [11] Since these publications, improvements in laser technology have resulted in increased energy delivery to tissue, with a resultant clinical in hemostasis over conventional holmium laser during HoLEP.", [["tissue", "ANATOMY", 131, 137], ["holmium", "CHEMICAL", 197, 204], ["[6] [7] [8] [9] [10] [11]", "SIMPLE_CHEMICAL", 0, 25], ["tissue", "TISSUE", 131, 137], ["laser technology", "TEST", 68, 84], ["increased energy delivery to tissue", "PROBLEM", 102, 137], ["conventional holmium laser", "TREATMENT", 184, 210], ["HoLEP", "TREATMENT", 218, 223], ["increased", "OBSERVATION_MODIFIER", 102, 111], ["energy", "OBSERVATION", 112, 118], ["hemostasis", "OBSERVATION", 168, 178]]], ["12 Furthermore, modifying the procedure by moving away from less blunt scope dissection (i.e. peeling) to more laser and bubble dissection (noncontact lasering) has also contributed to less bleeding.", [["bleeding", "DISEASE", 190, 198], ["the procedure", "TREATMENT", 26, 39], ["less blunt scope dissection", "TREATMENT", 60, 87], ["bubble dissection", "PROBLEM", 121, 138], ["less bleeding", "PROBLEM", 185, 198], ["dissection", "OBSERVATION", 77, 87], ["laser", "OBSERVATION_MODIFIER", 111, 116], ["bubble dissection", "OBSERVATION", 121, 138], ["less", "OBSERVATION_MODIFIER", 185, 189], ["bleeding", "OBSERVATION", 190, 198]]], ["We sought to determine if these technical and technological advancements would allow for successful same day catheter removal after HoLEP.Methods:After obtaining Institutional Review Board approval, we performed a retrospective review of patients undergoing HoLEP who underwent same day catheter removal at our institution by three surgeons from November 2019 through March 2020.Methods:Patients were offered same day catheter removal, as a potential option, being aware our standard practice was to dismiss patients on the same day of surgery and to remove the catheter as an outpatient on postoperative day one (POD1).", [["patients", "ORGANISM", 238, 246], ["Patients", "ORGANISM", 387, 395], ["patients", "ORGANISM", 508, 516], ["patients", "SPECIES", 238, 246], ["Patients", "SPECIES", 387, 395], ["patients", "SPECIES", 508, 516], ["successful same day catheter removal", "TREATMENT", 89, 125], ["HoLEP", "TREATMENT", 132, 137], ["HoLEP", "TREATMENT", 258, 263], ["same day catheter removal", "TREATMENT", 278, 303], ["same day catheter removal", "TREATMENT", 409, 434], ["surgery", "TREATMENT", 536, 543], ["the catheter", "TREATMENT", 558, 570], ["catheter", "OBSERVATION", 287, 295], ["catheter", "OBSERVATION", 562, 570]]], ["Patients who were not offered same day catheter removal were those with prostate volumes >250 ml on preoperative imaging study (all were required to have imaging to be considered).Methods:Additionally, the patient could not actively be taking therapeutic doses of anticoagulation.", [["prostate", "ANATOMY", 72, 80], ["Patients", "ORGANISM", 0, 8], ["prostate", "ORGAN", 72, 80], ["patient", "ORGANISM", 206, 213], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 206, 213], ["same day catheter removal", "TREATMENT", 30, 55], ["prostate volumes", "TEST", 72, 88], ["preoperative imaging study", "TEST", 100, 126], ["imaging", "TEST", 154, 161], ["anticoagulation", "TREATMENT", 264, 279], ["prostate", "ANATOMY", 72, 80]]], ["Furthermore, only the first 2 cases of the day were candidates for same day catheter removal due to time limitations within the clinic.", [["same day catheter removal", "TREATMENT", 67, 92]]], ["Postoperatively, 3 L of normal saline was run as continuous bladder irrigation at the maximum rate allowed per the tubing, and the catheter was clamped to assess for hematuria.", [["bladder", "ANATOMY", 60, 67], ["hematuria", "DISEASE", 166, 175], ["saline", "SIMPLE_CHEMICAL", 31, 37], ["bladder", "ORGAN", 60, 67], ["normal saline", "TREATMENT", 24, 37], ["continuous bladder irrigation", "TREATMENT", 49, 78], ["the tubing", "TREATMENT", 111, 121], ["the catheter", "TREATMENT", 127, 139], ["hematuria", "PROBLEM", 166, 175], ["bladder", "ANATOMY", 60, 67], ["irrigation", "OBSERVATION", 68, 78], ["tubing", "OBSERVATION", 115, 121], ["catheter", "OBSERVATION", 131, 139], ["hematuria", "OBSERVATION", 166, 175]]], ["The decision to continue irrigation versus discharge for catheter removal was made by one of the surgeons on the team.", [["catheter", "ANATOMY", 57, 65], ["irrigation", "TREATMENT", 25, 35], ["catheter removal", "TREATMENT", 57, 73], ["catheter", "OBSERVATION", 57, 65]]], ["Overall this was a judgement call but essentially there needed to be an absence of clots and the urine needed to flow freely in the catheter tubing.", [["clots", "ANATOMY", 83, 88], ["urine", "ANATOMY", 97, 102], ["clots", "ORGANISM_SUBSTANCE", 83, 88], ["urine", "ORGANISM_SUBSTANCE", 97, 102], ["clots", "PROBLEM", 83, 88], ["the urine", "TEST", 93, 102], ["the catheter tubing", "TREATMENT", 128, 147], ["clots", "OBSERVATION", 83, 88], ["catheter tubing", "OBSERVATION", 132, 147]]], ["A maximum of 9 L of catheter irrigation were allowed to be run before the patient was no longer a candidate for same day catheter removal.", [["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["catheter irrigation", "TREATMENT", 20, 39], ["same day catheter removal", "TREATMENT", 112, 137], ["maximum", "OBSERVATION_MODIFIER", 2, 9], ["catheter", "OBSERVATION", 20, 28], ["catheter", "OBSERVATION", 121, 129]]], ["No opioids and no anticholinergics were given after induction.", [["opioids", "TREATMENT", 3, 10], ["anticholinergics", "TREATMENT", 18, 34], ["opioids", "OBSERVATION", 3, 10]]], ["Patients were typically dismissed from the postoperative care unit (POCU) to the clinic for catheter removal, voiding trial and post void residual check.", [["catheter", "ANATOMY", 92, 100], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["catheter removal", "TREATMENT", 92, 108], ["voiding trial", "TREATMENT", 110, 123], ["post void residual check", "TEST", 128, 152], ["catheter", "OBSERVATION", 92, 100]]], ["Voiding trial was performed by retrofilling the catheter with 300-500 ml of saline or until the patient felt the subjective urge to urinate.", [["saline", "SIMPLE_CHEMICAL", 76, 82], ["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103], ["Voiding trial", "TREATMENT", 0, 13], ["retrofilling the catheter", "TREATMENT", 31, 56], ["saline", "TREATMENT", 76, 82], ["the subjective urge to urinate", "PROBLEM", 109, 139], ["catheter", "OBSERVATION", 48, 56]]], ["The volume voided, color of urine and post-void residual (PVR) were assessed to ensure there was no concern for hematuria or possible clot retention.", [["urine", "ANATOMY", 28, 33], ["clot", "ANATOMY", 134, 138], ["hematuria", "DISEASE", 112, 121], ["urine", "ORGANISM_SUBSTANCE", 28, 33], ["clot", "ORGANISM_SUBSTANCE", 134, 138], ["The volume voided", "TEST", 0, 17], ["PVR", "TEST", 58, 61], ["hematuria", "PROBLEM", 112, 121], ["clot retention", "PROBLEM", 134, 148], ["volume voided", "OBSERVATION", 4, 17], ["urine", "OBSERVATION", 28, 33], ["post-void residual", "OBSERVATION", 38, 56], ["no concern for", "UNCERTAINTY", 97, 111], ["hematuria", "OBSERVATION", 112, 121], ["possible", "UNCERTAINTY", 125, 133], ["clot retention", "OBSERVATION", 134, 148]]], ["PVR of less than half the voided volume was considered adequate for passing.", [["PVR", "TEST", 0, 3], ["the voided volume", "TEST", 22, 39], ["less", "OBSERVATION_MODIFIER", 7, 11]]], ["Patients were asked to stay within 30 miles of our facility on POD0, but were not required to come to clinic on POD1.", [["Patients", "ORGANISM", 0, 8], ["POD1", "GENE_OR_GENE_PRODUCT", 112, 116], ["Patients", "SPECIES", 0, 8]]], ["All patients were contacted within seven days of catheter removal for telephone follow-up.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["catheter removal", "TREATMENT", 49, 65]]], ["A diagram of our process for same day catheter removal can be found in Figure 1 .Methods:There was no external funding for this study.", [["same day catheter removal", "TREATMENT", 29, 54], ["this study", "TEST", 123, 133], ["no", "UNCERTAINTY", 99, 101], ["external", "OBSERVATION_MODIFIER", 102, 110], ["funding", "OBSERVATION", 111, 118]]], ["Data was obtained and statistically analyzed using JMP Pro 14 (SAS Institute, Cary, NC).", [["JMP Pro", "TREATMENT", 51, 58]]], ["Median with interquartile ranges (IQR) are presented for continuous statistics and total number with percentage are presented for nominal statistics.ResultsA total of 30 patients were included in our cohort.", [["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178]]], ["Median age was 68.6 years (IQR 61.8-73.3) and BMI was 28.5 (IQR 25.5-33.2).", [["IQR", "TEST", 27, 30], ["BMI", "TEST", 46, 49], ["IQR", "TEST", 60, 63]]], ["Median prostate volume was 81 ml (IQR 53-114.8) with a total range of 37-235 ml.", [["prostate", "ANATOMY", 7, 15], ["prostate", "ORGAN", 7, 15], ["Median prostate volume", "TEST", 0, 22], ["IQR", "TEST", 34, 37], ["prostate", "ANATOMY", 7, 15]]], ["There were 9 patients (30%) who were in urinary retention requiring a urinary catheterization (indwelling or intermittent) prior to surgery.", [["urinary", "ANATOMY", 40, 47], ["urinary", "ANATOMY", 70, 77], ["urinary retention", "DISEASE", 40, 57], ["patients", "ORGANISM", 13, 21], ["urinary", "ORGANISM_SUBDIVISION", 40, 47], ["urinary", "ORGANISM_SUBDIVISION", 70, 77], ["patients", "SPECIES", 13, 21], ["urinary retention", "PROBLEM", 40, 57], ["a urinary catheterization", "TREATMENT", 68, 93], ["surgery", "TREATMENT", 132, 139], ["urinary", "ANATOMY", 40, 47], ["retention", "OBSERVATION", 48, 57], ["urinary", "ANATOMY", 70, 77], ["catheterization", "OBSERVATION", 78, 93]]], ["Of the 21 patients who were not in urinary retention, 16 were on medication therapy: 11 (52%) on an alpha-1 antagonist only and six (29%) were on combination alpha-1 antagonist and 5-alpha reductase inhibitor.", [["urinary", "ANATOMY", 35, 42], ["urinary retention", "DISEASE", 35, 52], ["patients", "ORGANISM", 10, 18], ["urinary", "ORGANISM_SUBDIVISION", 35, 42], ["alpha-1 antagonist", "GENE_OR_GENE_PRODUCT", 100, 118], ["alpha-1 antagonist", "GENE_OR_GENE_PRODUCT", 158, 176], ["5-alpha reductase", "SIMPLE_CHEMICAL", 181, 198], ["patients", "SPECIES", 10, 18], ["urinary retention", "PROBLEM", 35, 52], ["medication therapy", "TREATMENT", 65, 83], ["an alpha-1 antagonist", "TREATMENT", 97, 118], ["alpha", "TEST", 158, 163], ["antagonist", "TREATMENT", 166, 176], ["alpha reductase inhibitor", "TREATMENT", 183, 208], ["urinary retention", "ANATOMY", 35, 52]]], ["Four (13%) patients had previously undergone a prior procedure to treat BPH, two prostatic urethral lifts, one PVP of the prostate and one TURP.", [["BPH", "ANATOMY", 72, 75], ["prostatic urethral", "ANATOMY", 81, 99], ["prostate", "ANATOMY", 122, 130], ["BPH", "DISEASE", 72, 75], ["prostatic urethral lifts", "DISEASE", 81, 105], ["PVP", "CHEMICAL", 111, 114], ["patients", "ORGANISM", 11, 19], ["BPH", "CANCER", 72, 75], ["prostatic urethral", "MULTI-TISSUE_STRUCTURE", 81, 99], ["prostate", "CANCER", 122, 130], ["patients", "SPECIES", 11, 19], ["a prior procedure", "TREATMENT", 45, 62], ["BPH", "PROBLEM", 72, 75], ["two prostatic urethral lifts", "PROBLEM", 77, 105], ["one PVP of the prostate", "TREATMENT", 107, 130], ["one TURP", "TREATMENT", 135, 143], ["BPH", "OBSERVATION", 72, 75], ["prostatic urethral", "ANATOMY", 81, 99], ["lifts", "OBSERVATION", 100, 105], ["PVP", "OBSERVATION", 111, 114], ["prostate", "ANATOMY", 122, 130], ["one", "OBSERVATION_MODIFIER", 135, 138], ["TURP", "OBSERVATION", 139, 143]]], ["There were 6 patients (20%) were on anticoagulation preoperatively, and one patient was on therapeutic anticoagulation at the time of the procedure.", [["patients", "ORGANISM", 13, 21], ["patient", "ORGANISM", 76, 83], ["patients", "SPECIES", 13, 21], ["patient", "SPECIES", 76, 83], ["anticoagulation", "TREATMENT", 36, 51], ["therapeutic anticoagulation", "TREATMENT", 91, 118], ["the procedure", "TREATMENT", 134, 147]]], ["This patient had his catheter inadvertently removed in the postanesthesia care unit (PACU) after his continuous bladder irrigation had been shut off and voided successfully so he was included in the results of the study.", [["bladder", "ANATOMY", 112, 119], ["patient", "ORGANISM", 5, 12], ["bladder", "ORGAN", 112, 119], ["patient", "SPECIES", 5, 12], ["his catheter", "TREATMENT", 17, 29], ["his continuous bladder irrigation", "TREATMENT", 97, 130], ["the study", "TEST", 210, 219], ["catheter", "OBSERVATION", 21, 29], ["bladder", "ANATOMY", 112, 119], ["irrigation", "OBSERVATION", 120, 130]]], ["No patients underwent preoperative urodynamic studies were performed since that is not our standard practice if the patient shows a compromised uroflow and is endoscopically obstructed on cystoscopy even after prior surgical intervention.", [["uroflow", "DISEASE", 144, 151], ["patients", "ORGANISM", 3, 11], ["patient", "ORGANISM", 116, 123], ["patients", "SPECIES", 3, 11], ["patient", "SPECIES", 116, 123], ["preoperative urodynamic studies", "TEST", 22, 53], ["a compromised uroflow", "PROBLEM", 130, 151], ["endoscopically obstructed", "PROBLEM", 159, 184], ["cystoscopy", "TEST", 188, 198], ["prior surgical intervention", "TREATMENT", 210, 237], ["obstructed", "OBSERVATION", 174, 184]]], ["Table 1 has other preoperative data for our cohort.ResultsOf note, subjective and objective voiding parameters are provided only for those patients who were not in urinary retention prior to surgery.DiscussionOur cohort highlights that same day catheter removal is feasible in select patients after HoLEP.", [["urinary", "ANATOMY", 164, 171], ["urinary retention", "DISEASE", 164, 181], ["patients", "ORGANISM", 139, 147], ["urinary", "ORGANISM_SUBDIVISION", 164, 171], ["patients", "ORGANISM", 284, 292], ["patients", "SPECIES", 139, 147], ["patients", "SPECIES", 284, 292], ["urinary retention", "PROBLEM", 164, 181], ["surgery", "TREATMENT", 191, 198], ["same day catheter removal", "TREATMENT", 236, 261], ["HoLEP", "TREATMENT", 299, 304]]], ["We demonstrate 90% success of same day catheter removal, and 100% success in removal catheters by POD1.", [["POD1", "PROTEIN", 98, 102], ["same day catheter removal", "TREATMENT", 30, 55], ["removal catheters", "TREATMENT", 77, 94], ["catheter", "OBSERVATION", 39, 47], ["removal catheters", "OBSERVATION", 77, 94]]], ["Overall, three patients required catheter replacement after same day catheter removal, two after an immediate failed voiding trial and one 10 hours after catheter removal.", [["catheter", "ANATOMY", 33, 41], ["catheter", "ANATOMY", 154, 162], ["patients", "ORGANISM", 15, 23], ["catheter", "IMMATERIAL_ANATOMICAL_ENTITY", 154, 162], ["patients", "SPECIES", 15, 23], ["catheter replacement", "TREATMENT", 33, 53], ["same day catheter removal", "TREATMENT", 60, 85], ["an immediate failed voiding trial", "TREATMENT", 97, 130], ["catheter removal", "TREATMENT", 154, 170], ["catheter", "OBSERVATION", 33, 41], ["catheter", "OBSERVATION", 69, 77], ["catheter", "OBSERVATION", 154, 162]]], ["Of the patients who required catheter replacement, there were no obvious differences between these groups.", [["patients", "ORGANISM", 7, 15], ["catheter", "IMMATERIAL_ANATOMICAL_ENTITY", 29, 37], ["patients", "SPECIES", 7, 15], ["catheter replacement", "TREATMENT", 29, 49], ["obvious differences between these groups", "PROBLEM", 65, 105], ["catheter replacement", "OBSERVATION", 29, 49], ["no obvious", "UNCERTAINTY", 62, 72]]], ["All patients were catheter free by POD1.", [["patients", "ORGANISM", 4, 12], ["POD1", "PROTEIN", 35, 39], ["patients", "SPECIES", 4, 12], ["catheter", "OBSERVATION", 18, 26]]], ["Patients had a significant improvement in voiding symptoms without lasting dysuria/incontinence.DiscussionAlthough patients with very large glands (>250 ml on preoperative imaging) were excluded from this approach, our cohort's prostate volume is similar to other outpatient HoLEP series 6, 7, 11 , with a wide range of 37-235 ml.", [["glands", "ANATOMY", 140, 146], ["prostate", "ANATOMY", 228, 236], ["dysuria", "DISEASE", 75, 82], ["incontinence", "DISEASE", 83, 95], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 115, 123], ["glands", "ORGAN", 140, 146], ["prostate", "ORGAN", 228, 236], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 115, 123], ["voiding symptoms", "PROBLEM", 42, 58], ["dysuria", "PROBLEM", 75, 82], ["incontinence", "PROBLEM", 83, 95], ["very large glands", "PROBLEM", 129, 146], ["preoperative imaging", "TEST", 159, 179], ["our cohort's prostate volume", "TEST", 215, 243], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["improvement", "OBSERVATION_MODIFIER", 27, 38], ["voiding", "OBSERVATION", 42, 49], ["incontinence", "OBSERVATION", 83, 95], ["glands", "ANATOMY", 140, 146], ["prostate", "ANATOMY", 228, 236], ["wide", "OBSERVATION_MODIFIER", 306, 310]]], ["The successful application of same day catheter removal for prostates <250 grams is encouraging as HoLEP by nature is size independent 1, 2 and would apply to the vast majority of patients undergoing HoLEP.", [["prostates", "ANATOMY", 60, 69], ["prostates", "MULTI-TISSUE_STRUCTURE", 60, 69], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 180, 188], ["same day catheter removal", "TREATMENT", 30, 55], ["prostates", "TREATMENT", 60, 69], ["HoLEP", "TREATMENT", 99, 104], ["HoLEP", "TREATMENT", 200, 205], ["successful", "OBSERVATION_MODIFIER", 4, 14], ["catheter", "OBSERVATION", 39, 47], ["size", "OBSERVATION_MODIFIER", 118, 122]]], ["The rate of passage of voiding trial on the same day as surgery is also similar to recent studies, 11, 12 demonstrating there is no added risk to patient of catheter reinsertion after BPH procedures.DiscussionRecently, there has been an effort to reassess perioperative HoLEP care and reduce stays postoperatively.", [["catheter", "ANATOMY", 157, 165], ["BPH", "ANATOMY", 184, 187], ["BPH", "DISEASE", 184, 187], ["patient", "ORGANISM", 146, 153], ["catheter", "IMMATERIAL_ANATOMICAL_ENTITY", 157, 165], ["patient", "SPECIES", 146, 153], ["voiding trial", "TREATMENT", 23, 36], ["surgery", "TREATMENT", 56, 63], ["recent studies", "TEST", 83, 97], ["catheter reinsertion", "TREATMENT", 157, 177], ["BPH procedures", "TREATMENT", 184, 198], ["perioperative HoLEP care", "TREATMENT", 256, 280], ["catheter", "OBSERVATION", 157, 165], ["BPH", "OBSERVATION", 184, 187]]], ["Technical progress and new laser technology have reduced morbidity and hospital stay associated with HoLEP.", [["HoLEP", "TREATMENT", 101, 106], ["new", "OBSERVATION_MODIFIER", 23, 26], ["reduced", "OBSERVATION_MODIFIER", 49, 56], ["morbidity", "OBSERVATION", 57, 66]]], ["12, 13 Multiple studies have demonstrated feasibility of HoLEP as an outpatient case, 7-10 including two recent studies.", [["Multiple studies", "TEST", 7, 23], ["HoLEP", "TREATMENT", 57, 62], ["two recent studies", "TEST", 101, 119]]], ["6, 11 This series builds off the previous work by removing the catheter on the same day as the procedure, HoLEP can be transitioned to a a true single day encounter for the patient.", [["6, 11", "CHEMICAL", 0, 5], ["patient", "ORGANISM", 173, 180], ["patient", "SPECIES", 173, 180], ["the catheter", "TREATMENT", 59, 71], ["the procedure", "TREATMENT", 91, 104], ["HoLEP", "TREATMENT", 106, 111], ["catheter", "OBSERVATION", 63, 71]]], ["Our cohort did not experience significant dysuria, incontinence or postoperative complications.DiscussionThere is limited literature regarding same day catheter removal with TURP and PVP, 14, 15 and by removing the catheter the same day we can offer HoLEP with a single day encounter as well.", [["dysuria", "DISEASE", 42, 49], ["incontinence", "DISEASE", 51, 63], ["TURP", "CHEMICAL", 174, 178], ["PVP", "CHEMICAL", 183, 186], ["significant dysuria", "PROBLEM", 30, 49], ["incontinence", "PROBLEM", 51, 63], ["postoperative complications", "PROBLEM", 67, 94], ["same day catheter removal", "TREATMENT", 143, 168], ["TURP", "TREATMENT", 174, 178], ["PVP", "TREATMENT", 183, 186], ["the catheter", "TREATMENT", 211, 223], ["HoLEP", "TREATMENT", 250, 255], ["dysuria", "OBSERVATION", 42, 49], ["incontinence", "OBSERVATION", 51, 63], ["postoperative complications", "OBSERVATION", 67, 94], ["catheter", "OBSERVATION", 152, 160], ["TURP", "OBSERVATION", 174, 178], ["catheter", "OBSERVATION", 215, 223]]], ["Although patients required around two additional hours in the facility after post procedure discharge from the hospital, the practice of same day catheter removal saved patients many more potential hours of catheterization and a return trip to the clinic.", [["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 169, 177], ["same day catheter removal", "TREATMENT", 137, 162], ["catheterization", "TEST", 207, 222]]], ["Our clinic is attached to our hospital, and patients often had a meal in between hospital dismissal and their appointment for clinic voiding trial.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["clinic voiding trial", "TREATMENT", 126, 146]]], ["The timing of catheter removal is often dictated by clinic scheduling restraints, and not necessarily reflective of actual time needed.DiscussionSame day catheter removal brings several benefits to patients.", [["catheter", "ANATOMY", 14, 22], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["catheter removal", "TREATMENT", 14, 30], ["restraints", "TREATMENT", 70, 80], ["DiscussionSame day catheter removal", "TREATMENT", 135, 170], ["catheter", "OBSERVATION", 14, 22], ["catheter", "OBSERVATION", 154, 162]]], ["The first is the reduction in time of indwelling catheterization.", [["the reduction", "TREATMENT", 13, 26], ["indwelling catheterization", "TREATMENT", 38, 64], ["reduction", "OBSERVATION_MODIFIER", 17, 26], ["indwelling catheterization", "OBSERVATION", 38, 64]]], ["At our institution, we utilize a 22 French three-way catheter for continuous bladder irrigation and for effective hematuria drainage.DiscussionThe size of this catheter, even for men managed with indwelling catheter preoperatively, increases discomfort after this procedure.", [["bladder", "ANATOMY", 77, 84], ["hematuria", "DISEASE", 114, 123], ["bladder", "ORGAN", 77, 84], ["men", "ORGANISM", 179, 182], ["men", "SPECIES", 179, 182], ["a 22 French three-way catheter", "TREATMENT", 31, 61], ["continuous bladder irrigation", "TREATMENT", 66, 95], ["effective hematuria drainage", "PROBLEM", 104, 132], ["this catheter", "TREATMENT", 155, 168], ["indwelling catheter", "TREATMENT", 196, 215], ["discomfort", "PROBLEM", 242, 252], ["this procedure", "TREATMENT", 259, 273], ["catheter", "OBSERVATION", 53, 61], ["bladder", "ANATOMY", 77, 84], ["irrigation", "OBSERVATION", 85, 95], ["drainage", "OBSERVATION", 124, 132], ["size", "OBSERVATION_MODIFIER", 147, 151], ["catheter", "OBSERVATION", 160, 168], ["catheter", "OBSERVATION", 207, 215]]], ["Additionally, less indwelling catheter time should theoretically decrease rate of postoperative urinary tract infections.", [["urinary tract", "ANATOMY", 96, 109], ["postoperative urinary tract infections", "DISEASE", 82, 120], ["urinary tract", "ORGANISM_SUBDIVISION", 96, 109], ["less indwelling catheter time", "TREATMENT", 14, 43], ["postoperative urinary tract infections", "PROBLEM", 82, 120], ["less", "OBSERVATION_MODIFIER", 14, 18], ["indwelling", "OBSERVATION_MODIFIER", 19, 29], ["catheter", "OBSERVATION", 30, 38], ["decrease", "OBSERVATION_MODIFIER", 65, 73], ["urinary tract", "ANATOMY", 96, 109], ["infections", "OBSERVATION", 110, 120]]], ["Patients also ambulate less with a catheter in place, 16, 17 which has the potential to increase the risk for postoperative deep venous thrombosis.", [["venous", "ANATOMY", 129, 135], ["postoperative deep venous thrombosis", "DISEASE", 110, 146], ["Patients", "ORGANISM", 0, 8], ["venous thrombosis", "PATHOLOGICAL_FORMATION", 129, 146], ["Patients", "SPECIES", 0, 8], ["a catheter", "TREATMENT", 33, 43], ["postoperative deep venous thrombosis", "PROBLEM", 110, 146], ["catheter", "OBSERVATION", 35, 43], ["deep", "ANATOMY_MODIFIER", 124, 128], ["venous", "ANATOMY", 129, 135], ["thrombosis", "OBSERVATION", 136, 146]]], ["Catheter dysfunction is also a postoperative issue, causing for patient concern and unintended emergency room visits for clogging and/or poor drainage.", [["Catheter", "ANATOMY", 0, 8], ["Catheter dysfunction", "DISEASE", 0, 20], ["patient", "ORGANISM", 64, 71], ["patient", "SPECIES", 64, 71], ["Catheter dysfunction", "PROBLEM", 0, 20], ["clogging", "PROBLEM", 121, 129], ["poor drainage", "PROBLEM", 137, 150], ["dysfunction", "OBSERVATION", 9, 20], ["drainage", "OBSERVATION", 142, 150]]], ["With same day catheter removal, patients are able to pass small clots per urethra that could otherwise obstruct a catheter.", [["clots", "ANATOMY", 64, 69], ["urethra", "ANATOMY", 74, 81], ["patients", "ORGANISM", 32, 40], ["clots", "ORGANISM_SUBSTANCE", 64, 69], ["urethra", "ORGAN", 74, 81], ["patients", "SPECIES", 32, 40], ["same day catheter removal", "TREATMENT", 5, 30], ["small clots per urethra", "PROBLEM", 58, 81], ["a catheter", "TREATMENT", 112, 122], ["catheter", "OBSERVATION", 14, 22], ["small", "OBSERVATION_MODIFIER", 58, 63], ["clots", "OBSERVATION", 64, 69], ["urethra", "ANATOMY", 74, 81], ["catheter", "OBSERVATION", 114, 122]]], ["Anecdotally from postoperative calls within the first week of surgery, patients whose catheter removal was performed the same day rarely passed urinary clots beyond POD1.", [["urinary clots", "ANATOMY", 144, 157], ["patients", "ORGANISM", 71, 79], ["urinary", "ORGANISM_SUBDIVISION", 144, 151], ["clots", "ORGANISM_SUBSTANCE", 152, 157], ["POD1", "PROTEIN", 165, 169], ["patients", "SPECIES", 71, 79], ["surgery", "TREATMENT", 62, 69], ["patients whose catheter removal", "TREATMENT", 71, 102], ["urinary clots", "PROBLEM", 144, 157], ["catheter", "OBSERVATION", 86, 94], ["urinary", "ANATOMY", 144, 151], ["clots", "OBSERVATION", 152, 157]]], ["They also did not experience prolonged dysuria/incontinence or postoperative complication or reintervention.DiscussionIn order to facilitate same day catheter removal, we provide a few suggestions from lessons we have learned to date.", [["dysuria", "DISEASE", 39, 46], ["incontinence", "DISEASE", 47, 59], ["prolonged dysuria", "PROBLEM", 29, 46], ["incontinence", "PROBLEM", 47, 59], ["postoperative complication", "PROBLEM", 63, 89], ["reintervention", "TREATMENT", 93, 107], ["same day catheter removal", "TREATMENT", 141, 166], ["incontinence", "OBSERVATION", 47, 59]]], ["It is important to have an effective plan in place for patients to undergo a successful voiding trial.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["a successful voiding trial", "TREATMENT", 75, 101]]], ["At our institution, PACU/POCU do not have time, ability or experience to carry out effective voiding trials.", [["effective voiding trials", "TREATMENT", 83, 107]]], ["We initially found that patients were not ambulated or retrofilled before voiding trial, and this was leading to false failures.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["voiding trial", "TREATMENT", 74, 87], ["false failures", "PROBLEM", 113, 127], ["false failures", "OBSERVATION", 113, 127]]], ["These patients then went to clinic and passed.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14]]], ["The PACU/POCU's inability to perform successful voiding trials led to a change in our protocol for same day catheter removal in HoLEP patients to undergo catheter removal in our office, which is in the same physical location as our operating room.", [["catheter", "ANATOMY", 154, 162], ["patients", "ORGANISM", 134, 142], ["catheter", "IMMATERIAL_ANATOMICAL_ENTITY", 154, 162], ["patients", "SPECIES", 134, 142], ["successful voiding trials", "TREATMENT", 37, 62], ["our protocol", "TREATMENT", 82, 94], ["same day catheter removal", "TREATMENT", 99, 124], ["HoLEP", "TREATMENT", 128, 133], ["catheter removal", "TREATMENT", 154, 170], ["catheter", "OBSERVATION", 154, 162]]], ["Additionally, we hypothesize neuromuscular paralysis required for endotracheal intubation may have a negative effect on postoperative ability to generate a detrusor contraction.", [["neuromuscular", "ANATOMY", 29, 42], ["endotracheal", "ANATOMY", 66, 78], ["detrusor", "ANATOMY", 156, 164], ["neuromuscular paralysis", "DISEASE", 29, 52], ["detrusor", "ORGANISM_SUBDIVISION", 156, 164], ["neuromuscular paralysis", "PROBLEM", 29, 52], ["endotracheal intubation", "TREATMENT", 66, 89], ["a detrusor contraction", "PROBLEM", 154, 176], ["neuromuscular", "ANATOMY", 29, 42], ["paralysis", "OBSERVATION", 43, 52], ["detrusor contraction", "OBSERVATION", 156, 176]]], ["We opted for all patients to undergo supraglottic airway without paralysis, but two patients did undergo intubation without the knowledge of the operating surgeon.", [["supraglottic airway", "ANATOMY", 37, 56], ["paralysis", "DISEASE", 65, 74], ["patients", "ORGANISM", 17, 25], ["supraglottic airway", "MULTI-TISSUE_STRUCTURE", 37, 56], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 84, 92], ["paralysis", "PROBLEM", 65, 74], ["intubation", "TREATMENT", 105, 115], ["supraglottic airway", "ANATOMY", 37, 56], ["without", "UNCERTAINTY", 57, 64], ["paralysis", "OBSERVATION", 65, 74]]], ["Of these patients, one of two patients did not void; however, this sample is not large enough to draw a conclusion.", [["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 30, 38]]], ["Likewise, we minimized narcotic and anticholinergic use in these patients to avoid the cognitive and detrusor effects that these medications can cause.", [["detrusor", "ANATOMY", 101, 109], ["patients", "ORGANISM", 65, 73], ["detrusor", "MULTI-TISSUE_STRUCTURE", 101, 109], ["patients", "SPECIES", 65, 73], ["narcotic", "TREATMENT", 23, 31], ["anticholinergic use", "TREATMENT", 36, 55], ["the cognitive and detrusor effects", "PROBLEM", 83, 117], ["these medications", "TREATMENT", 123, 140]]], ["This is the first study demonstrating same day catheter removal is possible and successful after HoLEP.", [["the first study", "TEST", 8, 23], ["same day catheter removal", "TREATMENT", 38, 63], ["HoLEP", "TREATMENT", 97, 102], ["catheter", "OBSERVATION", 47, 55]]], ["All surgeons are fellowship-trained in HoLEP and each perform >100 cases annually.", [["HoLEP", "TREATMENT", 39, 44]]], ["All cases were done with Moses Optimized for BPH which is technology that may not be available to all providers at this time.", [["BPH", "DISEASE", 45, 48], ["BPH", "PROBLEM", 45, 48]]], ["Limitations of this study include retrospective review and low sample size.", [["this study", "TEST", 15, 25], ["retrospective review", "TEST", 34, 54], ["low sample size", "PROBLEM", 59, 74], ["low sample", "OBSERVATION_MODIFIER", 59, 69], ["size", "OBSERVATION_MODIFIER", 70, 74]]], ["The patients who were permitted to undergo same day catheter removal were limited by gland size, anticoagulation, and medical fitness for an outpatient procedure.", [["gland", "ANATOMY", 85, 90], ["patients", "ORGANISM", 4, 12], ["gland", "ORGAN", 85, 90], ["patients", "SPECIES", 4, 12], ["same day catheter removal", "TREATMENT", 43, 68], ["anticoagulation", "TREATMENT", 97, 112], ["an outpatient procedure", "TREATMENT", 138, 161], ["catheter", "OBSERVATION", 52, 60], ["gland", "ANATOMY", 85, 90], ["size", "OBSERVATION_MODIFIER", 91, 95]]], ["The method outlined for our same day catheter is also dependent on the OR and clinic to be in close proximity.DiscussionPatients could be safely driven by their accompanying adult to a clinic for catheter removal if it was not attached to the operating location; however, we found that having the patient walk from the OR to the clinic was the best way to initiate normal bladder function after the HoLEP procedure.", [["catheter", "ANATOMY", 196, 204], ["bladder", "ANATOMY", 372, 379], ["patient", "ORGANISM", 297, 304], ["bladder", "ORGAN", 372, 379], ["patient", "SPECIES", 297, 304], ["our same day catheter", "TREATMENT", 24, 45], ["catheter removal", "TREATMENT", 196, 212], ["the HoLEP procedure", "TREATMENT", 395, 414], ["catheter", "OBSERVATION", 37, 45], ["bladder", "ANATOMY", 372, 379]]], ["A larger series or multi-institutional series would provide power to assess for different factors for failure of the same day voiding trials such as prior treatment, mode of anesthesia and other potential factors.", [["different factors", "PROBLEM", 80, 97], ["failure", "PROBLEM", 102, 109], ["the same day voiding trials", "TREATMENT", 113, 140], ["prior treatment", "TREATMENT", 149, 164], ["anesthesia", "TREATMENT", 174, 184]]], ["However, despite these limitations this study is the first to demonstrate the feasibility and high success rate of same day catheter removal after HoLEP.ConclusionSame day catheter removal after HoLEP is feasible and safe in selected patients, making the procedure truly minimally invasive for the patients.", [["HoLEP", "CHEMICAL", 195, 200], ["patients", "ORGANISM", 234, 242], ["patients", "ORGANISM", 298, 306], ["patients", "SPECIES", 234, 242], ["patients", "SPECIES", 298, 306], ["this study", "TEST", 35, 45], ["same day catheter removal", "TREATMENT", 115, 140], ["HoLEP", "TREATMENT", 147, 152], ["ConclusionSame day catheter removal", "TREATMENT", 153, 188], ["HoLEP", "TREATMENT", 195, 200], ["the procedure", "TREATMENT", 251, 264], ["catheter", "OBSERVATION", 172, 180]]], ["Newer laser technology likely has a significant impact on the success in these patients due to reduced rates of hematuria.", [["hematuria", "DISEASE", 112, 121], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["reduced rates of hematuria", "PROBLEM", 95, 121], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["hematuria", "OBSERVATION", 112, 121]]], ["A prospective trial will be helpful to affirm the safety and success of the same day catheter removal outpatient HoLEP approach.", [["A prospective trial", "TREATMENT", 0, 19], ["the same day catheter removal outpatient HoLEP approach", "TREATMENT", 72, 127]]]]}